



Safeguarding human health, by preventing the
unseen & treating the ailing

Become a world-class biopharmaceutical enterprise

Address

50F, Building T1, IFS, No.1
Qingyun Road, Jiangbei
District, Chongqing, China

Tel

023 - 8635 8226

E-mail

IRM@zhifeishengwu.com




Safeguarding human health, by
preventing the unseen & treating the ailing
Become a world-class biopharmaceutical enterprise

2025 SUSTAINABILITY REPORT

CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.

In case of any divergence,
the Chinese version shall prevail





Content

About This Report	001
Message from Zhifei	003
About Zhifei	005
Key performance in 2025	008
Sustainable Development Management	013
Appendix	133

01

Structural Optimization for Governance Effectiveness	023
Standardize Governance and Consolidate the Foundation	025
Deepen Compliance and Strengthen the Bottom Line	030
Guided by Party Building, Empowering Development	034

02

Dedication in R&D for Health and Wellbeing	037
Innovation Guided by Ethics	039
Strategic Guidance for a Healthy Future	042
Assessing Impacts and Seizing Opportunities	046
Efficient Advancement and Pipeline Breakthroughs	047

03

Quality First for Product Responsibility	051
Quality Assurance and Responsibility First	053
Responsible Marketing and Professional Services	061
Global Accessibility and Health for All	067

04

Secure Environment for Continuous Management	075
Target-Oriented System Construction	077
Ensuring Safety and Protecting Health	080
Reduction of Resource Consumption and Improvement of Quality and Efficiency	083
Pollution Prevention and Ecological Protection	086
Building Resilience in Response to Climate Change	089

05

Employee Care and Talent Cultivation	091
Diversity and Inclusion, Laying the Foundation for Talent	093
Empower growth, drive innovation	096
Value Sharing to Stimulate Vitality	101
A Warm-Hearted Work Environment for a Happy Workplace	104

06

Cooperation and Industry Growth	109
Collaboration with Partners for a Responsible Supply Chain	111
Win-Win Cooperation across Industry, Academia, Research and Healthcare	118

07

Public Welfare and Social Development	125
Standardized Management for Long-Term Drive	127
Inclusive Healthcare for Better Health	128
Integration of Industry and Education to Empower the Future	130
Rural Development and Industrial Revitalization	131



About This Report

Report Overview

This is the 9th Sustainability Report (formerly the Social Responsibility Report) released by Chongqing Zhifei Biological Products Co., Ltd. (hereinafter referred to as "the Company" or "Zhifei"). Adhering to the principles of objectivity, regulation, transparency, and comprehensiveness, the report systematically discloses the Company's strategic guidelines, management measures, and performance in environmental, social, and corporate governance (ESG) and sustainability in 2025, aiming to meet the expectations of stakeholders regarding the Company's sustainability and information disclosure and enhance their understanding and confidence in the Company.

Reporting Period

This is an annual report. Unless otherwise specified, the time span of the reported content is from January 1, 2025, to December 31, 2025 (hereinafter referred to as "this year" or "during the Reporting Period"). To enhance the comparability and completeness of the report content, some related information dating back to outside the Reporting Period is separately noted in the text.

Report Standards

The Report is compiled in accordance with *Self-Regulatory Guidelines No. 17 for Companies Listed on Shenzhen Stock Exchange-Sustainability Report (For Trial Implementation)* (hereinafter "SZSE Guidelines") and *Self-Regulatory Guidance No. 3 for Companies Listed on the ChiNext Market of Shenzhen Stock Exchange-Preparation of Sustainability Report* released by the Shenzhen Stock Exchange (SZSE) and draws on *Global Reporting Initiative (GRI) Reporting Standards* (hereinafter "GRI Standards"). A content index of SZSE Guidelines and GRI Standards is presented in the Appendix for quick reference.

Scope of the Report

The information and data provided in this report cover Chongqing Zhifei Biological Products Co., Ltd., Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. and Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. If some information or data is different from the above scope, it has been noted separately in the text.

Unless otherwise specified, the currency amounts involved in this report are measured in RMB.

Approval of the Report

This report has been reviewed and approved by the Company's Board of Directors and is released concurrently with the Company's annual report. The Company's Board of Directors promises that there are no false records or misleading statements in this report and is responsible for the authenticity, accuracy, and completeness of its content.

Access to the Report and Contact Information

This report is published in both Chinese and English. In case of any ambiguity between the versions, the Chinese text shall prevail. The electronic version of this report can be obtained on the CNINFO (www.cninfo.com.cn), the designated information disclosure website of the Shenzhen Stock Exchange (hereinafter referred to as "SZSE"), and the Company's official website (<http://www.zhifeishengwu.com/>).

If you have any questions or comments about this report and its content, please feel free to contact the Company through the following contact information:



Address: 50F, Building T1, IFS, No.1 Qingyun Road, Jiangbei District, Chongqing, China



Tel: 023-86358226



Email: IRM@zhifeishengwu.com

Message from Zhifei



We will work hard for development and start a new journey with diligence. 2025 is a challenging year in the development of Zhifei. In the face of the complex and ever-changing macro environment and the in-depth adjustment of the industry due to changes in market demand, the Company faced the difficulties and actively responded to the changes, coordinated the overall situation with strategic determination, broke through the difficulties with innovation momentum, and steadily moved forward amid in-depth adjustment, maintaining a stable development trend, demonstrating the resilience and vitality of the Company's development.

We know that only difficulties show courage; Only with diligent practice can we achieve far. In the face of short-term fluctuations, the Company has always maintained its strategic focus, adhered to the original intention of "preventing diseases and treating diseases before diseases, and protecting human health", not reducing R&D investment due to performance pressure, not relaxing quality standards due to cost considerations, and not forgetting social responsibility due to market challenges. By laying a solid foundation in fluctuations and breeding new opportunities in reforms, we have built a solid foundation for leapfrog development in the future with perseverance.



● Innovation and Quality: Building a Moat to Cross Cycles

We firmly believe that the continuous increase in R&D investment is a strong engine for future growth, and short-term performance fluctuations will not shake our long-term belief in deepening technological innovation. In 2025, the Company's R&D investment reached RMB 1.436 billion, and the cumulative R&D investment in the past five years exceeded RMB 6 billion. Relying on the "Seven + N" technology platforms, the Company has laid out more than 40 independent research and development projects, and a number of blockbuster products such as Quadrivalent Meningococcal Conjugate Vaccine, 15-Valent Pneumococcal Conjugate Vaccine and Insulin Degludec Injection have achieved key breakthroughs this year.

Quality is the lifeline of an enterprise through the cycle. Against the background of intensifying competition in the industry, the Company insisted on benchmarking international standards, successfully passed 39 internal and external quality audits during the reporting period, and 100% of the production lines of listed products passed GMP certification. With the record of zero major quality and safety liability accidents throughout the year, the Company proved to the market that no matter how the external environment changes, Zhifei's commitment to quality is rock-solid.

● Inclusiveness and Accessibility: Eliminating the Global Health Gap

As industry leaders, our vision has never been limited to a single market. The company is committed to making high-quality vaccines not only "made" but also "usable and affordable". In China, the self-owned tuberculosis diagnostic reagent Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) continues to be included in the national medical insurance catalogue, and the agent products HPV Vaccine and Recombinant Zoster Vaccine actively participate in local activities to benefit the people; Internationally, the Company is a member of the Developing Country Vaccine Manufacturers Alliance (DCVMN), promoting vaccine production in developing countries and implementing differentiated tiered pricing strategies in overseas markets.

The Company fills the health gap with practical actions and the temperature of science and technology. The company's tetravalent meningococcal polysaccharide vaccine and other products are stably supplied to overseas markets. The tuberculosis diagnostic reagent EC has been approved for marketing in Indonesia, and the product registration has been promoted in Malaysia, the Philippines, Thailand and other countries. The international clinical trial of bivalent dysentery conjugate vaccine has been carried out in Bangladesh in conjunction with the International Center for Research on Diarrheal Diseases to empower regional public health capacity building with scientific research cooperation.

● Climate and Ecology: Building a Green and Resilient Foundation

While managing operational risks, the Company also actively managed climate risks and explored new growth drivers under a low-carbon economy. The Company has established a top-level design that embeds EHS governance in strategic planning, and built a solid foundation for sustainable development through the organic unification of standardized governance and clear objectives. The comprehensive energy consumption of Zhifei Longcom decreased by 24% year-on-year, exceeding the annual target, and its Mingzhu Avenue Industrial Park factory was awarded the title of "Waste-free Factory".

Facing the climate challenge, the Company built a governance system with reference to the TCFD framework, and launched a combination of "carbon quota clearance + multi-carbon offset". In 2025, Zhifei Lvzhu fully fulfilled the carbon quota of 5,208 tonnes, and through the cancellation of carbon assets such as BCER, CCER and EBA, it supported the national "dual carbon" strategy with real money and fulfilled its commitment to green development.

● Co-Creation and Sharing: Building a Warm-Hearted Value Ecosystem


The more difficult it is, the more it shows the profound power of "co-creation and sharing". The Company regards talents as the most valuable asset, protects the rights and interests of employees and development opportunities, supports employees to enhance their professional skills, builds a solid bond between employees and the enterprise, and injects a steady stream of endogenous power into the innovation and inheritance of the enterprise.

As a responsible person in the biomedical industry, the Company embedded business ethics in its governance genes and maintained zero major commercial bribery lawsuits throughout the year. In the field of public welfare, the Company has donated more than RMB 400 million in funds, especially in the field of tuberculosis prevention and control. It has formed the dual empowerment of materials and technology with professional ability, and practiced the original mission of "preventing diseases and treating diseases".

Wherever you want, you can go far and wide. Looking ahead, Zhifei will cultivate new productivity as the engine of scientific and technological innovation, take social responsibility as the cornerstone, sharpen resilience in challenges and reshape value in changes. The Company will join hands with shareholders, customers, employees and all stakeholders to unswervingly follow the road of high-quality and sustainable development, and use the warmth of science and technology and the thickness of responsibility to contribute more "Zhifei power" to building a healthy China and enhancing social well-being.

About Zhifei

Chongqing Zhifei Biological Products Co., Ltd. was established in 2002. It is an international high-tech biopharmaceutical enterprise with a whole industrial chain integrating research and development, production, sales, distribution and import and export of vaccines and biological products. The Company was listed on the Growth Enterprise Market of Shenzhen Stock Exchange in September 2010, and is the first private vaccine company listed on the Growth Enterprise Market. The company has always adhered to the business tenet of "social benefit go before corporate profits", undertaken the mission of "preventing diseases before diseases and treating existing diseases, and protecting human health", implemented the development model of "technology & market" two-wheel drive, guided by people's health needs, constantly improved the industrial layout of "prevention & treatment", and strengthened the capability of scientific and technological innovation and commercialization.



The Company has five wholly-owned subsidiaries and one holding subsidiary. Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. (hereinafter referred to as "Zhifei Lvzhu"), Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (hereinafter referred to as "Zhifei Longcom") and Chongqing Chen'an Biopharmaceutical Co., Ltd. (hereinafter referred to as "Chen'an Bio") are the core research and production bases of the Company, and continue to iteratively upgrade bacterial, viral, tuberculosis prevention products and chronic disease treatment drugs such as diabetes and obesity; The parent company Zhifei, as the main promotion body, is committed to building a diversified, convenient and comprehensive service system; Zhifei Airport (Beijing) International Trade Co., Ltd. (hereinafter referred to as "Zhifei Airport") plays a key hub role for import and export, providing the Company with services such as bonded warehousing, customs clearance and filing, and batch issuance of imported vaccines. In addition, through the platform of Chongqing Zhirui Investment Co., Ltd. (hereinafter referred to as "Zhirui Investment"), the Company incubates and cultivates promising preventive and therapeutic biotechnologies and products in the mode of equity investment.

In March 2025, the Company expanded its independent R&D pipeline in the fields of GLP-1 and insulin analogs by increasing its capital to control Chen'an Bio. Chen'an Bio has mastered the construction technology of highly expressed recombinant protein strains. By directionally optimizing the expression system of yeast and E. coli, it can realize high-density fermentation and efficient expression of recombinant human insulin and GLP-1 analogue precursor proteins. At present, it has laid out more than ten projects under research. As the Company's local research and production base in Chongqing, integrating R&D, clinical research and production, it will focus on the fields of metabolic diseases such as diabetes and obesity, and become one of the core growth engines of the Company's therapeutic biological products segment.

In terms of preventive products, the Company has a total of 15 products on the market, one of which is conditionally listed, including vaccine products to prevent infectious diseases such as meningococcal encephalitis, pneumonia, HPV, influenza, rotavirus, and herpes zoster, as well as drugs that provide effective solutions for the diagnosis, prevention and treatment of tuberculosis infection. Through the "Seven + N" technology research and development platform, the Company has built a seven-product matrix with outstanding clinical advantages and reasonable echelon distribution. The Company's products cover a wide range of people, including infants, teenagers and adults, effectively providing strong product support for the prevention and control of infectious diseases, and also providing diversified disease protection options for citizens. For detailed information on the Company's products and pipelines under development, please refer to the Company's 2025 Annual Report.

Development Model

Taking the dual-wheel drive mode of "technology _ Market" as the core path, Zhifei has formed a virtuous circle of mutual promotion of technology research and development and marketing, and accelerated the transformation of products from technology research and development to value landing. Focusing on people's health needs, the Company kept abreast of the frontier of biopharmaceutical technology, continued to deepen the industrial layout of "prevention & treatment", continuously strengthened its independent innovation capabilities, and injected lasting impetus into the development of the enterprise.

The Company follows the R&D strategy of "internationalization of project sources, precision of project selection, pipeline of project development and localization of project production", adheres to the innovation strategy of "independent R&D as the primary focus, collaborative R&D as a supplementary approach, and investment & incubation as a complementary measure", and firmly follows the road of independent innovation. Relying on the "Seven + N" technology platforms of polysaccharide protein binding, recombinant protein, inactivation and attenuation, polyvalent, mRNA, viral vector delivery, and long-acting peptide drugs, the company has successfully built seven product matrices with outstanding technical advantages, significant clinical value, and reasonable echelon distribution, including respiratory tract transmission vaccine matrix, digestive tract transmission vaccine matrix, tuberculosis product matrix, tumor-related vaccine matrix, polyvalent vaccine matrix, adult vaccine matrix, and metabolism-related drug matrix. By integrating resources, we have increased R&D investment, broadened R&D paths, and created a rich product pipeline. As of the disclosure date of this report, the Company has 35 independent prevention projects under research, of which 26 projects are in the stage of application, clinical trial and registration application. At the same time, the Company actively carries out cooperative research and development with top scientific research institutions and universities, focuses on investment and incubation in cutting-edge technology fields, drives the transformation of scientific research results into high-quality products serving people's health, and achieves both social benefits and commercial value enhancement of innovative technologies.

As of the disclosure date of this Report

The Company has **35** independent prevention research and development projects | of which **26** are in the stages of application, clinical trial, and registration application

The Company has laid out independent therapeutic research projects through its holding subsidiary Chen'an Bio, and has entered **6** key research projects in the clinical stage, of which **2** are under listing review.





At the level of professional marketing promotion, the Company relies on its self-built professional marketing team to build an in-depth service network covering 31 provinces, autonomous regions and municipalities directly under the Central Government, including more than 300 cities, more than 2,600 districts and counties, and more than 30,000 primary health service points (including township vaccination points and community outpatient clinics), and continuously provides fast and comprehensive high-quality service support for terminals. Deeply engaged in the market for more than 20 years, the Company has continuously strengthened the professional ability and service awareness of market personnel, promoted diversified market work with the support of professional medicine, continued to carry out online and offline disease science popularization and vaccination publicity, responded to the government's call to participate in projects to benefit the people, improved the public's awareness of disease prevention, and promoted the public's willingness to be vaccinated. On the cooperation side, the Company continued to consolidate cooperative relationships with business partners to jointly respond to market changes. In addition, the Company closely follows the international development strategy, promotes international market cooperation and overseas certification of self-developed products, and actively expands and strengthens global partnerships.

Company Culture

As an important global vaccine R&D and supply entity, Zhifei is committed to building a "world-class biopharmaceutical enterprise". Since its establishment, the Company has always adhered to the principle of "social benefit go before corporate profits", fulfilled the mission of "Safeguarding human health, by preventing the unseen & treating the ailing", and gathered the team with the core values of "six firsts and six seconds". The Company takes Zhifei culture as the core link, and attracts, gathers and retains talents with common values. At the same time, the Company provides talent support for long-term sustainable development through diversified incentive mechanism, sound benefit sharing system and stable talent development strategy, and makes unremitting efforts to continuously promote the development of public health.


Our Principle





Corporate Values

Priority to Moral Quality over Ability	Priority to Quality over Speed
Priority to Compliance over Performance	Priority to Discipline over Excuse
Priority to Integrity over Profit	Priority to Collective over Individuals




Missions

Safeguarding human health, by preventing the unseen & treating the ailing






Visions

Become a world-class biopharmaceutical enterprise



Key Performance in 2025

Business Performance

 <p>Operating income RMB 8.958 billion</p>	 <p>Net cash flows from operating activities RMB 5.167 billion</p>
 <p>Total assets RMB 31.72 billion</p>	 <p>Earnings per share RMB -6.15 per share</p>
 <p>Owners' equity RMB 16.106 billion</p>	 <p>Tax payment RMB 1.275 billion</p>



Key Performance Indicators for Sustainability

Dedicated R&D

R&D investment in 2025 reached RMB **1.436** billion

The cumulative R&D investment in the past five years exceeded RMB **6** billion

89 authorized patents have been obtained (including patents obtained overseas)

77 of them are within the validity period of the patent

Product Responsibility

National service: Covering **31** provinces and municipalities

Over **2,600** districts and counties

More than **30,000** primary health service points across the country

Product quality assurance: **Zero** actual product recalls throughout the year

With a **100%** complaint handling rate

Quality audit and certification: A total of **39** quality audits were completed throughout the year

100% of the production lines of listed products have obtained quality certification

Safety and Environment

EHS investment: RMB **7.2235** million

Zero major safety accidents and work-related injuries throughout the year

Standardized certifications: The Company's subsidiaries, Zhifei Lvzhu and Zhifei Longcom, have both passed the ISO 14001 Environmental Management System Certification and the ISO 45001 occupational health and safety management system certification

Employee Care

Total number of employees: **6,292**

Proportion of Female employees: **42.21%**

Proportion of Female in the Management: **33.99%**

Number of disabled employees hired: **31**

Employee training: The average training hours per employee reached **61.66** hours

Benefiting the Public

In 2025, the Company actively participated in **12** public welfare projects

Made a cumulative donation of over RMB **0.4** billion

With the actual donation amount exceeded RMB **3.22** million



Corporate Honors


Comprehensive Strength



Top 500 Chinese private enterprises-All China Federation of Industry and Commerce




Top 100 private manufacturing enterprises in Chongqing Chongqing Federation of Industry and Commerce and Chongqing Economic and Information Technology Commission



Member unit of Beijing Integrative Medicine Association Beijing Integrative Medicine Association



Top 10 Party building work cases in the "Two Enterprises and Three New" field in Jiangbei District in 2024 Working Committee of Non-public Economic Organizations and Social Organizations of the CPC Chongqing Jiangbei District Committee



Outstanding private enterprise in Chongqing CPC Chongqing Municipal Committee and Chongqing Municipal People's Government



Enterprise making economic contributions in Jiangbei District, Chongqing in 2024 CPC Chongqing Jiangbei District Committee and Chongqing Jiangbei District People's Government



Outstanding defense unit Administrative Office of the Cybersecurity and Informatization Commission of the CPC Chongqing Banan District Committee



(Zhifei Lvzhu) Beijing Advanced-level Smart Factory in 2025 Beijing Economic and Information Technology Bureau



Biomedical Pilot Award Pharmaceutical Intelligence Manufacturing Industry Alliance, Oral Solid Formulation Industry Alliance, Dandelion



Top 100 Chongqing Enterprises Chongqing Enterprise Federation

(Zhifei Lvzhu) 2025 Beijing Advanced Smart Factory Beijing Municipal Bureau of Economic and Information Technology



2025 Top 100 Manufacturing Enterprises in Chongqing Chongqing Enterprise Federation



National Civilized Unit Central Leading Group for Propaganda, Ideology and Culture



Sustainability



Outstanding practice case of sustainability of listed companies in 2025 China Association of Listed Companies



Top 100 ESG listed companies Securities Times

Sustainable Development Management

Zhifei has deeply integrated the concept of sustainable development into the daily business operation and corporate culture construction process, and steadily improved the professional management level of sustainable development by establishing and continuously improving the sustainable development governance structure and management system.

The Company always regards the practice of environmental and social responsibility as the core task of high-quality development, and takes raising the national awareness of health prevention as its own responsibility to provide long-term value to stakeholders. With its continuous investment and continuous improvement in product quality and safety, health and inclusive benefits, the Company has been highly praised by authoritative ratings such as CNI ESG, and its sustainable development practice has become a leading paradigm in the biomedical industry.


Sustainable Development Governance Structure

In order to identify, assess and manage impacts, risks and opportunities related to sustainable development, the Company has established a sustainable development governance structure, which specifically covers three levels: the Board of Directors, special committees of the Board of Directors and ESG working groups. Under the guidance of the Board, the Company continued to improve and implement *the Sustainable Development (ESG) Management Working System and Working System of the Strategy and Sustainable Development Committee of the Board* and other system requirements, so as to clarify the responsibilities of all levels in sustainable development work and achieve more transparent and efficient management. Relying on their professional background and practical capabilities in public health, legal compliance, R&D operation, financial internal control and other fields, the Board of Directors and relevant performing personnel provided all-round professional support for the formulation, implementation and supervision of sustainable development strategies, and actively participated in relevant trainings to ensure the compliance and effectiveness of the implementation of the strategies.

















Sustainable Development Strategy

As a global citizen, Zhifei integrates the concept of sustainability into the Company's core management strategy, and is committed to continuously improving its ESG management level. It always aligns its actions and goals with the United Nations Sustainable Development Goals (SDGs). The Company focuses on seven aspects, namely Safeguard good corporate governance, Build hubs for research and innovation, Strengthen product responsibility, Promote green development, Focus on talent growth, Drive industry development, and Practice social responsibility, to build Zhifei's ESG management strategy. Zhifei adheres to the core value of "social benefits go before corporate profits", and pursues innovation-driven development. It promotes cooperation among all parties to create long-term business value. While continuously enhancing its own sustainable development capabilities, it contributes positively to global sustainable development.





Sustainable Development Strategy	Response Section	Response to SDGs	Response to ESG Issues
Safeguard good corporate governance	Structural Optimization for Governance Effectiveness The Company continuously improves its corporate governance system and working mechanism. Guided by Party building, it simultaneously strengthens the construction of the sustainable development management and compliance management systems, and conducts a number of compliance trainings to comprehensively enhance the awareness of integrity, anti-corruption, and compliance among all employees.		<ul style="list-style-type: none"> Credible and compliant operation Corporate governance Risk management Business ethics and anti-corruption Due diligence Anti-unfair competition
Build hubs for R&D innovation	Dedication to R&D for Health and Wellbeing Guided by the health needs of the public, the Company focuses on building an innovative product pipeline with prominent technological advantages and obvious clinical value. Relying on its own R&D strength, it accelerates the transformation of innovation results, promotes the accessibility of products and services, and protects the public's health and well-being through inclusive healthcare practices.		<ul style="list-style-type: none"> R&D and innovation Product and service accessibility Protection of intellectual property rights Affordable healthcare
Strengthen product responsibility	Quality First for Product Responsibility The Company builds a full-process product quality management system, strictly implements quality control standards, prevents risks of quality and safety incidents, fully guarantees product safety, continuously improves product quality, and provides safe, high-quality, and accessible products and services.	  	<ul style="list-style-type: none"> Product quality and safety Responsible marketing Customer service management Affordable healthcare Information security and privacy protection Product and service accessibility Ethics in Science and Technology
Promote green development	Secure Environment for Continuous Management The Company implements the concept of sustainable development. Through a comprehensive environment, health, and safety management system, it fulfills its environmental protection commitments, protects the health of employees, and continuously builds a green enterprise that is safe and environmentally friendly.	   	<ul style="list-style-type: none"> Employee occupational health and safety Emissions management Energy use Water resources management Climate change mitigation and adaptation Waste treatment Environmental compliance management Circular economy Ecosystem and biodiversity conservation

Sustainable Development Strategy	Response Section	Response to SDGs	Response to ESG Issues
Focus on talent growth	Employee Care and Talent Cultivation The Company attaches importance to talent development, implements an open, fair, and diversified talent introduction and cultivation mechanism, builds a fair promotion channel and a diversified development platform. By improving the salary and welfare system, strengthening all-round training, and ensuring the health and safety of employees, it helps employees and the enterprise grow together.	    	<ul style="list-style-type: none"> Employee training and development Compliant employment Diversity and equal opportunity
Drive industry development	Cooperation and Industry Growth The Company joins hands with various parties such as scientific research institutions, universities, and industrial chain partners to promote the optimal allocation of industry resources and collaborative innovation. It continuously leverages its own advantages to empower industry partners, and jointly builds and shares with all parties in the industrial chain to promote the high-quality and sustainable development of the industry.	   	<ul style="list-style-type: none"> Responsible supply chain Industry cooperation and development Equal treatment of small and medium-sized enterprises
Practice social responsibility	Public Welfare and Social Development The Company actively carries out public welfare activities such as rural revitalization, medical assistance, educational support, and disaster relief. It continuously pays attention to the social and people's livelihood needs, conveys warmth through practical actions, and promotes the harmonious development of society through responsible practices.	    	<ul style="list-style-type: none"> Community development and public welfare Affordable healthcare Rural revitalization

Stakeholder Engagement

Zhifei attaches great importance to the needs and expectations of stakeholders. It has established a systematic and regular communication and feedback mechanism to actively maintain close connections with investors, partners, employees, the public and other parties, and drives the sustainability process through positive interactions. Based on the impact assessment results of business decisions, the Company adjusts its strategic direction in a timely manner and continuously improves its sustainability performance.

Stakeholders	Main Communication Methods	Expectations and Needs	Communication and Response	
 <p>Shareholders and investors</p>	<ul style="list-style-type: none"> Shareholders' meetings Information disclosure 	<ul style="list-style-type: none"> Investor hotline, email, and interactive platform The Company's official website 	<ul style="list-style-type: none"> Financial performance Rights protection Company transparency Risk control 	<ul style="list-style-type: none"> Improve economic efficiency Hold shareholders' meetings Daily information disclosure Optimize the risk control and compliance system
 <p>Government regulatory agencies</p>	<ul style="list-style-type: none"> Information submission Visits and research 	<ul style="list-style-type: none"> On-site inspections 	<ul style="list-style-type: none"> Comply with laws and regulations Pay taxes in accordance with the law Compliant operations Respond to national policies Support local development 	<ul style="list-style-type: none"> Operate in compliance with laws and regulations Pay taxes on time and in full Actively implement policies Provide employment opportunities
 <p>Employees</p>	<ul style="list-style-type: none"> Trade union activities Company communication platform Employee care activities 	<ul style="list-style-type: none"> Employee training Employee satisfaction Company mailbox 	<ul style="list-style-type: none"> Salary and benefits Employee rights Cross-level interaction and communication opportunities Efficient and transparent work process Career development opportunities Healthy and safe working environment 	<ul style="list-style-type: none"> Optimize the salary and benefits system Equal communication and grievance mechanism Increase employee interaction activities Improve operational management efficiency Improve the career promotion mechanism Implement EHS management
 <p>Customers</p>	<ul style="list-style-type: none"> Customer satisfaction surveys Academic and technical exchange conferences 	<ul style="list-style-type: none"> The Company's official website Official WeChat public account 	<ul style="list-style-type: none"> Product quality and safety Customer service management Customer information security 	<ul style="list-style-type: none"> Strict product quality control Compliant marketing Product innovation Optimize the complaint feedback mechanism Network security and permission settings
 <p>Suppliers</p>	<ul style="list-style-type: none"> Supplier tender review Regular evaluation and audit 	<ul style="list-style-type: none"> Supplier communication Supplier training 	<ul style="list-style-type: none"> Good and stable cooperative relationship Business ethics and reputation Supply chain sustainability 	<ul style="list-style-type: none"> Promote project cooperation Promote daily communication Fulfill contractual obligations Build a responsible supply chain
 <p>Partners</p>	<ul style="list-style-type: none"> Expert training Academic and technical conferences 	<ul style="list-style-type: none"> Company research activities 	<ul style="list-style-type: none"> Resource and information sharing Industry-university-research cooperation opportunities 	<ul style="list-style-type: none"> Improve social media platform management Promote cooperation and communication among expert teams Promote strategic cooperation and organizational communication
 <p>Society and the public</p>	<ul style="list-style-type: none"> The Company's official website Official WeChat public account 	<ul style="list-style-type: none"> News reports Community public welfare activities 	<ul style="list-style-type: none"> Social public welfare Resources and environment Poverty alleviation and education promotion Assistance for the disabled and the vulnerable 	<ul style="list-style-type: none"> Promote rural revitalization Adhere to green operations Carry out health science popularization Engage in charity

Double Materiality Assessment

During the Reporting Period, Zhifei followed the "double materiality" methodology. From the two dimensions of "financial materiality" and "impact materiality", it invited various stakeholders to participate in the issue materiality assessment, comprehensively analyzed the impact of sustainability issues on the Company's finances and the Company's impact on the economy, society, and environment. This served as the basis and core for determining the Company's sustainability management policies, strategies, management priorities, and goals, and the assessment results were used as a reference for information disclosure in this year's report. In the future, the Company will continue to pay attention to the updates of the *SZSE Guidelines*, improve the Company's double materiality assessment process and methods, and provide a scientific basis for the Company's sustainability planning.

Assessment Method

Scope

In the impact materiality assessment dimension, the Company focuses on the positive and negative impacts, actual and potential impacts related to ESG issues. In the financial materiality assessment dimension, the Company takes into account the positive and negative impacts, actual and potential risks and opportunities generated by the Company's business.

Stakeholder Participation

Since the application of the "double materiality" principle has a profound impact on the Company's management and disclosure affairs, and involves many ESG issues, and some assessments require a certain threshold of industry knowledge, the Company invites internal and external stakeholders to widely participate in the impact materiality assessment. The participants in the financial materiality assessment are limited to some senior internal management and external sustainability experts.

Scoring Method

When assessing the "severity" of the impact, the Company comprehensively scores from three dimensions: impact scale, coverage, and irreparability of negative impacts. Specifically, it includes the degree of impact on humans or the environment, the breadth of impact coverage, and the time and economic cost of repairing the damage. The score range is from 1 to 5 points. When assessing the "likelihood of occurrence" of the impact, the Company scores based on the probability of the potential impact occurring within five years, with a score range of 0.1 to 1 point.


When assessing the "impact scale" in the financial dimension, the Company uses a certain proportion of the pre-tax profit in 2024 as the judgment threshold, with a score range of 1 to 5 points. When assessing the "likelihood of occurrence" of financial risks or opportunities, the Company scores based on the probability of their occurrence within five years, with a score range of 0.1 to 1 point.

Threshold

The Company classifies each ESG issue into "material", "relevant" or "weakly relevant" groups based on its score and ranking in the dimensions of impact materiality and financial materiality.

Assessment Process

This year, the Company carried out the double materiality assessment through the following four steps:



According to the results of this year's double materiality assessment, the Company compiled a double materiality matrix to show the materiality level of each issue, as shown in the following figure.

Financial Material, Impact Material	Financial Relevant, Impact Relevant	Financial Relevant, Impact Material
<ul style="list-style-type: none"> R&D and Innovation 	<ul style="list-style-type: none"> Business Ethics and Anti--corruption Product and Service Accessibility Risk Management Responsible Supply Chain Anti-unfair Competition Stakeholder Communication Compliant Employment Industry Cooperation and Development Information Security and Privacy Protection Due Diligence Scientific and Technological Ethics Environmental Compliance Management 	<ul style="list-style-type: none"> Protection of intellectual property rights Credible and compliant operation Product Quality and Safety Employee Training and Development Employee Occupational Health and Safety Corporate Governance Customer Service Management Responsible Marketing
Financial Weakly Relevant, Impact Weakly Relevant	Financial Weakly Relevant, Impact Relevant	
<ul style="list-style-type: none"> Circular Economy Energy Use Emissions Management Water Resources Management Equal Treatment of SMEs Rural Revitalization Ecosystem and Biodiversity Conservation Climate Change Mitigation and Adaptation 	<ul style="list-style-type: none"> Community Development and Public Welfare Inclusive Healthcare Waste Disposal Diversity and Equal Opportunity 	

● Environmental Issues ● Social Issues ● Governance Issues

The results of the double materiality assessment show that R&D and innovation, protection of intellectual property rights, product quality and safety, credible and compliant operation, employee training and development, employee occupational health and safety, corporate governance, customer service management, and responsible marketing are the Company's most core current sustainability issues.

Among them, R&D and innovation have both impact materiality and financial materiality. Currently, the Company's existing vaccine products are facing the pressure of homogeneous competition. This risk may weaken the Company's market share and brand influence, and even cause customer loss, which will further affect the Company's profitability and growth potential. Therefore, technological iteration, upgrading, and innovation breakthroughs are the core of the Company's continuous business development. The Company will continue to deepen its technological reserves and promote product innovation to address challenges such as the accelerating technological changes and the upgrading of market demand, and to consolidate its market competitiveness. For the specific content of "R&D and innovation", please refer to the "Dedication to R&D for Health and Well-being" section of this report.

The following table shows the major sustainability-related impacts, risks, and opportunities faced by Zhifei. The measures and actions taken for their monitoring, prevention, management, and control will be further elaborated in the subsequent sections.

The following table shows the major sustainability-related impacts, risks, and opportunities faced by Zhifei. The measures and actions taken for their monitoring, prevention, management, and control will be further elaborated in the subsequent sections.

ESG Issues	Impact Materiality		Financial Materiality		Time Horizon ¹	Response Actions	
	Main Impacts	Impact Category ²	Importance Level ³	Main Risks/ Opportunities			Importance Level
R&D and innovation	Promote the iteration of vaccine technology and product upgrading through R&D and innovation, enrich the differentiated vaccine pipeline, and enhance the market competitiveness and added value of products.	+	III	Risk: R&D and innovation require large-scale investment and a long cycle, facing high resource consumption and risks.	III	Long-term	Dedication to R&D for Health and Well-being
Protection of intellectual property rights	Drive technological innovation and facilitate product upgrading.	+	III	Risks: More funds need to be invested in patent applications, and enforcement costs and legal litigation costs need to be borne, which will have a certain impact on profitability.	II	Medium-term	Dedication in R&D for Health and Wellbeing
Credible and compliant operation	Maintaining credible and compliant operation ensures legal compliance, minimizes disputes and penalties, and safeguards financial stability. Non-compliant practices may trigger severe legal repercussions and increase operational costs.	+	III	Risks: Non-compliant behavior may lead to severe legal consequences and increase operating costs.	II	Short-term	Compliance and integrity first in operation
Product quality and safety	Strengthen the management and control of product quality and safety, enhance consumer trust, and increase market share and profitability.	+	III	Risk: Product quality and safety issues may reduce consumer trust and lead to a decline in sales.	II	Short-term	Product Responsibility, Adhere to Quality First
Employee training and development	Enhancing employee training and development elevates workforce skills and professional competencies, driving operational efficiency, innovation capacity, and corporate revenue growth. Sustained investment in talent cultivation enables enterprises to nurture high-caliber professionals, ensuring long-term talent pipelines and intellectual capital for strategic growth.	+	III	Opportunities: Through continuous employee training and development, enterprises can cultivate more high-quality talents, providing talent security for the Company's long-term development and promoting company revenue and profits.	II	Medium term	Employee training and development
Employee occupational health and safety	Workplace accidents and occupational diseases may severely impact corporate financial stability. By elevating occupational health and safety standards, enterprises can enhance employee satisfaction and productivity, reduce operational costs, and strengthen market competitiveness.	+	III	Opportunities: By improving occupational health and safety management standards, enterprises can enhance employee satisfaction and productivity, reduce operating costs, and strengthen market competitiveness.	II	Short term	Secure environment for continuous management
Corporate governance	Governance failures may impair solvency, escalate operational costs, and strain liquidity. Robust corporate governance enhances organizational credibility and investor confidence, attracting greater capital inflows.	+	III	Opportunities: Good corporate governance helps to enhance the Company's reputation and investor confidence, thereby attracting more capital inflows.	II	Short term	Standardized management for good corporate governance
Customer service management	Superior customer service management enhances client satisfaction and loyalty, drives positive word-of-mouth referrals, increases repurchase rates, and ultimately boosts corporate revenue and profitability.	+	III	Risks: Low customer satisfaction or improper complaint handling can lead to customer churn, thereby requiring more resources to attract new customers and increasing market development costs.	II	Short term	Responsible and professional services
Responsible Marketing	Through responsible marketing strategies, the Company can shape a positive corporate social image, strengthen brand influence and market competitiveness, and expand more business cooperation and market opportunities.	+	III	Opportunities: Responsible marketing can accurately convey the value information of product safety and compliance, strengthen the trust of disease control institutions, vaccination providers, and the public in the brand, and promote the long-term and sustainable improvement of brand value.	II	Short term	Product responsibility, adhering to quality first

1. Combining the strategic planning and business operations of Zhifei, the Company defines the time periods as follows: short-term (<1 year), medium-term (1-5 years), and long-term (>5 years).
 2. "+" represents a positive impact, and "-" represents a negative impact.
 3. The importance level is the degree of importance of the issues determined by Zhifei in each dimension. The more "I"s, the higher the degree of importance.

Structural Optimization for Governance Effectiveness

Consolidating corporate governance and upholding a prudent business style are the key paths for an enterprise to achieve sustainable development. Zhifei continued to improve its corporate governance structure and risk management mechanism, proactively responded to investors' concerns, and effectively protected the legitimate rights and interests of investors. The Company attaches great importance to Party building, establishes the organization of the Communist Party of China in the Company, carries out Party activities, and gives full play to the exemplary and leading role of Party members. The Company adheres to the business ethics principles, builds a clean and clean business environment, and effectively enhances the overall value of the enterprise.




Standardize Governance and Consolidate the Foundation

Zhifei regards a sound and efficient risk management and internal control system as the cornerstone for the stable and long-term development of the enterprise. We have established a sound, effective, and transparent corporate governance structure composed of the shareholders' meeting, the Board of Directors, various special committees of the Board of Directors, and senior management. The purpose is to standardize the organization and behavior of the Company, accurately identify and control operational risks, and drive the high-quality development of the Company. At the same time, the Company integrates the culture of integrity and honesty into the foundation of governance and optimizes the supply chain management mechanism to ensure the stable and long-term development of the Company.

Corporate Governance Structure

Zhifei adheres to the principle of compliance and integrity, and promotes the Company's long-term, stable and high-quality development. The Company strictly abides by the *Company Law of the People's Republic of China* (hereinafter referred to as the *Company Law*), the *Securities Law of the People's Republic of China* (hereinafter referred to as the *Securities Law*), the *Governance Guidelines for Listed Companies*, the *Rules for the Listing of Shares on the Growth Enterprise Market of the Shenzhen Stock Exchange* (hereinafter referred to as the *GEM Listing Rules*), the *Self-regulatory Guidelines for Listed Companies of the Shenzhen Stock Exchange No. 2-Standardized Operation of Listed Companies on the Growth Enterprise Market* (hereinafter referred to as the *Standardized Operation of Listed Companies on the Growth Enterprise Market*) and other relevant laws and regulations, and continuously improves the governance system of the Company. The Board of Directors of the Company has established the Strategy and Sustainable Development Committee, the Nomination Committee, the Remuneration and Appraisal Committee and the Audit Committee, which perform their duties in accordance with the *Articles of Association of Chongqing Zhifei Biological Products Co., Ltd.* (hereinafter referred to as the "*Articles of Association*") and the authorization of the Board of Directors, and the Audit Committee performs the functions and powers of the Board of Supervisors in accordance with law. The Board of Directors of the Company effectively protects the rights and interests of shareholders and stakeholders, ensures the truthfulness, accuracy, completeness, timeliness and fairness of information disclosure, so as to protect all shareholders' right to equal access to information. During the reporting period, the Company did not violate the relevant laws and regulations on information disclosure.

Corporate Governance Structure



Shareholders and Shareholders' Meetings

The Company strictly abides by the *Rules of General Meeting of Shareholders of Listed Companies* and, in accordance with internal systems such as the *Articles of Association* and the *Rules of Procedure of General Meeting of Shareholders*, standardizes the procedures for convening, proposing, notifying, and holding shareholders' meetings. To ensure the legality and fairness of the meetings, the Company hires lawyers to attend and issue legal opinions. The Company is committed to providing convenience for shareholders to participate in shareholders' meetings, ensuring that all shareholders, especially small and medium-sized shareholders, have an equal status and can fully exercise their shareholder rights to safeguard their legitimate rights and interests.

In terms of independence, the Company has an independent and complete business layout and independent operation ability, and is independent of the controlling shareholder in terms of business, personnel, assets, institutions, and finance. The Board of Directors and internal institutions operate independently. The controlling shareholder strictly regulates its own behavior, exercises its rights and assumes its obligations in accordance with the law, does not directly or indirectly interfere with the Company's decision-making and business operations beyond the shareholders' meeting, and has not occupied the Company's assets in violation of regulations or damaged the interests of the Company and other shareholders.

In 2025

the Board of Directors convened
3 shareholders' meetings in total

and reviewed
13 proposals



Directors and the Board of Directors

The Board of Directors of the Company has a total of 9 Directors, including 2 female Directors, 3 independent Directors and 1 employee representative Director, and the number and composition of Directors meet the requirements of relevant laws and regulations. Members of the Board have diverse professional backgrounds, including industry experts and professionals in key fields such as biomedicine, law, finance and finance, possess solid professional knowledge, rich practical experience and comprehensive qualities required to perform their duties, and actively participate in professional trainings organized by relevant institutions in strict compliance with regulatory requirements to continuously improve their ability to perform their duties.

All Directors abide by internal systems such as the *Rules of Procedures of the Board* and the *Work System of Independent Directors*, perform their duties faithfully and diligently, ensure high-quality decision-making by the Board, promote more standardized and efficient corporate governance, and lay a solid foundation for the sustainable development of the Company.

In 2025

The Board of Directors convened a total of **6** meetings

Reviewed **29** proposals


The attendance rate of board members was **100%**



Special meetings of the Audit Committee of the Board and independent directors

The Audit Committee under the Board of Directors of the Company continues to improve the internal supervision mechanism of listed companies. The Audit Committee of the Board of Directors of the Company has a total of three members, including two independent Directors, and accounting professionals with extensive accounting expertise and experience among the independent Directors are the conveners. In accordance with the *Articles of Association*, the *Working System of the Audit Committee of the Board* and other internal systems, the Audit Committee diligently supervises the financial information, internal control, internal and external audits of the Company, and performs the functions and powers of the Supervisory Committee as stipulated by laws and regulations.

The Company has established a special meeting system of independent directors comprising three independent directors to strengthen the support of independent directors in performing their duties. In accordance with the *Working System for Independent Directors* and *Working System for Special Meetings of Independent Directors* and other internal systems, the Company conducted prior deliberations on major matters such as related party transactions, and effectively played the role of independent directors in participating in decision-making, supervising checks and balances, and providing professional advice, so as to safeguard the overall interests of the Company and protect the legitimate rights and interests of minority shareholders.



Senior Management


The Company has 15 senior managers, of which 6 are female executives, and continues to optimize and diversify the management structure. The management is composed of industry experts and professionals in legal, quality, marketing and other fields, with complementary advantages, synergy and efficiency, aiming to quickly respond to market changes and operational challenges, provide professional support for the sustainable development of the Company, and achieve a win-win situation between social and economic benefits.

Protection of Investors' Rights and Interests

Information Transparency

Zhifei always upholds the core concept of investor relations management and effectively protects the legitimate rights and interests of investors, especially small and medium-sized investors. The Company strictly abides by the *Securities Law of the People's Republic of China*, the *Standardized Operation of Companies Listed on the Growth Enterprise Market*, the *Administrative Measures for Information Disclosure*, the *Registration System for Insiders of Insider Information* and other relevant laws and regulations and internal system provisions, consolidates the management of information disclosure affairs, fulfills its information disclosure obligations on the websites of stock exchanges and media that meet the requirements stipulated by the CSRC in accordance with law, abides by the disclosure principles of truthfulness, accuracy, completeness, concision, clarity and easy to understand, and protects the legitimate rights and interests of investors. At the same time, the Company strengthened voluntary information disclosure to enhance investors' understanding of the Company's R&D projects and enable investors to have a more comprehensive, intuitive and objective understanding of the Company's situation.

In 2025, the Company issued 126 announcements and online documents in accordance with regulations, including 4 periodic reports, temporary announcements and other voluntary disclosures; No false records, misleading statements, material omissions or other improper disclosures were made.



Return to Shareholders

Zhifei has always adhered to the concept of "investor-oriented", attached great importance to sustained, stable and reasonable investment returns for investors, and clearly stipulated a relatively stable and reasonable profit distribution policy in the *Articles of Association*. Since its listing, the Company's accumulated cash dividends have reached RMB 7.318 billion, which is 5.11 times of the net funds raised by the initial offering.

However, factors such as increasing vaccine hesitancy and declining people's willingness to vaccinate continue to affect the development of the vaccine industry, and the overall short-term pressure of the industry is obvious. After careful evaluation, the Company has decided not to pay dividends for the year after comprehensive consideration of the actual business development and capital needs, combined with the industry development trend and future long-term development plan, in order to ensure the normal production and operation of the Company, enhance the ability to resist risks and better safeguard the long-term interests of all shareholders.

Despite facing many challenges, under the guidance of the Board, the Company has always maintained its strategic focus, actively responded to market changes, continuously optimized its business strategies, achieved stable development, and made new progress in innovative research and development and internationalization strategies. In the future, the Company will, as always, attach great importance to providing reasonable investment returns to investors, actively explore diversified return paths, take into account both the immediate and long-term interests of shareholders, improve the level of shareholders' returns, implement a long-term, stable and sustainable shareholders' value return mechanism, and strive to improve operating results on the premise of complying with the principle of profit distribution and ensuring the normal operation and long-term development of the Company, with a view to creating greater value for shareholders at an appropriate time.

Investor Relations Management

Regarding investor relations management as the link of value transmission, Zhifei has formulated and continuously improved internal systems such as *Investor Relations Management System*, *Information Disclosure Management System* and *Board Secretary Work System*. By refining the division of jobs and clarifying the boundary of responsibilities, it has arranged a special person to be responsible for the consultation response and appeal response of Shenzhen Stock Exchange's "Interactive Easy" platform, investor hotline and official email, so as to ensure smooth and efficient communication channels. At the same time, the Company institutionalized and streamlined the daily investor relations management, handled every investor demand with professional, compliant and patient standards, and enhanced communication and mutual trust. In 2025, the Company's investor relations management staff will maintain regular and close communication with investors through various channels such as shareholders' meetings, hotlines, e-mails, collective reception days in jurisdictions and strategy meetings of securities firms. At the same time, the Company held an annual performance briefing meeting to answer investors' questions on the Company's operating results, financial status, governance structure and environmental and social issues in a timely manner, convey the Company's development philosophy and core values in an all-round way, and steadily build a mutually trustworthy and win-win capital market relationship.



Risk Management and Internal Control


Zhifei has established an effective risk management and internal control system to identify and control potential risks in a timely manner, driving the continuous improvement of its operation and management. In 2025, the Company revised a number of policies, such as the *Management System of Third Party Conduct Standards*, the *Measures for Handling Violations of Market Personnel*, and the *Due Diligence and Risk Assessment Process of Third Party Organizations such as the Institute*, to comprehensively standardize the daily work behavior of market academic conferences and market personnel to adapt to the changing market environment and regulatory requirements.

In terms of organizational structure, the Company has established an Audit Committee under the Board of Directors, which is fully responsible for supervising, inspecting and evaluating the internal control, financial information and internal audit of the Company, and improving the internal supervision mechanism of listed companies. Under the overall guidance of the Board, the Company has specially established an internal audit department and a risk control department to jointly strengthen the internal control and compliance management of the Company. At the same time, the Audit Committee supervises the supervision and inspection of the Company's business activities, risk management, internal control and financial information by the Internal Audit Department.

The risk control department adopts various methods such as unannounced compliance inspection and in-depth verification to accurately locate various risk points and management loopholes. In response to the risks in internal control and marketing, the Risk Control Department works closely with the Legal Compliance Department to timely manage and control existing and emerging risks, establish a scientific risk assessment model, and build a solid line of defense against business risks. For specific operational projects, the Company has specially established a project management committee to coordinate the legal compliance department, risk control department, finance department and other departments to jointly manage project risks and effectively protect the interests of the Company.

In order to ensure the effectiveness of the first and second lines of defense of the Company, the Internal Audit Department independently conducted internal audits on the Company's internal institutions, holding subsidiaries and relevant joint-stock companies to evaluate the effectiveness of internal control. The scope of the audit covered all business links related to financial reporting and information disclosure, such as procurement, human resources and information system management, and fully performed the supervisory role of the third line of defense. The Internal Audit Department reports to the Audit Committee at least quarterly, and submits an internal audit report to the Audit Committee after the end of each year. For deficiencies and problems in the implementation of the Company's internal control, the Internal Audit Department urges the relevant responsible departments to formulate rectification measures and rectification time, conducts follow-up review of internal control, supervises the implementation of rectification measures, and reports to the Audit Committee in a timely manner if significant deficiencies or risks in internal control are found.

Three Lines of Defense for Risk Management and Internal Control



Deepen Compliance and Strengthen the Bottom Line

Zhifei adheres to the core concept of "compliance in heart, responsibility in action", based on the integrated compliance management system and supervision mechanism of prevention, monitoring and punishment, comprehensively prevented all kinds of compliance risks, ensured that its business activities complied with national laws and regulations, pharmaceutical industry norms and the requirements of the Company's business development, and strived to establish a corporate image of integrity and responsibility. During the Reporting Period, the Company did not have any commercial bribery or corruption incidents, nor did it result in litigation or major administrative penalties due to unfair competition.



Compliance Governance System


Zhifei strictly abides by the red lines, abides by the *Company Law*, the *Interim Provisions on the Prohibition of Commercial Bribery*, the *Anti-Money Laundering Law of the People's Republic of China*, the *Anti-Unfair Competition Law of the People's Republic of China* and other relevant laws and regulations, and benchmarks the industry code of conduct of the *China Association of Enterprises with Foreign Investment & D-Based Pharmaceutical Association Committee (RDPAC)*, formulates and regularly reviews compliance management systems, anti-corruption policies and business ethics systems and standards such as the *Trade Secret Protection Management System*, the *Employee Complaint and Whistleblowing Management System* and the *Third Party Code of Conduct Management System*, clarify the compliance management requirements for the behavior of employees, suppliers and other relevant parties, and resolutely prevent bribery, extortion, fraud, money laundering and unfair competition. During the Year, Zhifei further improved the *Measures for Handling Violations by Market Personnel* and tightened the compliance management requirements simultaneously. In response to employees' false reimbursement behavior, the Company has further strengthened the punishment on the basis of upholding the "zero tolerance" attitude. Once verified, the Company has the right to terminate the labor contract, and at the same time, a new punishment clause has been added, which clearly covers the violation of laws, regulations or company systems in marketing, government procurement and other business links.

In order to drive the efficient operation of the compliance management system, the Company deeply integrated digital technology, built a compliance management information platform, and opened the full link of promotion plan declaration, behavior control, budget management, expense reimbursement and file filing, so as to realize full-link closed-loop management and full-process traceability. In addition, the internal audit department of the Company regularly carries out audits covering all business lines to verify the implementation of the compliance management system, anti-corruption policies and business ethics standards; For key projects, the Company implemented full-process tracking and control, and established a complete cycle management and control model including preliminary review, mid-term review and post-review of projects.

The Company has established an effective compliance, business ethics and anti-corruption management structure, which is divided into decision-making, management and executive levels: the Board of Directors of the Company is the highest decision-making body for compliance, business ethics and anti-corruption matters; The Company has established a special compliance committee, comprising the chief compliance officer, senior management and heads of relevant departments, which is directly responsible for the management of compliance, business ethics and anti-corruption matters of the Company, and performs the duties of considering major compliance matters, conducting compliance risk assessment and discussion on risk handling in strict compliance with the Rules of *Procedure of the Compliance Committee*, and reports to the Board; In addition, the Legal Compliance Department, the Risk Control Department and other departments, as the compliance management execution departments, are responsible for timely identifying compliance requirements in the focused areas, optimizing compliance management measures, and implementing compliance management systems and execution procedures.

Under the supervision and guidance of the Audit Committee of the Board, the Internal Audit Department independently conducts internal audit work on all departments of the Company, its holding subsidiaries and relevant associated companies to evaluate the effectiveness of internal control. Its audit scope covers all business operations related to financial reporting and information disclosure, including procurement, human resources, information system management, etc., and makes recommendations and urges rectification of all problems found in the audit.

Compliance Management Framework



In 2025

The Compliance Committee held nearly **50** meetings

Compliance Management Framework

Zhifei adheres to the "zero tolerance" principle for behaviors such as commercial bribery, embezzlement, and money laundering. It takes multiple measures to comprehensively implement the full-process control of prevention, identification, correction, and punishment of violations, deeply integrates the core concepts of integrity in operations and self-discipline into all aspects of daily management, and effectively builds a defense barrier against compliance risks.

Capabilities

To strengthen the awareness of honest employment, the Company requires all employees to sign the *Compliance Commitment Letter* and the *Compliance Convention on Integrity and Self-discipline*. This year, to enable employees to fully understand and agree with the Company's compliance policy, the Company further requires employees to state in the "Compliance Commitment Letter" signed by new employees that they will abide by laws related to anti-bribery and corruption and clearly promise not to take any illegal actions to seek commercial interests, trading opportunities, or unfair competitive advantages.

The Company has established a strict cooperation access and compliance control mechanism for relevant suppliers, customers, and third parties in product promotion, academic conference cooperation, storage and distribution, etc. Before the cooperation, the cooperation parties need to sign the *Integrity Agreement* or embed business ethics clauses to clarify compliance management requirements such as anti-corruption, anti-bribery, and conflicts of interest. The Company strengthens the compliance control of suppliers with a high sense of responsibility, entrusts a third-party due diligence institution to conduct special compliance due diligence and conflicts of interest investigations on suppliers to be cooperated with, such as academic conference cooperation societies and storage and distribution providers, and comprehensively evaluates the feasibility of cooperation. If any non-compliant behaviors such as commercial bribery and embezzlement are found in the cooperation parties, the cooperation will be terminated immediately. At the same time, the Company requires the cooperation partners to issue compliance commitments. After the relevant supporting materials and due diligence report results are jointly reviewed and approved by multiple departments, a formal cooperation relationship can be established. In 2025, the Company further expanded the scope of signing business ethics statements or clauses and reserved the right to conduct compliance inspections on the cooperation parties. This year, the Company also conducted a conflicts of interest survey on employees and lecturers, etc., and implemented targeted mitigation measures for substantial conflicts of interest to resolve conflicts of interest and prevent potential adverse impacts.

To continuously enhance the compliance awareness and business ethics of all directors and employees, the Company has established a compliance and business ethics training system covering all employees (including full-time employees and third-party personnel involved in operations). It conducts comprehensive publicity and education on multiple themes such as anti-commercial bribery, anti-corruption, anti-unfair competition, publicity compliance, compliance in the use of sales data, confidentiality, responsible marketing, and intellectual property protection to prevent behaviors that violate laws and regulations, industry norms, and the Company's business ethics guidelines. In addition, the Company explicitly requires suppliers to conduct anti-commercial bribery compliance training for their employees and keep relevant records. In 2025, the Company adopted a combination of online and offline methods to conduct multiple compliance training sessions for all employees through full-staff meetings, special market meetings, and new employee onboarding training. It also increased the intensity of special compliance training for potential risks such as commercial bribery and drug advertising in the implementation of the people-benefiting projects. The Company also published anti-commercial bribery tips on the training platform, and helped employees identify risk scenarios and master compliance requirements by interpreting the scope of application, prohibited behaviors, and reporting mechanisms of anti-commercial bribery and anti-corruption policies in combination with typical cases. This year, the Company organized three full-staff compliance tests, and the test pass rate was 100%, ensuring that employees deeply understand and practice compliance codes of conduct.

In 2025

The Company carried out 154 compliance training sessions	Covering more than 72,000 person-times in total	The employees who received moral standard training accounted for 100% of all employees	
--	---	--	--

Monitoring

To further strengthen the prevention and control of compliance risks, the Company continued to promote internal and external compliance inspection work. At the internal level, under the overall organization of the Risk Control Department, the Company carried out surprise inspections on academic conferences on a regular basis. This year, to systematically prevent the risks of violating relevant laws and regulations such as the *Advertising Law* and *the Drug Administration Law*, the Company included promotional materials in the key scope of compliance inspections, strictly supervised the standardized use of promotional materials, and organized special compliance training on promotional materials several times. The Company seriously punished all illegal behaviors found during the surprise inspections and internal verifications in accordance with regulations. At the external level, the Company cooperated with two suppliers to conduct global compliance audits this year and promptly implemented rectification and optimization work based on the reasonable suggestions put forward in the audits.

In addition, the Company continued to smooth the internal and external channels for complaints and reports and specially set up a reporting mailbox to encourage stakeholders such as employees, suppliers, and customers to supervise and report suspected illegal behaviors. It also handled various reports in accordance with internal regulations such as the *Complaint and Report System* and the *Employee Complaints and Reports Management System*. To protect the legitimate rights and interests of reporters, the Company established and continuously improved the reporter protection mechanism, providing confidentiality management, legal aid, etc. for reporters. It clearly stipulated that information such as the reporter's name, affiliated unit, position, and contact information should only be used for investigation and evidence collection or notification of the processing results, and it was strictly prohibited for anyone to disclose such information to the complained party or the reporter, effectively preventing malicious retaliation against reporters.


Punishment

The Company established and strictly implemented a mechanism for punishing violations. Based on the nature, degree of harm, and scope of influence of the violations, it imposed corresponding disciplinary punishments on the involved personnel. At the same time, it continued to supervise, educate, and guide them to correct and rectify, so as to prevent the recurrence of similar violations.



Guided by Party Building, Empowering Development

In 2025, Zhifei will adhere to the guidance of * Thought on Socialism with Chinese Characteristics for a New Era, fully implement the spirit of the 20th National Congress of the Communist Party of China and the Second, Third and Fourth Plenary Sessions of the 20th Central Committee of the Communist Party of China, and promote the deep integration of Party building and corporate operations. As a biopharmaceutical company, we take this opportunity to actively assume social responsibilities: integrate the Party's education philosophy into team building and talent training to help employees grow; In the ideological construction and work style construction, strictly implement the spiritual requirements of the Party, tempering pragmatic work style; At the same time, we will continue to promote the brand building of party building, promote the coordination of party building work and business development, and demonstrate the responsibility and responsibility of biopharmaceutical companies to protect public health with pragmatic actions.



Organizational Talent Cultivation

Zhifei adheres to the guidance of Party building, aggregates ideological consensus, and pools development strength. The Party committee always puts political construction in the first place, strictly implements the "dual-entry, cross-appointment" mechanism, and deeply integrates the Party committee leadership team into the corporate governance structure. Among the seven members of the Party committee leadership team, Comrade Jiang Rensheng, the chairman of the board, also serves as the secretary of the Party committee, and the other members are all senior executives in charge of core fields such as strategy, market, human resources, and legal affairs, comprehensively coordinating and overseeing corporate governance and major business decisions. At the same time, the Party committee has set up Party member vanguard posts in important positions to give full play to the leading role of Party members. It has deeply promoted and continuously implemented the "Three Cultivations" talent project, that is, cultivating Party members into business backbones, developing business backbones into Party members, and promoting outstanding Party member backbones to middle and senior management positions.

As of December 31, 2025		
A total of 22 Party branches have been established across the country	201 registered Party members	The proportion of Party members in the senior management team exceeded 50%
This year The Company added 2 Party membership applicants	2 probationary Party members	4 probationary Party members were successfully converted, continuously replenishing new forces for the Party organization



Characteristic Brand Building

Zhifei deepens the brand building of party building, deeply integrates party building culture with corporate culture, and carefully builds the characteristic brand of "party building, navigating and protecting health". Focusing on this brand, the Company systematically implements four projects of "consolidating roots and casting soul, shaping practices and improving quality, gathering seedlings and prospering talents, and keeping integrity and trust" to create a clean and upright party building ecology. In May 2025, the project won the honor of "Top 10 Cases of Party Building Work in the 'Two Enterprises and Three New Fields in Jiangbei District, Chongqing'", fully demonstrating the demonstration effect of Party Building Work in the field of non-public economy.

In May 2025, this project won the honor of **Top 10 Cases of Party Building Work in the 'Two Enterprises and Three New Fields in Jiangbei District, Chongqing'** fully demonstrating the exemplary effect of Party building work in the non-public economic field.



In 2025, the Company continued to strengthen the construction of the Party building publicity platform. It produced a total of **13** Party building activity briefings, Released **7** WeChat official account publicity articles and **8** media publicity articles, comprehensively spreading the voice and positive energy of Party building.



Discipline and Work Style Construction

The Party Committee of Zhifei adheres to strengthening the work style construction with a strict tone, thoroughly implements the spirit of the eight regulations of the Central Committee, and resolutely corrects formalism and bureaucracy. Throughout the year, all Party branches of the Company successively carried out special studies, emphasizing the need to put an end to the "four winds" problem, strengthen the construction of the Party's work style, conduct in-depth grass-roots research, and practice the mass line with practical actions. Through such study and self-examination, the Company guides Party members and cadres to transform "integrity and self-discipline" and "pragmatic responsibility" into endogenous motivation to overcome difficulties, effectively improve management efficiency and execution, and provide strong disciplinary guarantee for the Company's compliance and high-quality development in a complex market environment.

In 2025, The Company carried out more than **30** internal Party building activities, **8** Party building joint activities with external units.



Micro-Scenes of Party Building Activities

Red-themed Movie-watching Activity: "Remember History and Forge Ahead with Courage"

From August to September 2025, the Company organized Party members to watch the movie "Nanjing Photo Studio", aiming to inherit the red gene, stimulate patriotism, and transform the inspiration from the movie into a sense of responsibility and dedication in work. Party members are encouraged to do their jobs well based on their positions and contribute to the development of the enterprise and the progress of the country.



Round-table Conference on "Guided by Party Building for High-quality Development of the Biotech Industry Chain"

The Company continuously builds the "Red Gene" biotech industry chain brand. It joined hands with 9 units including subsidiaries, partner enterprises, and relevant government departments to establish a joint Party committee for the industry chain and held a round-table conference on "Guided by Party Building for High-quality Development of the Biotech Industry Chain" to explore the integration path of Party building and high-quality development of the industry chain.



Fire Safety Promotion and Drill Activity

The Party members of the Company gave full play to their exemplary vanguard role. They took the lead in participating in the fire safety training and emergency drill at the warehousing and logistics base, and comprehensively investigated potential safety hazards in base facilities, fire-fighting equipment, and evacuation channels to strengthen the safety defense line.




Dedication in R&D for Health and Wellbeing

Zhifei adheres to the innovation-driven development strategy, takes serving the health needs of the public as the orientation, and constructs a scientific and reasonable R&D and innovation governance system, strategic path, and risk-opportunity management mechanism. The Company accelerates the transformation of R&D pipelines through platform-based technological breakthroughs and strengthens the industry's competitive barriers through matrix-based layout. While protecting the health of the public, it drives the long-term sustainable development of the Company.



Innovation Guided by Ethics

Zhifei has always adhered to the corporate tenet of "social benefit go before corporate profits", deeply cultivated the field of biopharmaceuticals, improved the R&D and innovation system, strictly abided by laws, regulations and ethical norms, ensured the scientific, compliant, orderly and efficient advancement of R&D work, and consolidated the image of a responsible biopharmaceutical company.



Organizational Guarantee

Zhifei incorporates R&D and innovation governance into the top-level design of the Company's sustainability Governance framework to ensure that R&D issues are highly coordinated with the Company's long-term strategy. Under the overall deployment of the Board of Directors and the Strategy and Sustainable Development Committee, the Company organizes feasibility analysis and project initiation demonstration for R&D and innovation projects and is responsible for project management. The project leader takes the lead in the full-life-cycle management of products, fulfilling the full-process management responsibilities from project initiation, process review, change management to the protection of R&D achievements. The functional departments of subsidiaries are responsible for the implementation of R&D, clinical trials, registration, quality control, and production transfer, fully assuming the implementation responsibilities for R&D and innovation.

The Company has built a scientific and technological innovation platform system, forming a strategic layout of three R&D and production bases, namely Zhifei Lvzhu, Zhifei Longcom, and Chen'an Bio, and the Beijing Innovation Incubation Center. Zhifei Lvzhu and Zhifei Longcom focus on the cause of disease prevention and steadily advance their R&D pipelines. Chen'an Bio focuses on metabolic diseases such as diabetes and obesity, and arranges R&D pipelines around GLP-1 analogs, insulin analogs, etc., achieving coordinated development of "prevention & treatment". The Beijing Innovation Incubation Center closely tracks the cutting-edge biomedical technologies, explores efficient incubation management mechanisms, actively links universities, research institutes and innovative enterprises, integrates technology, talents and platform resources through cross-domain collaborative innovation, focuses on layout and promotion of source technological innovation and forward-looking research, and concentrates resources to overcome key core technical problems in the industry.

Institutional Guarantee

To actively align with the Company's overall strategic layout, the Company has formulated the *Management System for Research and Development of Scientific Research Projects (Trial)* and the *Interim Measures for the Administration and Incentives of Scientific Research Achievements*, covering aspects such as R&D project initiation management, project management, and production transfer management. These measures standardize the full-cycle management of scientific research projects, improve R&D efficiency and quality, and ensure the smooth implementation of projects.

Optimize the R&D management system

Promote a modular R&D management system, covering modules such as R&D document management, R&D product management, R&D technology management, registration management, and clinical stage management. Through systematic integration, the overall optimization and upgrade of the R&D management system was realized.

Improve R&D management efficiency

In order to systematically improve the efficiency of R&D management, the Company continued to promote the comprehensive optimization of the R&D process, and effectively streamlined redundant links and simplified operating procedures through implementing regional management of small-scale and pilot workshops, optimizing the design of environmental cleaning and disinfection records, and strengthening the management of key batches of products, thereby further improving the overall R&D efficiency.

Implement R&D compliance management

Keep up with regulatory trends, benchmark against the latest regulatory requirements, conduct difference analysis, and update R&D quality management documents; standardize R&D data management, strengthen data traceability, and enhance the compliance awareness and professional capabilities of R&D personnel.

Ethical Safeguards

Zhifei strictly adheres to science and technology ethics norms, implements measures such as ethical supervision of clinical trials, ethical management of animal experiments, and substitution of animal-derived substances, strengthens ethical compliance awareness, and promotes responsible innovation in the biopharmaceutical field.

In 2025, the Company **did not** engage in any behavior that violated science and technology ethics.⁴

Clinical Ethics

The Company always puts the rights and safety of subjects first, strictly abides by laws and regulations such as the *Good Clinical Practice (GCP)*, the *Development Safety Update Report (Trial)*, and the *Good Pharmacovigilance Practices (GVP)*. It provides corresponding materials as required by the ethics committees of each province and institution, conducts clinical trials after approval, and regularly submits corresponding reports to the ethics committee during the implementation process to ensure that clinical R&D activities meet ethical requirements.

The Company has established a sound clinical quality management system, comprehensively sorted out clinical standard operating procedures and management charter, covering important sectors such as quality manual, clinical operation, medical affairs, project management, risk management, problem management, quality control and intellectual property management, and combined with clinical trial quality management practice, formed a clinical trial quality management system applicable to the Company's management process, and standardized the key links of the whole process of clinical trial such as quality control, data management, subject protection, risk assessment and adverse event reporting.

Based on this system, the Company continuously optimizes clinical digital management methods. It enhances the scientificity and reliability of data collection through electronic data capture systems and emergency unblinding systems. Meanwhile, the Company conducts internal reviews and third-party audits, strengthens ethical supervision of clinical research, and regularly carries out training and assessments on clinical safety knowledge and medical ethics to improve the professional qualities of the clinical team and ensure the compliance of clinical trials and the safety of subjects.

Animal Ethics

The Company has formulated management systems such as the *Good Laboratory Practice for Animal Experiments*, the *Standard Operating Procedures for the Welfare and Ethical Review of Laboratory Animals*, and the *Standard Operating Procedures for Animal Welfare, Ethical Review, and Biosafety Management* to standardize the process of animal experiments and effectively protect animal welfare. In addition, Zhifei Longcom has established an Experimental Animal Welfare and Ethics Committee to conduct full-process ethical review and supervision of animal experiment projects.

At the same time, the Company fully follows the "3R" principle of "reduce, replace and refine", actively promotes the replacement of animal-derived substances, optimizes vaccine production processes, adopts non-animal-derived component detection technologies, deepens the research and application of non-animal-derived vaccine production, and formulates vaccine production plans that meet ethical standards.



4. All data in this section contain Chen'an Bio

Animal Ethics Practice

Adoption of Genetically Engineered Trypsin

- Genetically engineered trypsin is used to replace animal-derived trypsin. It is produced through microbial fermentation without the need for animal-derived substances. This eliminates the risk of pathogen contamination that may be caused by the use of animal-derived trypsin in traditional vaccine production.

Animal-derived Substance Replacement Technology


- The cell culture technology is improved. The "Serum-free synthetic medium (containing recombinant transferrin)" is used to culture cells, which enhances the adaptability of cells to low-serum or serum-free media and reduces the dependence on newborn bovine serum.
- The completely synthetic culture medium is adopted to realize cell culture and bacterial fermentation without animal-derived substances through accurately proportioned chemical synthesis components, thereby ensuring the quality of vaccine production.
- Introduce serum substitutes, use recombinant proteins, immune factors, specific growth factors, etc. to replace some functional components in animal serum, improve virus expression level, ensure vaccine quality and consistency, avoid impurities or immune response risks that may be brought by animal serum and other components, reduce ethical problems in animal feeding, slaughter and extraction, and meet modern biotechnology and animal welfare standards.

Reduction of the Use of Limulus Amebocyte Lysate (LAL)

- The dynamic chromogenic assay is used to replace the traditional gel methods, which improves the detection efficiency and reduces the use of Limulus Amebocyte Lysate (LAL) by 50% to protect the endangered Chinese horseshoe crab and promote the upgrading of biological detection technology.
- The Company pays attention to the application of recombinant Factor C (rFC) and recombinant Limulus Amebocyte Lysate (rLAL) at home and abroad. This technology has been recognized by the FDA and can completely replace traditional Limulus Amebocyte Lysate (LAL). The Company is continuously monitoring the development and verification progress in the industry.

Exploration of New Animal-free Experiment Technologies

Actively pay attention to the application of non-animal experiment methods at home and abroad, and explore more efficient and sustainable biological detection technologies, including:



Strategic Guidance for a Healthy Future


Zhifei adheres to the R&D and innovation strategy of "Independent R&D as a priority, cooperative R&D as a supplement and investment and incubation as a complement". It accurately seizes the opportunities of new quality productive forces, proactively manages R&D and innovation risks, improves R&D capabilities, promotes intellectual property protection, deepens the integration of industry, academia, research, and application, accelerates technology transformation, and realizes the two-way empowerment of innovation value and social benefits.

In the process of formulating the R&D and innovation strategy, Zhifei fully considers its own operational characteristics and development plans, combines external factors such as market demand and industry trends, and identifies R&D and innovation risks and opportunities that have substantial financial and non-financial impacts on its own business and value chain to anchor the future direction.

Risks/Opportunities and Their Impacts		Response Measures
	Technical risks	The R&D of biological products is characterized by large investment, long cycle, and high risk. There are uncertain factors in the product R&D process.
	Policy risks	The biopharmaceutical industry, especially the vaccine industry, is subject to strict policy supervision. With the rapid development of the social economy and the profound transformation of the biopharmaceutical industry, changes in industry policies may have unpredictable impacts on the Company's R&D and production.
	Market risks	The sales of the Company's products are affected by multiple factors such as macro policies, product supply, and market demand. If the Company actively invests in product R&D and innovation, its products may face overstock or shortages when the above factors change.
	Products and services	The Company continuously promotes product R&D and innovation. Innovative products will help attract more new customers, expand market share, and enhance the Company's competitive edge.
		Relying on its strong R&D strength, the Company has a rich reserve of R&D projects, a reasonable echelon layout of product pipelines, adheres to risk management and control, strengthens the construction of the R&D team, and reduces the risks of product R&D.
		The Company strictly complies with the requirements of various laws, regulations, and regulatory documents, improves and implements enterprise management systems, closely monitors policy changes, and promptly adjusts business strategies to meet regulatory and compliance requirements.
		The Company follows a production model based on sales to produce innovative products and adjusts the procurement plan of agency products in a timely manner according to changes in market demand.
		The Company closely follows policy guidance, continuously consolidates and enhances its R&D and innovation capabilities, accurately grasps new situations, changes, and requirements to better embrace technological innovation and industrial upgrading, and launches more innovative products.

Enhance R&D and Original Innovation

Adhering to the R&D philosophy of "internationalization of project sources, precision of project selection, pipeline of project development and localization of project production", the Company focuses on the iterative upgrading of traditional products and the construction of barriers to innovative technologies, forming a rich pipeline under research. The Company has built the "Seven + N" technology platforms to realize the optimal allocation of R&D resources by covering a wide range of R&D paths, providing a solid technical base for ensuring the efficient advancement of various R&D projects. Relying on the "Seven + N" technology platform, the Company has also successfully built seven product matrices with outstanding technical advantages, significant clinical value and reasonable echelon distribution, covering the fields of prevention and treatment, and continuously consolidating its core competitiveness.



The Company attaches great importance to the construction of the R&D talent team, focuses on improving the professional capabilities of the team, and enhances R&D efficiency and innovation quality. The Company organizes R&D personnel to participate in training covering project management, R&D quality management, drug registration, process technology, quality research, and the latest regulatory policies every year. The R&D series of training covers all R&D personnel, strengthens their professional qualities and standardized operation capabilities, and provides sustainable intellectual resource support for high-quality R&D.

The Second R&D Training Series of Zhifei

From March to December 2025, Zhifeiologics conducted its second series of R&D training programs, focusing on R&D capacity building and technical exchange. Centered on two main themes—process development and regulatory affairs—the programs systematically covered key areas such as cultivation, purification, formulation, quality control, safety evaluation, as well as antigen design, on-site inspections, and process planning. The training attracted a cumulative total of over 3,000 participants across both online and in-person sessions, effectively promoting the sharing of internal R&D expertise and fostering collaborative innovation.



• The Second R&D Training Series of Zhifei

R&D Capacity Improvement Training of Zhifei Lvzhu

In 2025, Zhifei Lvzhu organized a number of R&D capacity improvement training programs. Training was carried out on topics such as the development trend of the vaccine industry, international registration, sequence design and patent mining, construction of inactivated vaccine virus strains, development of fermentation and purification processes, adjuvant quality control, and formulation design. It covered key links in technology development, regulatory requirements, intellectual property management, and pharmaceutical research, systematically explaining the core technologies and practical points at each stage of vaccine R&D, and effectively improving the professional capabilities and comprehensive levels of R&D personnel.



• R&D Capacity Improvement Training of Zhifei Lvzhu

Special Training on R&D Quality Management of Zhifei Longcom

In 2025, Zhifei Longcom carried out special training on R&D quality management. By explaining the three core modules of R&D technology management, registration management, and R&D product management, it strengthened the front-end risk awareness and whole-process traceability ability of R&D personnel, laying a solid foundation for improving project efficiency and reducing development risks.



• R&D Quality Management Training of Zhifei Longcom

Focus on Promoting R&D and Innovation Cooperation

Zhifei focuses on building a collaborative innovation ecosystem of industry-university-research. By breaking the transformation barriers between basic research and industrial application and deepening the multi-party linkage mechanism of universities, research institutions, and enterprises, it effectively shortens the cycle from laboratory to commercialization of cutting-edge technologies.

In terms of academic cooperation, the Company has established good cooperative relationships with more than 20 scientific research institutions, including the Institute of Microbiology, Chinese Academy of Sciences, the National Center for Clinical Research of Infectious Diseases, and the Cancer Prevention Center of Sun Yat-sen University. It conducts clinical research and academic cooperation on projects such as innovative vaccines and tuberculosis prevention and control, continuously strengthening its core technology research and development capabilities.

In terms of industrial cooperation, the Company actively collaborates with leading enterprises in the industry to promote exchanges and cooperation between original innovation and industrialization. In terms of technical cooperation, focusing on its "Seven + N" technology platforms and seven product matrices, the Company conducts external cooperation through multi-dimensional collaborative innovation in aspects such as new antigens, new targets, new adjuvants, and upgrading technologies.

Investing to Explore R&D and Innovation Opportunities

The Company deepens its independent R&D and innovation capabilities in biopharmaceuticals through investment and incubation. While focusing on "preventive medicine", the Company uses the Zhirui Investment platform to layout and incubate and cultivate promising preventive and therapeutic biotechnologies and products through equity investment. It mainly targets areas such as oncology, autoimmune diseases, metabolic diseases, neurodegenerative diseases, and cardiovascular diseases, and has laid out more than 30 R&D projects, including several Class I new drugs in China.

During the Reporting Period, the Company achieved control of Chen'an Bio through capital increase, expanding its self-developed pipeline layout in areas such as GLP-1 and insulin analogs. Chen'an Bio has mastered the Construction technology of recombinant protein strains. By directionally transforming the yeast and Escherichia coli expression systems, it can achieve high-density fermentation and expression of recombinant human insulin and GLP-1 analog precursor protein, and has formed more than ten R&D projects. As a research and production base integrating R&D, clinical research, and production in Chongqing, Chen'an Bio will focus on metabolic diseases such as diabetes and obesity, and become one of the important growth engines for the Company's future therapeutic biopharmaceuticals. Currently, Chen'an Bio's Liraglutide Injection and Insulin Degludec Injection have entered the application stage for market approval. The Semaglutide Injection (Hypoglycemic Indication) has completed Phase III clinical trials, the Semaglutide Injection (Weight Loss Indication) and Insulin Degludec and Insulin Aspart Injection are in Phase III clinical trials, and the GIP and GLP-1 dual-receptor agonist CA111 Injection has entered Phase I clinical trials.

Protecting R&D and Innovation Knowledge Achievements

The Company attaches great importance to the standardized management of intellectual property. It strictly abides by laws and regulations such as the *Patent Law of the People's Republic of China* and the *Trademark Law of the People's Republic of China in intellectual property management*. The Company's patent management department is responsible for overall management of patent-related work and formulates the Patent Application and Management Policy, which covers patent management, patent application mechanism, patent incentive mechanism, R&D results disclosure, and patent risk early-warning, continuously optimizing the principles and processes of intellectual property management.


Patent Management Specifications
The Company formulates internal systems related to intellectual property protection, clarifying the processes for patent application, maintenance, and information change; it builds an online intellectual property management system to achieve full-lifecycle process management.

Patent Filing Awards
In accordance with *the Implementation Measures for the Management and Reward of Scientific Research Achievements (for Trial Implementation)*, employees are provided with comprehensive patent application support and rewards to encourage innovation. After the solution is successfully transformed into a patent achievement, corresponding rewards will be given according to the reward mechanism.

Patent Database
The Company introduces a patent database and specialized databases to provide professional information support for R&D project initiation and efficient project execution, avoiding infringement risks.

Intellectual Property Training
In 2025, the Company organized four training sessions on topics such as patent mining and creativity review to maximize the protection of the Company's innovation achievements and promote the protection of technological innovation and core competitiveness.

Assessing Impacts and Seizing Opportunities



Zhifei has established a sound risk management and internal control system, standardizing the procedures for identifying, evaluating, and reporting major risks, and examining the effectiveness of various risk response mechanisms to adapt to changes in the external environment and updates in internal requirements. This is conducive to the Company's scientific decision-making, risk prevention, and opportunity seizing, ensuring the Company's sustainable operation. At the same time, during the Reporting Period, the Company conducted a double materiality assessment of ESG issues. By analyzing the impacts, risks, and opportunities of various sustainability-related matters, it clarified major management and disclosure items. With the effective operation of the Company's risk management and internal control system and further research on the double materiality assessment, the Company identified R&D and innovation as the most material issue. For more details on relevant mechanisms and assessment results, please refer to the *Risk Management and Internal Control* and *Double Materiality Assessment* sections of this report.

In the daily management of risks and opportunities related to R&D and innovation, the Company regularly conducts special self-inspections, covering key modules such as document management, retention samples of clinical trial drugs, material sample retention, and drug shipment. It practices the concept of "quality-by-design" to effectively reduce quality, process, and compliance risks in the R&D and production processes. At the same time, the Company has formulated relevant management systems to timely assess the possibility of occurrence and impact of identified R&D and innovation risks, formulate effective management measures, strengthen the acceptance of each key node, and ensure that relevant risks and their impact are within a controllable range. In addition, the Company continuously monitors changes in the external environment such as policy changes, market demand, and technological development to capture potential growth points and emerging trends. The Company also conducts in-depth analysis of its own resources and advantages, and matches the identified opportunities based on the Company's core capabilities to ensure the consistency between the R&D innovation direction and the long-term strategy.



Efficient Advancement and Pipeline Breakthroughs⁵

Zhifei continuously increases its R&D investment to provide solid support for technological innovation. In recent years, the R&D investment has been steadily increasing, the scale and strength of the R&D team have been continuously enhanced, and innovation achievements have been emerging at an accelerated pace, injecting strong impetus into the high-quality development of the enterprise.

During the Reporting Period, Zhifei

The R&D investment reached	The cumulative R&D investment in the past five years exceeded	
RMB 1.436 billion	RMB 6 billion	
The R&D team reached	Accounting for	A total of 89 authorized patents (including overseas patents) were obtained, 77 of them are within the validity period of the patent
1,109 people	17.63% of all employees	

The Company efficiently promoted the pipeline under development, accelerated product updates and iterations, and helped the Company create greater social and economic benefits. As at the end of the Reporting Period, the Company had a total of 35 preventive independent research projects, of which 26 were in the stage of application, clinical trial and registration application; Chen'an Bio, a holding subsidiary of the Company, has laid out independent therapeutic research projects, and has entered 6 key research projects in the clinical stage, of which 2 are under listing review.

Note: The following is the progress of the main pipelines under development as of the end of the reporting period, which demonstrates the Company's deep product reserves and sustainable growth potential.

Overview of the Progress of R&D Projects

Name of R&D project ⁶	Pre-clinical	Application for clinical trial	Phase I clinical trial	Phase II clinical trial	Phase III clinical trial	Completed Phase III clinical trials	Marketing application
Rabies Vaccine(Human Diploid Cell)for Human Use, Freeze-dried Use	[Progress bar]						Under review
15-Valent Pneumococcal Conjugate Vaccine	[Progress bar]						Under review

5. All data in this section contain Chen'an Bio
6. The above does not cover all independent research projects of the Company

Name of R&D project	Pre-clinical	Application for clinical trial	Phase I clinical trial	Phase II clinical trial	Phase III clinical trial	Completed Phase III clinical trials	Marketing application
ACYW135 Meningococcal Conjugate Vaccine	[Progress bar]						Under review
Liraglutide Injection	[Progress bar]						Under review
Insulin Degludec Injection	[Progress bar]						Under review
Semaglutide Injection (Indication: Type II Diabetes)	[Progress bar]						Completed
Semaglutide Injection (Indication: Overweight/Obesity)	[Progress bar]						In progress
Insulin Degludec and Insulin Aspart Injection	[Progress bar]						Completed
Rabies Vaccine (Vero Cell)for Human Use, Freeze-dried	[Progress bar]						In progress
S. Flexneri and S. Sonnei Bivalent Shigella Conjugate Vaccine	[Progress bar]						In progress
Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed	[Progress bar]						In progress
Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)	[Progress bar]						In progress
Therapeutic BCG Vaccine	[Progress bar]						In progress
CA111 Injection	[Progress bar]						In progress

Name of R&D project ⁶	Pre-clinical	Application for clinical trial	Phase I clinical trial	Phase II clinical trial	Phase III clinical trial	Completed Phase III clinical trials	Marketing application
Recombinant Tuberculosis Vaccine (AEC/BC02), Freeze-dried				In progress			
BCG-PPD				In progress			
26-Valent Pneumococcal Conjugate Vaccine				Phase I/II			
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant				Phase I/II			
BCG Vaccine for Intradermal Injection			In progress				
Inactivated Rotavirus Vaccine			In progress				
Recombinant Group B Meningococcal Vaccine (E. coli)			In progress				
Tetanus Vaccine, Adsorbed			In progress				
Influenza Vaccine(Split Virion), Inactivated, Trivalent, ZFA02 Adjuvant					Phase I/III		
Diphtheria, Tetanus and Acellular Pertussis Adsorbed (Component) and Haemophilus Type b Conjugate Vaccine			Approved				
Recombinant Zoster Vaccine (CHO cell)			Approved				
Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine for Adult and Adolescent, Adsorbed			Approved	1.19			
Varicella Vaccine, Inactivated, Freeze-dried			Approved				
Recombinant Zoster Vaccine (CHO cell), ZFA01			Approved				

Name of R&D project	Pre-clinical	Application for clinical trial	Phase I clinical trial	Phase II clinical trial	Phase III clinical trial	Completed Phase III clinical trials	Marketing application
MVA Mpox Live Attenuated Vaccine			Approved				
HK.3-JN.1 SARS-CoV-2 mRNA Vaccine			Approved				
Zoster Vaccine (mRNA)			Approved				
Japanese Encephalitis Vaccine (Human Diploid Cell), Inactivated, Freeze-dried		Accepted					
RSV Vaccine	Preclinical research						
Quadrivalent Inactivated HFMD Vaccine	Preclinical research						
EBV Vaccine	Preclinical research						
Pentavalent Meningococcal Conjugate Vaccine	Preclinical research						
Rabies Vaccine (ZFB-3 Cell) for Human Use, Freeze-dried	Preclinical research						
Pertussis OMV Vaccine	Preclinical research						
Diphtheria, Tetanus and Pertussis-based Combined Vaccine	Preclinical research						
Recombinant Hepatitis B Vaccine (Hansenula Polymorpha)	Preclinical research						
Recombinant Rotavirus Vaccine	Preclinical research						

6. The above does not cover all independent research projects of the Company

B

Quality First for Product Responsibility

Zhifei is committed to fulfilling its original aspiration of safeguarding human health. It integrates high-standard quality requirements throughout the entire product lifecycle and drives the improvement of product and service quality through refined management. The Company is dedicated to promoting the accessibility, affordability, and standardized use of high-quality products among a wider population. It also actively participates in the development of global public health initiatives, using reliable products and professional support to contribute to disease prevention and health promotion, and making "Zhifei's contribution" to strengthening the human immune defense.



Quality Assurance and Responsibility First

Zhifei adheres to the core concept of "quality first" and integrates its commitment to quality into the entire process of product R&D, manufacturing, and post-marketing quality management. The Company is committed to building a closed-loop quality governance system covering the entire product lifecycle. It strengthens the compliance foundation through regular audits and testing mechanisms and takes public health as the core to drive the dynamic upgrade of the product safety management system.

As of the end of the Reporting Period, the Company has **not experienced** any major safety and quality liability accidents related to its products and services.

Quality Management System

Zhifei strictly complies with laws, regulations, and industry standards such as the *Drug Administration Law of the People's Republic of China*, the *Vaccine Administration Law of the People's Republic of China*, the *Pharmacopoeia of the People's Republic of China*, the *Good Manufacturing Practice of Medical Products (GMP)*, and the *Good Supply Practice (GSP)*. It has established a system matrix centered around the *Quality System Documentation Management Policy* and the *Quality Policy and Objective Management Protocol*. At the same time, the Company actively aligns with the quality standards of international authoritative organizations such as the World Health Organization (WHO), the U.S. Food and Drug Administration (FDA), and the International Conference on Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) to ensure that product quality consistently meets global mainstream regulatory requirements.

Quality Management Operation Mechanism

The Company has established a quality leadership group to coordinate the construction of the quality assurance system, organize, and supervise the implementation of the quality policy and objectives. Relying on a professional quality assurance team, the Company conducts full-process risk management and control of key quality management links. At the same time, referring to the *Provisions on the Supervision and Administration of the Fulfillment of Medicinal Product Quality and Safety Responsibilities by Holders of Marketing Authorization for Medicinal Products*, the Company has established a regular analysis and evaluation mechanism, held regular quality analysis meetings, and strictly implemented corrective and preventive actions (CAPA) to achieve continuous improvement in the operation level of the quality management system.

Digital Ecosystem for Quality Management

Through the matrix application of platforms such as Quality Management System (QMS), Manufacturing Execution System (MES), Laboratory Information Management System (LIMS), Warehouse Management System (WMS), and Supervisory Control and Data Acquisition System (SCADA), the Company realizes digital collaboration from production execution to quality control, strongly supporting the continuous stability of product quality, and gradually building a modern quality management system featuring "process-driven, data-supported, and closed-loop management".

Quality Management System Certification

As of December 31, 2025, the quality management systems of the Company's headquarters and its subsidiaries Zhifei Longcom, Zhifei Lvzhu, and Zhifei Airport have all passed the ISO 9001:2015 certification; 100% of the production lines of the listed products have passed the GMP certification or compliance inspection.

Full-process Product Quality Management System



In terms of international certifications, the Company has obtained 5 overseas registrations for 3 proprietary products in countries including Pakistan, Uzbekistan, and Indonesia; 2 proprietary products have received halal certification; and 2 proprietary products have obtained declarations of conformity issued by EU Qualified Person. In addition, both Zhifei and Zhifei Airport have obtained Authorized Economic Operator (AEO) certification. Leveraging this comprehensive portfolio of authoritative certifications covering multiple regional markets, the Company is accelerating its global business expansion, while its quality management capabilities have achieved a leap forward in alignment with international best practices.

Quality Inspection

Zhifei regards high-standard quality inspection as a key barrier to safeguard public drug safety. The Company strictly complies with domestic and international regulatory requirements such as GMP and ICH, and continuously improves its quality management system. Through a number of regulations such as the *Standard Operating Procedures for Inspection Management*, and the *Standard Operating Procedures for Self-inspection Management*, it standardizes product management and inspection processes; all batches of products are inspected using strictly verified analytical methods before leaving the factory to ensure accurate and reliable test results and guarantee product quality.

Penetrative Inspection Matrix

The Company has comprehensive product quality inspection capabilities, and the quality inspection process covers the entire process from the entry of raw and auxiliary materials, in-process sample testing, finished product quality inspection to equipment and production process verification. The Company timely identifies potential quality risks through precautionary inspection to ensure stable and controlled product quality.



Independent Organization Structure

Each production base has established a specialized quality inspection department responsible for material and product inspection. Meanwhile, a validation department has been set up to be responsible for the validation and confirmation of facilities and equipment, process methods, and cleaning production procedures, thereby ensuring a high level of safety in production hardware and technical processes.



Strict Release Control Line

Strictly implement systems such as the *Product Release Management Procedure*. Materials and products must undergo full internal inspection and review, and can only be released for distribution after obtaining a biological product batch release certificate.



Zero Tolerance for Defects


For non-conforming products identified during the process, strictly implement the *Standard Operating Procedures for Non-conforming Products*, firmly uphold the bottom line of "not allowed to be used as raw materials for production and not permitted to leave the factory" and safeguard consumer health and interests.

To support high-standard quality inspection, the Company has established a multi-level training and assessment mechanism based on the *Standard Operating Procedures for Technical Evaluation of Inspection Personnel*, and regularly conducts technical improvement and qualification confirmation for inspection personnel. The Company realizes the dynamic overall allocation of talents in key positions through the inspection ability map to ensure that the inspection accuracy meets the top industry standards; a product inspection technical leader is set up in the laboratory to continuously deepen the professional, standardized, and international construction of laboratory testing technology, and comprehensively improve the global competitiveness of quality inspection.

Quality Culture Construction

While consolidating the governance foundation, Zhifei continuously promotes the construction of a company-wide quality culture. The Company formulates and implements the *Standard Operating Procedures for Employee Training Management*, and constructs a multi-dimensional annual training system covering compliance requirements, key position capabilities, and cultural cultivation to guide all employees to form a common quality concept.

The Company continuously expands employees' channels to obtain professional knowledge by building a systematic training database and coordinating and optimizing cross-departmental resources; it organizes employees to participate in special training carried out by national and industry associations to form a continuous learning mechanism combining internal and external learning. The Company promotes knowledge internalization and the combination of learning and application through special discussions and experience sharing, and is equipped with a rigorous assessment and evaluation mechanism to ensure that the training effectiveness is transformed into the continuous optimization of the quality management system. The panoramic training content covers more than a dozen core areas such as 3C management, clean area behavior control, microbial knowledge and application, electronic data and production execution system operation, cold chain storage and transportation, and after-sales quality management, comprehensively improving employees' quality awareness and quality management practice ability.



Implement Compliance Will and Carry out Special Training on the Popularization of Two Laws

In October 2025, Zhifei Longcom carried out a special training on "*Drug Administration Law and Vaccine Administration Law*". Focusing on the core requirements of drug and vaccine production quality management, the training systematically interpreted the key provisions and their applicable scenarios in actual work, helping employees accurately understand the connection points between the spirit of the regulations and operating specifications, effectively unifying the understanding of quality compliance, and strengthening the awareness of performing duties in accordance with laws and regulations.



Special Training on "*Drug Administration Law and Vaccine Administration Law*" by Zhifei Longcom

Review Typical Deviations to Drive Active Quality Risk Defense

In January 2025, based on the GMP scientific management series training, Zhifei Lvzhu carried out a special training on "Deviation Management and Analysis of Deviation Cases in 2024" for typical quality deviations in production management, guiding employees to systematically review the root causes and disposal processes of quality deviations, realizing the transformation from "passive response" to "active defense", and ensuring the effective implementation of quality management requirements at the production front line.

Quality Audit

Zhifei regards quality audit as the fundamental driving force for optimizing operational levels and preventing risks. In 2025, the Company established a dual-wheel audit closed-loop of "endogenous evolution and external cooperation for credibility", strengthening compliance governance across the entire value chain through 39 systematic audits.

12 Internal Quality Audits

The audit scope has been extended deeply across the entire value chain of drug operation. The Company systematically identifies and dynamically addresses risk points across all processes, achieving full coverage of all elements, with a focus on institutional staffing, high-standard factory facilities, equipment validation and operation, end-to-end control of material flow, integrity of the file system, stability of manufacturing processes, quality control capabilities, entrusted testing specifications, rectification of deficiencies identified during registration site inspections, and the safety of cold-chain transportation of pharmaceuticals.

27 External Quality Audits

The Company proactively underwent inspections by the China National Vaccine Control Center, drug regulatory authorities at all levels, and a recertification audit for the ISO 9001:2015 quality management system. No serious deficiencies were identified in any of these external audits, fully validating the robustness of the Company's quality management system. Regarding potential areas for improvement identified during the audits, the Company promptly implemented corrective measures and reported back in a timely manner to ensure that its production and quality control processes remain at the forefront.

Pharmacovigilance System


In the full-life cycle management of drugs, pharmacovigilance is the key support for identifying product risks and ensuring public drug safety. Zhifei strictly adheres to laws, regulations and industry standards such as the *Drug Administration Law of the People's Republic of China*, the *Vaccine Administration Law of the People's Republic of China*, the *Good Pharmacovigilance Practice (GVP)*, and the *Provisions for Adverse Drug Reaction Reporting and Monitoring*, and has built a network for risk monitoring, identification, assessment and control covering the entire R&D, clinical and post-marketing processes of products.

Pharmacovigilance Management System

The Company is committed to consolidating the institutional foundation and operating mechanism of pharmacovigilance. It has formulated and strictly implemented a number of management systems such as the *Standard Operating Procedures for Pharmacovigilance Management* and the *Standard Operating Procedures for Internal Audit of the Pharmacovigilance System*, achieving unified standardization of key links such as organizational structure, job responsibilities, personnel training, internal audit, and information reception, reporting, assessment and risk control.

The Company has established a dedicated Pharmacovigilance Department and built a three-dimensional governance structure involving the Drug Safety Committee, the implementation layer of pharmacovigilance work and relevant business departments. It has also allocated full-time pharmacovigilance personnel, clarified the division of responsibilities and the operating closed-loop, and comprehensively strengthened the safety management and risk control of products throughout their life cycle.

Pharmacovigilance Governance Structure




Drug Safety Information Monitoring

Adhering to the principle of "100% reporting of adverse reactions/events", the Company has formulated and implemented a series of procedures such as the *Standard Operating Procedures for the Management of Communication of Drug Safety Information* and the *Standard Operating Procedures for the Adverse Drug Event Reporting System*. In 2025, the Company continued to upgrade its pharmacovigilance information system. Relying on the "Zhiyitong" and the "Adverse Drug Event Reporting" platforms, it achieved all-round and digital capture of safety information.

The Company implements standardized management of drug safety risks throughout the entire process and implements the management policy of "early discovery, early investigation, early analysis and early response". The Company has clearly defined the reporting procedures, time-limit requirements, evaluation criteria and investigation and analysis mechanisms for drug safety information. After receiving safety information, the professional pharmacovigilance team will strictly conduct relevance evaluation and medical assessment to ensure that each risk signal can be promptly and scientifically handled and feedback, thus achieving a dynamic closed-loop and high-level controllability of product risk management.

Adverse Reaction/Event Handling Process



Pharmacovigilance Training

The Company regards talent development as the core support for the efficient operation of the pharmacovigilance system. The Company has formulated and implemented the *Pharmacovigilance Training Management System*, coordinated internal and external resources, and built a differentiated training matrix covering all employees. The Company conducts basic pharmacovigilance training for all employees to ensure that all levels of personnel have a keen awareness of safety risk identification and can accurately capture and standardize the reporting of safety information. It also provides targeted professional empowerment for key positions such as clinical research, production management and academic promotion, and is equipped with an assessment mechanism to ensure that pharmacovigilance compliance requirements are deeply integrated into all business links.



Benchmarking International Standards to Improve the Ability to Handle Complex Safety Events

In March and November 2025, Zhifei conducted training on pharmacovigilance regulations and the reporting and handling processes of adverse events and human safety information (AE/HSI) for all employees. On this basis, the Company connected with external authoritative resources and organized full-time pharmacovigilance personnel to participate in the "Drug Safety Monitoring and Evaluation Practice Class" of the National Medical Products Administration to deeply study real-case safety reports and regulatory practices. The relevant training results have been successfully applied to pharmacovigilance operations, significantly improving the team's level of safety risk identification and evaluation, and demonstrating the Company's professional leadership in ensuring public drug safety.

Pharmacovigilance Audit

To ensure the effective operation of the system, the Company has established and implemented a regular internal audit and continuous improvement mechanism for the pharmacovigilance system. The Company conducts independent and comprehensive reviews and assessments of core areas such as the organization, personnel and resource allocation of pharmacovigilance, quality management and document records, and adverse drug event monitoring and reporting every year, aiming to ensure the suitability, sufficiency and effectiveness of the system operation. For the identified potential defects, the Company strictly implements corrective and preventive actions (CAPA) to drive the dynamic iteration of the system.



Internal Audit Meeting of the Pharmacovigilance System

Responsible Marketing and Professional Services

Zhifei centers around customer needs, continuously improving its customer service system and strengthening service quality to ensure that customer issues are promptly responded to and effectively resolved. It is committed to providing customers with high-quality products and professional services. The Company always practices responsible marketing and promotion, ensuring the authenticity, transparency, and compliance of product information. It also constructs a comprehensive information security and privacy protection management system covering all aspects such as data collection, storage, and use, safeguarding the legitimate rights and interests of customers throughout the entire process and strengthening the foundation of customer trust.

Creation of Customer Value

Service Delivery System

Focusing on product accessibility and service response speed, the Company has built a three-dimensional service network that reaches the end-users. Under the overall strategic planning of the headquarters, the Company implements a provincial vertical management model, and its service has extended to over 30,000 primary health service points in 31 provinces, autonomous regions, and municipalities directly under the Central Government across the country. Relying on a professional marketing team of over 3,500 people, the Company provides precise technical support and service responses, and ensures continuous high-quality service delivery through professional empowerment programs.

As a supplement to the regular customer communication mechanism, the Company creates a communication window with medical and health professionals through the "Medical Express" project to answer questions about product applications and related medical issues, enhancing the pertinence and effectiveness of professional service responses.

Empowerment Driven by Academic Activities

The Company always adheres to the principle of "science first with rigorous approach" and adopts an "online + offline" integrated model to actively carry out diverse academic exchange and promotion activities. It provides customers and the public with information on product knowledge, disease prevention, immunization, and standardized vaccination, helping relevant personnel in disease control centers and primary vaccination clinics to more scientifically understand products and relevant medical knowledge.


In the field of tuberculosis prevention and control, the Company deepens the consensus on the prevention and control concept of "to end tuberculosis, latent infection must be controlled", contributing to the goal of ending the tuberculosis epidemic by 2035. In the field of preventable diseases in adults, the Company advocates the action plan of "both men and women prevent HPV infection to help eliminate cervical cancer", promotes the popularization of the concept of preventing multiple diseases in patients with chronic diseases, and actively serves the "Healthy China" strategy.

Complaints and Recalls

Zhifei regards customer feedback as the driving force for quality improvement and strictly complies with industry standards such as the *Good Manufacturing Practice of Medical Products*, the *Good Supply Practice*. It has established a closed-loop service system for the entire product lifecycle.

Agile Complaint Response

Based on internal regulations such as the *Quality Complaint Management Policy* and the *Standard Operating Procedures for the Management of Customer Complaints*, the Company has built an omnichannel customer response network, integrating hotlines, email, and digital platforms to immediately handle customer requests. The Company implements a hierarchical and classified disposal mechanism for customer complaints: the Medical Affairs Department is responsible for consulting, tracking, and handling safety issues such as suspected adverse reactions of products; the Quality Management Department coordinates and organizes relevant investigations; the Marketing Department follows up on service feedback; and the Administrative Office handles government affairs, ensuring that the disposal process is standardized, transparent, and highly responsive.




Drug Recall Mechanism

The Company has formulated and strictly implemented internal systems such as the *Regulations on Drug Recall Management* and the *Regulations on Product Recall Management*. In accordance with national requirements, a three-level recall mechanism has been established based on the degree of potential safety hazards and risks. The process of drug recall handling is clearly defined, covering key links such as investigation and assessment of drug safety hazards, determination of recall levels, recall notices, and subsequent disposal. The Company regularly conducts annual practical drills for simulated drug recalls to verify the execution of the recall procedures and the effectiveness of traceability management. In 2025, the Company organized 3 drills in total, and the results confirmed that the recall process was smooth, product traceability was standardized, and the recall system was operating efficiently. Since its establishment, the Company has not experienced any actual product recall incidents.

Satisfaction Survey

The Company conducts an annual customer satisfaction survey, systematically collecting customer opinions and suggestions from dimensions such as product quality, delivery cycle, and service quality to dynamically identify areas for product and service improvement.




Cornerstone of Business Trust

Responsible Marketing

Zhifei strictly abides by relevant laws and regulations such as the *Drug Administration Law of the People's Republic of China*, the *Vaccine Administration Law of the People's Republic of China*, and the *Advertising Law of the People's Republic of China*. It has formulated the *Responsible Marketing Policy*, prioritizing compliance risk prevention and safeguarding the public's right to know, and implementing full-cycle compliance control over market promotion activities. The Company maintains a "zero-tolerance" attitude towards false advertising, commercial slander, and misleading statements. Through a trinity mechanism of "system constraints, content review, and audit supervision", it strengthens the sense of responsibility of all employees and effectively implements responsible marketing. The Company implements unified compliance management for academic conference promotional materials and public education materials, and is equipped with clear requirements for handling violations to ensure that promotional and disease-popularization information is compliant, true, and accurate. To strengthen the process control of marketing activities, the Company has established a product promotion information review and control mechanism covering links such as the production, review, printing, distribution, and release of promotional materials. It has formed a Project Management Committee composed of representatives from the Risk Control Department and Finance Department, which is responsible for comprehensive evaluation and project approval. The Company's Project Management Committee conducts comprehensive evaluations and approvals for academic promotion projects; relevant departments such as the Medical Affairs Department and Legal & Compliance Department of the Company strictly review product-related promotional materials to ensure that product information and promotional materials are scientifically based, clearly and accurately conveyed, and avoid non-compliant situations such as misleading customers and consumers or casually evaluating competitors.

Product Promotion Information Review and Control Process



Regular Compliance Audit

The Company has established a systematic responsible marketing audit system to strengthen the compliance management of marketing activities. Through strict audit supervision and rectification mechanisms, it continuously optimizes the compliance of market promotion.

The Company has set up an internal audit team. Based on the risk levels of different businesses, it audits key areas of sales operations quarterly or semi-annually, covering links such as academic conference promotion and sales expense reimbursement. For problems found during the audit process, the audit team puts forward optimization or rectification suggestions and urges the implementation of relevant measures to ensure the improvement and efficient execution of the management system.

In addition, the Company organizes relevant functional departments such as the Risk Control Department and Finance Department to form a Project Management Committee, which conducts irregular compliance reviews of market promotion projects. By responding to questions from business departments, identifying and preventing potential risks, it ensures that market promotion activities are carried out efficiently while complying with regulatory requirements.

In 2025

The Company's Project Management Committee carried out more than **80** online and offline reviews



Employee Compliance Empowerment

The Company continuously conducts responsible marketing training for employees, covering core areas such as consumer rights and legal protection, product information knowledge, and sales behavior norms, aiming to achieve in-depth integration of compliance awareness and business practice to support the Company's development.

In 2025



109 responsible marketing training meetings were held around content such as strengthening compliance awareness and improving overall competence



Information Security Defense Line

Zhifei adheres to the trinity principle of "precautions by people, policy and technology", strictly abides by laws and regulations such as the *Data Security Law of the People's Republic of China*, the *Cybersecurity Law of the People's Republic of China*, and the *Personal Information Protection Law of the People's Republic of China*, and formulates and implements a system of regulations including the *Information Security Management Policy*, the *IT Risk Assessment Policy*, the *Software Development Lifecycle Management Policy*, and *Emergency Incident and Business Continuity Management Policy*, aiming to build a strong information security defense system. During the Reporting Period, the Company did not experience any data security incidents.

In 2025, Zhifei successfully obtained
**the ISO 27001 information security management system certification and
the Cybersecurity Classified Protection 2.0 (Level 2) certification**



In 2025, the Company participated in the regional network attack and defense drill organized by the Cyberspace Administration and was rated as an "Outstanding Defense Unit" for its excellent defense capabilities, fully verifying the effectiveness of the Company's network security protection system and emergency response mechanism.



Rated as an "Outstanding Defense Unit"

Customer Privacy Protection System

The Company attaches great importance to the protection of personal information of customers, employees, and partners. It has formulated and implemented the *Data Records Privacy and Security Management Policy*, and established a long-term privacy and security management mechanism based on the principles of "legality, propriety, and necessity".

The Company sets different access permissions according to different positions and responsibilities, and strictly restricts access to sensitive personal information. In non-production environments such as testing and analysis, the Company mandates the use of desensitized or anonymized data, removing direct identification information such as names and ID numbers to reduce the risk of privacy leakage from the source.

By signing the *Confidentiality Agreement* with employees, the Company clarifies the confidentiality obligations of personal and business information, and incorporates information security and privacy protection responsibilities into the performance appraisal of relevant personnel to ensure full-staff compliance.

To further meet the requirements of relevant laws and regulations on personal information protection, the Company has added a Privacy Notice Statement to the "Zhiyitong" system to strengthen the mechanism for informing customers about privacy and managing their authorization, ensuring the transparency and compliance of data collection and use.



Global Accessibility and Health for All


Zhifei is committed to meeting the global public health strategic needs, focusing on the core area of disease prevention. It continuously drives the R&D of cutting-edge products and the international strategic layout, aiming to provide safe, effective, and affordable vaccines and biological products to different regions and populations around the world, and actively advocates the standardized and scientific use of products. The Company leverages its technological accumulation and industrialization advantages to deeply integrate into the global public health cooperation system. By providing technical support and capacity building to underdeveloped regions, it empowers local disease prevention and control and the upgrading of public health systems, promoting the fair and accessibility of health benefits among a wider population.

Innovation-Driven Development

Zhifei adheres to the development concept of innovation-led development and continuously increases R&D investment. Based on the public's needs for disease prevention, it builds a systematic and forward-looking product matrix. Relying on a diversified and innovative development platform, it continuously drives the R&D of innovative vaccines and biological products, expands the disease coverage of products, and is committed to providing safe, efficient, and accessible health solutions to a wider population. As of the date of this Report's disclosure, the Company's drug candidates in clinical trial phases I, II, or III covered multiple disease areas with a high global disease burden, including respiratory infections and tuberculosis, neoplasms, maternal and neonatal disorders, diabetes and kidney diseases, enteric infections, and other infectious diseases. Relevant products under development include the Pneumococcal Vaccine Polyvalent, Lyophilized Recombinant Tuberculosis Vaccine, Therapeutic BCG Vaccine, Liraglutide Injection, Semaglutide Injection, Quadrivalent Recombinant Norovirus Vaccine, and Rabies Vaccine(Human Diploid Cell)for Human Use, Freeze-dried Use.

Technology Layout

The Company accelerates the application and transformation of new technologies in the field of disease prevention and treatment through strategic investment and collaborative R&D. Since 2020, the Company has made an equity investment in Innorna, making forward-looking arrangements for lipid nanoparticle (LNP) delivery technology and mRNA therapy. Its R&D pipeline covers key areas such as infectious diseases, rare genetic diseases, and tumor immunotherapy.



Key Progress in 2025

The mRNA drug IN013 of Innorna for the treatment of Wilson's disease has been granted the Rare Pediatric Disease Designation and Orphan Drug Designation by the US FDA, marking the international authoritative recognition of this technology. The world's first bivalent RSV mRNA vaccine IN006 has completed the recruitment and vaccination of subjects in the Phase II clinical trial, providing a promising treatment option for relevant disease areas.

Industrial Incubation


The Company accelerates the transformation of innovation achievements into clinical applications through investment and incubation. Since 2014, the Company has participated in the equity of Chongqing Zhirui Investment Co., Ltd., deeply deploying the biopharmaceutical and healthcare industrial ecosystem, and has incubated more than a dozen innovative enterprises, mainly targeting cutting-edge areas such as tumors, autoimmune diseases, metabolic diseases, neurodegenerative diseases, and cardiovascular diseases.

Incubation Achievements

Puzolcabtogene Autoleucel Injection has been successfully approved for marketing, becoming the first domestic CAR-T cell therapy product for leukemia in children and adolescents

Precision Biotech: CAR-T Products for Solid Tumors

Multiple CAR-T products for solid tumors have entered clinical research, filling the gap in domestic pediatric oncology treatment.



GeneSail Biotech: Oncolytic Virus Product

GO306 Recombinant Oncolytic Vaccinia Virus Injection has been approved for clinical trials and has officially entered the Phase I clinical stage, marking a significant step toward translating scientific research into clinical treatment options that are actually accessible to patients.

GO321 Recombinant Oncolytic Vaccinia Virus Injection received conditional approval for clinical trials in March 2026

Global Layout

Zhifei complies with the *Vaccine Administration Law of the People's Republic of China* and relevant international trade regulations, strategically deepens its international layout, actively promotes the global registration and certification of self-developed products, expands its market influence, and significantly improves product accessibility.

Global Supply Network

The Company's core products, such as the Group ACYW135 Meningococcal Polysaccharide Vaccine and Recombinant Mycobacterium Tuberculosis Fusion Protein (EC), have been launched and supplied on a large scale in emerging markets such as Indonesia, Pakistan, and Uzbekistan. At the same time, the Company is accelerating the registration and listing of multiple core products in countries such as Malaysia, the Philippines, and Thailand.

In the future, the Company will continue to deepen cooperation with low-and middle-income countries, actively participate in local government procurement and technical cooperation, promote more innovative products to enter the markets of low-and middle-income countries, and continuously improve product accessibility globally.

Capacity Co-building

Zhifei pays high attention to the current situation of the unbalanced development of global public health and focuses on the practical challenges faced by low- and middle-income countries in vaccine accessibility and medical system construction. The Company adheres to the equal emphasis on "product delivery" and "technology empowerment". Through continuous multi-level cooperation, it actively promotes technological exchanges and R&D collaboration. It shares experiences and technologies in clinical trials, vaccine production, and quality management to help improve the local vaccine R&D and production capabilities and promote the equitable accessibility and sustainability of vaccines.

Clinical Research Collaboration

Zhifei continuously contributes to the public health capacity building in developing countries. By cooperating with local relevant institutions in conducting clinical trials, it aims to improve the local drug R&D and drug supply capabilities. In 2025, the Company continued to vigorously expand internationally, striving to improve the accessibility and affordability of medical products in developing countries. It promoted the registration work in countries such as Malaysia, the Philippines, and Thailand, and carried out clinical research work in countries such as Bangladesh and Thailand. It deeply supported local scientific research institutions in conducting clinical empirical research, empowering regional public health capacity building through scientific research cooperation. This not only deepened the cooperation ties with low- and middle-income countries but also brought substantial health benefits to a wider global population.

EC Overseas Clinical Research Cooperation Network

The Company and local research institutions jointly promote the application and evaluation plans of multiple tuberculosis screening technologies:

Collaborating with the Indonesian research team to advance the clinical study titled "Clinical Study on the Use of EC (C-TST) for Diagnosing Latent Mycobacterium tuberculosis Infection in the 18-65 Age Group in Indonesia"

Indonesia

Collaborating with a Thai team to advance a clinical study on "The Accuracy of Two New Tuberculosis-Specific Skin Tests in Diagnosing Tuberculosis Infection"

Thailand

Collaborating with the Bangladeshi team to advance the clinical study titled "Evaluation of EC for the Diagnosis of Mycobacterium tuberculosis Infection in Individuals Aged 18 and Older in Bangladesh"

Bangladesh

Promote Clinical Trials and Build a Dysentery Defense Line

In 2025, Zhifei promoted Phase III clinical trials of the dysentery vaccine in Bangladesh. Facing the challenges of weak clinical base conditions and lack of compliance awareness in the local area, the Company took all-round empowerment measures:

Base Co-construction:

Closely cooperated with local personnel to establish multiple clinical trial bases from scratch in Dhaka, the capital, and its surrounding areas.

System Empowerment:

Established standard operating procedures and quality management systems around different trial links, carried out multiple rounds of training and on-site inspections, and effectively improved the operation level of the bases.

Technical Support:

Cooperated with the internationally renowned Bangladesh Diarrhea Disease Research Institute in terms of detection methods, equipment, and consumables, significantly enhancing the local detection ability of bacterial dysentery pathogens.



Site of the Bangladesh Dysentery Vaccine Clinical Meeting



Capacity Building of Healthcare Workers

The Company continuously strengthens the capacity building of healthcare workers in low-and middle-income countries. Through systematic training, it improves their quality management level and clinical practical ability, laying a long-term capacity foundation for subsequent public health research and vaccine development.

China-Africa Training Class

In 2025, the Company participated in the China-Africa International Training Class on Inspection and Testing Technology of Biological Products organized by the National Institutes for Food and Drug Control, providing training and lectures for African experts in relevant fields to strengthen their awareness and professional level in R&D and quality management.



● China-Africa International Training Class on Inspection and Testing Technology of Biological Products

On-site Guidance in Indonesia

In 2025, the Company provided support in product application and clinical research specifications to local tuberculosis medical staff in Indonesia through a combination of on-site guidance and training, helping them improve their ability to conduct clinical research and disease diagnosis in a standardized manner.



● Clinical Research Training in Indonesia

Localized Production and Supply

Zhifei focuses on the localized production and stable supply of preventive and therapeutic products in low-and middle-income countries. By exporting production techniques and analytical testing methods such as the use of production equipment, product inspection methods, and key control point requirements, it improves the management level of local pharmaceutical manufacturers in product production and quality control, and promotes the localized production of vaccines in line with international drug manufacturing standards.




Achievements of Technology Transfer in 2025

The Company carried out technology transfer cooperation with local partners in Bangladesh and Algeria. For products such as the epidemic meningitis vaccine, it provided technical support in preparation of preparations and quality control, and trained relevant production and quality personnel. It assisted the local area in completing the finished product filling production and achieving the localized launch of the first batch of products, helping to improve the local pharmaceutical production capacity.

In addition, the Company also continuously improved cold-chain management, assisted in safeguarding the pharmaceutical supply chain in low-and middle-income countries, and strengthened the quality guarantee and risk prevention and control in the medicine circulation link by introducing relevant processes and technologies.

Quality Management Initiatives for Overseas Medicine Circulation



Pharmacovigilance and Regulatory Support

To enhance the post-marketing safety regulatory capacity of drugs in low-and middle-income countries, Zhifei supports local health departments in promoting pharmacovigilance-related programs. It assists in collecting information on adverse reactions generated during the drug use process through multiple channels and conducts systematic safety assessment and management.

In this process, the Company establishes a cooperation mechanism by signing pharmacovigilance-related agreements with local product agents, standardizes the processes of collecting, analyzing and reporting adverse reaction data. Meanwhile, it shares safety data, technical experience and analysis results accumulated from global clinical trials and post-marketing monitoring to provide professional support for local regulatory decision-making and help improve the pharmacovigilance system and the management ability of safe drug use.

Global Cooperation Platform

Zhifei actively participates in the construction of vaccine R&D capabilities in developing countries. It has continuously joined the Developing Countries Vaccine Manufacturers Network (DCVMN) and attended its annual meetings. It expands cooperation through international industry exhibitions, establishes connections with enterprises and institutions in multiple developing countries, and improves the global accessibility of vaccines.



• Representatives of Zhifei Attended the 26th DCVMN Annual Meeting

Improving Affordability

Zhifei strictly implements the *Pricing Law of the People's Republic of China* and drug price management regulations. It is always committed to improving the affordability of its products. On the premise of ensuring high-quality standards, it reduces the economic burden on the public and benefits more people through multiple measures such as expanding market access, inclusion in the national medical insurance catalog, and reasonable pricing.

Domestic Market: Medical Insurance and Centralized Procurement Benefit the Public

Zhifei continuously promotes the provincial tender access and centralized procurement of vaccines and drugs, covering National Immunization Program (NIP) vaccines, non-NIP vaccines and innovative drugs. Through mechanisms such as centralized procurement and national online listing, it expands the product coverage, optimizes the price formation mechanism, and continuously improves the affordability and accessibility of products.

In 2025, EC was continuously included in the National Medical Insurance Drug Catalog, which reduced the out-of-pocket payment ratio for patients and alleviated their medication burden. This measure provides a more affordable solution for tuberculosis screening, prevention, and control, and helps promote the early screening, early detection, and early treatment of tuberculosis, thereby accelerating the goal of ending the tuberculosis epidemic.

Overseas Market: Differential and Tiered Pricing

In the overseas market, Zhifei implements a differential and tiered pricing strategy based on affordability of different countries and populations, promotes the reasonable pricing of products in different markets, and ensures that the products can serve a wider global population.

Differential Pricing Strategy

Inter-country Differential Pricing

Based on per capita GDP, the level of healthcare system development, and public health needs in different countries, differentiated pricing policies are implemented for the same product across countries, with a particular focus on emerging markets and low- to middle-income countries, so as to prioritize improving local affordability and accessibility of relevant products.



Intra-country Differential Pricing

Within the same country, differentiated pricing arrangements are made for public and private healthcare markets by taking into account the payment capacities of different socioeconomic groups. In the public healthcare market, reasonable price levels are determined through measurement and evaluation to support procurement and broad use by public health institutions; in the private healthcare market, prices are adjusted in light of market-based factors, so as to achieve balanced coverage across different populations and expand the overall reach of the products.

Advocate Rational Medication Use

Bacterial drug resistance has become one of the important challenges in the global public health field. The Company fully acknowledges the potential risks of antibiotic resistance to public health and the medical system, advocates the prudent and standardized use of antibiotics and other antimicrobial drugs in clinical practice, and promotes the concept of rational medication use. At the same time, the Company continuously increases R&D investment in innovative products, and provides long-term solutions to the problem of antibiotic resistance through technological innovation and product iteration.

Reduce Antibiotic Resistance in Treatment

Bacillary dysentery is an intestinal infectious disease with a relatively high incidence rate in China, often occurring in children under 5 years old. With the widespread use of antibiotics, the problem of drug-resistant strains has become increasingly prominent.

The *S. flexneri* and *S. sonnei* Bivalent Shigella Conjugate Vaccine independently developed by Zhifei Lvzhu is mainly used to prevent bacillary dysentery caused by *Shigella flexneri* and *Shigella sonnei*, and is suitable for people aged 6 months to 5 years. This product covers the two serotypes with the highest incidence of dysentery and is the first vaccine developed internationally that can prevent infections of both *Shigella flexneri* and *Shigella sonnei*. Clinical studies have shown that it has good safety and immunogenicity. Pre-preventive vaccination can effectively reduce the use of antibiotics in the treatment process, thereby greatly reducing the threat of antibiotic resistance to human life and health. The vaccine candidate is currently undergoing Phase III clinical trials in China and Bangladesh.


Secure Environment for Continuous Management

Zhifei firmly implements the strategy of green and low-carbon development and regards environmental, health, and safety management as the cornerstone of the Company's stable operation. The Company adheres to the principle of "safety first, prevention first, and green development", deeply integrates low-carbon circular technology with digital management means, strengthens the safety production defense line, protects the ecological environment, and builds a modern biopharmaceutical enterprise with harmonious coexistence between humans and nature.



Target-Oriented System Construction

Zhifei strictly complies with laws and regulations such as the *Work Safety Law of the People's Republic of China*, the *Law of the People's Republic of China on the Prevention and Control of Occupational Diseases*, the *Fire Protection Law of the People's Republic of China*, the *Environmental Protection Law of the People's Republic of China*, the *Law of the People's Republic of China on Prevention and Control of Water Pollution*, the *Regulations on Safety Supervision of Special Equipment*, and the *Safety Specifications of Special Work in Hazardous Chemicals Enterprises*. It has established an EHS system with the *Environmental and Occupational Health and Safety Management Manual* as the top-level guideline, and integrates the EHS management policy and goals into daily business decisions and processes.




Governance Structure and Responsibilities

Zhifei continuously optimizes the top-down EHS governance structure. The Board of Directors is the highest decision-making body for EHS matters, and the Strategy and Sustainability Committee under it is responsible for overseeing EHS-related strategies and performance. The Work Safety Committee is chaired by the Chairman, with the CEO as the deputy chairman and the in-charge Vice President as the executive director, responsible for top-level design and strategic implementation.

The Company's core production bases, Zhifei Longcom and Zhifei Lvzhu, specify their management structures according to their own characteristics, forming a responsibility network that "covers all aspects horizontally and vertically".

Target Management and Assessment

Zhifei implements the assessment of the work safety responsibility system, signs work safety target books and commitment letters at all levels, and includes the implementation of responsibilities in the performance assessment of safety responsible Person and senior management personnel; if environmental performance declines, points will be deducted from the relevant personnel's performance evaluations to ensure strict adherence to EHS duties.



System Certification and Audit

Zhifei continuously promotes the standardization and international integration of the EHS management system. All the Company's officially put-into-production production bases have established internal EHS management systems and obtained third-party certifications.

ISO 14001 Environmental Management System <ul style="list-style-type: none"> Zhifei Lvzhu Zhifei Longcom 	ISO 45001 Occupational Health and Safety Management System <ul style="list-style-type: none"> Zhifei Lvzhu Zhifei Longcom 	Level 2 Work Safety Standardization Certification <ul style="list-style-type: none"> Zhifei Lvzhu 	Level 3 Work Safety Standardization Certification <ul style="list-style-type: none"> Zhifei Longcom 	Eco-Credibility Enterprise <ul style="list-style-type: none"> Fushan Road Plant and Biopharmaceutical Industrial Park (Section A)
---	--	---	---	---

The Company has a dual supervision mechanism of "regular internal reviews and independent third-party audits". The Company regularly conducts compliance audits on toxic emissions, waste, sewage, exhaust gas, etc. All production operations are subject to an environmental management system compliance audit by a third-party certification body once a year and a recertification review every three years. In 2025, all production bases certified with ISO 14001 and ISO 45001 successfully passed the independent third-party compliance audit.

Risk Management and Emergency Response


Zhifei conducts monthly, quarterly and special safety inspections in accordance with the *Procedures for Hazard Identification, Risk Evaluation and Risk Control Measures Determination and Control*, the *Hazard Investigation and Management Policy* and the *EHS Risk Management and Control Manual*. Focusing on dimensions such as equipment operation, working environment, personnel behavior and pollution prevention facilities, it comprehensively investigates EHS hazards, continuously tracks the rectification progress, and realizes the closed-loop management of hazard treatment.

For emergency management, the Company has formulated emergency management systems such as the *Procedures for Handling Work Emergencies*, established an accident emergency organizational structure, and improved the ability to respond to emergencies, prevent accidents and reduce losses through measures such as establishing emergency plans and conducting safety emergency drills.

Special Investment Guarantee

Zhifei continuously invests special resources to ensure soft power with hard investment, effectively reducing the impact of the Company's production and operation on the ecological environment.

In 2025

The environmental protection investment reached RMB 2.1416 million, mainly used for the treatment of waste, sewage and exhaust gas, and daily management	The safety investment reached RMB 5.0819 million, mainly used for the operation and maintenance of safety facilities and employee protection	With a coverage rate of 100%	
---	---	-------------------------------------	---

Ensuring Safety and Protecting Health

The Company adheres to the safety development concept of "life first" and regards safe operation as the bottom-line and red-line for enterprise development. The Company strictly implements the policy of "safety first, prevention as priority, and integrated management", constructs a dual-prevention mechanism for safety risks covering all employees, the whole process and all aspects for multiple work scenarios, and makes every effort to create a safe production and operation environment.

The Company has established a system covering key areas such as production, biosafety, fire safety and construction, including the *Regulations on Work Safety Management*, the *All-Staff Work Safety Responsibility System Management Policy*, the *Biosafety Management Manual*, the *Laboratory Safety Management Policy*, the *Regulations on Fire Safety Management* and the *Project Construction Management Policy*. During the Reporting Period, no general or above-level work safety accidents or fire accidents occurred in the Company, the incidence of occupational diseases was zero, and the work safety situation remained stable and good.

Work and Fire Safety

Under the overall planning and supervision of the Work Safety Committee, Zhifei fully implements the main responsibility for work safety. This year, Zhifei Longcom compiled the *Special Operation Management Policy* and established the EHS Service Center, realizing the standardization and high-efficiency of special operation approval.

Work Safety

Source Control Strictly implement the "three-simultaneous" requirements for safety facilities of construction projects (simultaneous design, simultaneous construction and simultaneous commissioning). Compile the design of project safety facilities and the safety acceptance evaluation report, and pass the expert review to ensure that potential hazards are eliminated from the design stage of new, renovated and expanded projects.

Process Supervision Implement a network of full-time and part-time safety officers, regularly hold work safety meetings, and carry out regular production safety hazard investigations, special inspections, emergency drills, training and education and other control measures.

Special Operation Management Establish a ledger for special equipment operators, track the annual review of certificates, and implement the guardianship system; as of the end of the Reporting Period, a total of 1,070 person-times held certificates, and 307 person-times had their certificates renewed or newly obtained during the Reporting Period.	Equipment and Facility Inspection In 2025, the subsidiaries carried out special safety inspections and promptly repaired the equipment with potential hazards to ensure the 100% safe operation of equipment and facilities.
---	--

Closed-loop Management of Accidents Establish a sound reporting, investigation and handling mechanism for production safety accidents, and adhere to the principle of "four no-releases", that is, do not let the matter rest until the cause has been identified, until those responsible have been held accountable, until corrective measures have been implemented, and until relevant personnel have been educated. Through root-cause analysis and rectification implementation, prevent the recurrence of similar accidents.

Fire and Related-party Safety

Fire Management

Actively carry out the identification of fire safety risk points and the investigation of potential hazards, and build a fire safety network of "human-based + technology-based prevention" through fire education and emergency drills.


Related-party Management

Sign agreements with relevant parties such as contractors to clarify the safety responsibility boundaries of both parties; regularly organize on-site safety and civilized construction inspections, strictly enforce the red-line of special-type workers holding certificates, and ensure the safety and controllability of the whole construction process.

Biosafety

The Company established a Biosafety Committee and, based on applicable laws, regulations and standards, built a biosafety management system containing six major modules such as legal compliance, construction project management and risk assessment.

During the Reporting Period, Zhifei Longcom customized a biosafety technical manual for the core production area, covering key processes, equipment, facilities, and emergency response plans, achieving refined closed-loop management of biosafety risks.



In 2025, The cumulative number of participants in Zhifei Longcom's biosafety management training reached **1,136**

Covering all key positions and major business units

Occupational Health and Safety Management

Zhifei has formulated internal systems such as the *Regulations on Occupational Health Management*, the *Occupational Health Monitoring and Archive Management Policy for Workers*, and the *Occupational Hazard Detection and Evaluation Policy*, and constructed a full-cycle occupational health and safety management system from the three dimensions of "protection, evaluation, and physical examination".

Source Protection

Strictly implement the "three simultaneous" requirements for occupational disease prevention facilities, prepare pre-evaluation reports, protection facility designs, and hazard control effect evaluation reports, and pass expert reviews to ensure the safety of the working environment.

Monitoring and Evaluation

Entrust qualified institutions to regularly carry out the detection of occupational disease hazard factors. The detection data is true and compliant, and targeted improvement measures are formulated based on the detection results.

Health Monitoring

Establish a "one file for one employee" occupational health file for employees in hazard-related positions, strictly implement the three-stage physical examination system of "before taking up a post, during the employment period, and when leaving the post", and continuously track the health status of employees.

In 2025

The detection coverage rate of occupational disease hazard factors reached **100%**

Safety Culture and Emergency Response Capability

Zhifei actively promotes the construction of safety culture. Through the three-level safety onboarding training at the "company, department and team/group levels", regular safety management training in the factory area, and the promotion of the "one question one day for work safety", it promotes the implementation of the concept of health and safety.

The Company continuously conducts safety emergency drills and special first-aid training to prepare for emergencies, effectively improving the Company's emergency response and coordinated handling capabilities for emergencies.

In 2025

27 special safety training sessions were carried out

23 emergency drills were carried out

Safety Skills Competition

In 2025, Zhifei Longcom held a safety skills competition. 12 teams competed fiercely in practical subjects such as the use of fire extinguishers, the operation of fire hoses, and the wearing of air respirators. Through the competition, the practical emergency response skills of front-line employees were effectively improved.

Reduction of Resource Consumption and Improvement of Quality and Efficiency

Zhifei strictly abides by laws and regulations such as the *Energy Conservation Law of the People's Republic of China* and the *Water Law of the People's Republic of China*, formulates and implements internal systems such as the *Management Policy for Energy Saving and Consumption Reduction*, and constructs a resource conservation responsibility system involving all employees. The Company vigorously promotes energy-saving technological transformation and circular economy projects, effectively improving resource utilization efficiency and fulfilling its solemn commitment to green and low-carbon development with practical actions.


Energy Usage

Zhifei relies on digital means to strengthen the refined management of energy. By building an online energy management platform, it statistics the power consumption data during peak, off-peak, and low-demand periods, and uses big data analysis and abnormal alarms to quickly trace abnormal energy consumption points, achieving intelligent control of energy consumption. The Company has no difficulties in energy use and has achieved excellent energy management performance.

In 2025

Zhifei Longcom set an energy-saving target of "a **10%** year-on-year decrease in comprehensive energy consumption costs"

Actually achieved a year-on-year **decrease of 24%**, exceeding the annual energy-saving task



Intensive and Intelligent Group Control Transformation of the Air Compression System

In 2025, Zhifei Longcom implemented energy-saving transformation of the air compression system, centrally relocating the scattered air compressors in the factory area to a dedicated station building. Through the newly built pipeline network, it realized the centralized production and unified distribution of compressed air. With the group control optimization strategy, the unnecessary no-load and unloading energy consumption of the equipment was eliminated. This measure is expected to save 20,000 kWh of electricity per month, with a power-saving rate of 15%-25%; save 30 tonnes of standard coal per year and reduce carbon emissions by 140 tonnes of carbon dioxide equivalent per year.

Special Project for Pipeline Insulation Repair


In 2025, to reduce Energy transmission losses, Zhifei Lvzhu carried out the insulation repair of chilled water and steam pipelines in the plant. By replacing old insulation materials, repairing damaged parts, and optimizing the sealing of the insulation layer, this measure effectively reduced the heat dissipation of the pipelines, ensured the stable and efficient supply of cold and heat sources required for production, and practiced the concept of lean management.

Water Resource Usage

Centering on improving water resource utilization efficiency, Zhifei established a leading group for water-saving actions to comprehensively promote the secondary utilization and recycling of water resources. The Company's water mainly comes from municipal supply, and there are no difficulties in obtaining water resources.

The Company fully uses water-saving appliances and metering equipment to strictly prevent leakage and other unnecessary waste of water resources. At the same time, the Company uses the reclaimed water generated by the water treatment system for plant greening, animal house flushing, and high-temperature pool cooling; and uniformly recovers steam condensate through the steam condensate device, significantly improving the water resource recycling efficiency.

In 2025

Zhifei Lvzhu recycled approximately	Zhifei Longcom recycled	
55,000 tonnes of	approximately 24,000	
condensate in total	tonnes of condensate in total	

Water-saving Renovation of the Purified Water System

In 2025, Zhifei Longcom optimized the process of the purified water preparation system in the Fushan Road Plant, adjusting the low-pressure circulation mode of four devices to "flushing for 20 minutes every 2 hours". On the premise of ensuring the stable operation of the system, this measure significantly reduced water consumption and wastewater discharge, and it is estimated that 70,000 tonnes of water resources can be saved annually.

Circular Economy

Adhering to the circular economy concept of "source reduction, lean design, efficient process, and recycling", Zhifei is committed to creating a green operation model with closed-loop resource flow and harmonious coexistence with the environment.

Green Design and Production

Zhifei incorporates energy conservation and consumption reduction considerations into building design, optimizes the thermal insulation performance of building envelopes, reduces heating, ventilation, and air conditioning energy consumption, and meets the construction requirements of green buildings. At the same time, the Company continuously promotes the substitution of toxic and harmful substances at the product design stage and preferentially selects non-toxic and harmless environmentally friendly reagents.

Through process innovation and equipment upgrading, the Company has improved production efficiency and reduced energy consumption per unit of product. In terms of solid waste management, the Company implements clean production, rationally selects and utilizes resources such as raw materials, strictly controls the storage and use of raw and auxiliary materials to reduce waste due to expiration, and actively promotes the creation of a "Zero-Waste Factory". During the Reporting Period, Zhifei Longcom (Mingzhu Avenue Industrial Park Factory) was awarded the title of "Zero-Waste Factory".

Green Storage and Distribution

In the product storage and transportation process, Zhifei has built a low-carbon cold-chain logistics system through technological innovation and model optimization.

Equipment Upgrade
In 2025, the Company newly purchased electric-driven refrigeration units, effectively promoting the decarbonization process in the transportation link.

Green Packaging Materials
The Company selects environmentally friendly warehouse boards and polyurethane insulation boxes. In air shipments, the insulation boxes can be reused dozens of times, significantly reducing packaging waste.

Low-carbon Transportation
The Company gives priority to using refrigerated trucks with dual refrigeration units or small-displacement environmentally friendly ones. For the demand in some provinces and cities, it shortens the transportation distance through off-site warehousing, multimodal transportation, and route optimization. It also optimizes the front-end order structure, centralizes unified distribution, and improves the full-load efficiency of vehicles.

In 2025
Each electric-driven refrigeration unit reduced
approximately **5,046** kg of carbon dioxide equivalent

Green Office and Operation

The Company has formulated and implemented the *Management Policy for Energy Saving and Consumption Reduction*, integrating the green concept into daily office details. The Company has implemented measures such as "turning off lights and controlling air-conditioning temperature and conducts daily inspections of the implementation. It also promotes the Clean Plate Campaign and paper-saving initiatives to enhance the environmental awareness of all employees. At the same time, the Company has optimized the commuting shuttle routes to improve vehicle utilization efficiency. In addition, the Company has expanded the application scope of paperless office, using digital means to support green office.

In 2025
The paper consumption in the workshops of Zhifei Lvzhu with the newly launched paperless office system decreased by **18%** year-on-year

Pollution Prevention and Ecological Protection

Zhifei strictly abides by relevant environmental protection laws and regulations and implements the requirements of the *Regulations on Administration of Pollutant Discharge Permits* to ensure "discharging pollutants with a permit and in accordance with the permit. The Company adheres to both source reduction and end treatment to minimize the environmental footprint of production and operation. During the Reporting Period, the Company did not receive any major administrative penalties or be investigated for criminal liability due to pollutant discharge or other environmental incidents. No major defects were found in the Company's environmental monitoring plan and risk management measures, and the environmental monitoring and risk management system is operating effectively.

Environmental Compliance Management System

To ensure the efficient implementation of environmental compliance, Zhifei has built a compliance matrix of "regulatory compliance-system implementation, set management goals of "zero environmental pollution accidents, pollutant discharge meeting standards, and 100% classified disposal rate of solid waste, and formulated a plan to reduce toxic emissions and hazardous waste in all business operations to drive continuous improvement of environmental performance.

Compliance Areas	Compliance with External Laws and Regulations	Implementation of Internal Policies
Comprehensive Management	<i>The Environmental Protection Law of the People's Republic of China</i> <i>The Law of the People's Republic of China on Environmental Impact Assessment</i>	<i>The Regulations on Environmental Protection Management</i> <i>The Regulations on Environmental Protection Facilities Management</i> <i>The Contingency Plans for Environmental Accidents</i>
Sewage Management	<i>The Law of the People's Republic of China on the Prevention and Control of Water Pollution</i> <i>The Integrated Wastewater Discharge Standard</i>	<i>The Regulations on Sewage Treatment System Operation</i> <i>The Online Monitoring Management Policy of Wastewater and Waste Gas</i> <i>The Wastewater Control Procedures</i>
Waste Gas Management	<i>The Law of the People's Republic of China on the Prevention and Control of Atmospheric Pollution</i>	<i>The Production Environment Operational Control Procedures</i> <i>The Air Pollution Prevention and Control Procedures</i>
Waste Management	<i>The Law of the People's Republic of China on the Prevention and Control of Environmental Pollution by Solid Wastes</i> <i>The Regulations on the Management of Medical Wastes</i>	<i>The Solid Waste Control Procedures</i> <i>The Hazardous Waste Management Policy</i> <i>The General Industrial Solid Waste Management Regulations</i> <i>The Hazardous Waste Management Regulations</i>

The Company strictly implements the self-monitoring plan for the environment, establishes an electronic ledger to ensure that the monitoring data is "true, accurate, and complete. At the same time, the Company conducts environmental impact assessments for construction projects, monitors the environment by third-party institutions, and strictly controls source risks. In addition, the Company formulates contingency plans for environmental accidents, regularly conducts environmental emergency management training and practical drills, and builds a solid environmental safety defense line.

Comprehensive Treatment of Sewage, Waste Gas and Waste

Sewage Management

For sewage classification and purification, Zhifei implements the strategy of "separating rainwater and sewage, separating clean and dirty water, and classifying disposal covering all business operations. The waste organic acid solution in the production process is separately collected, transported, and disposed of as hazardous waste and is strictly prohibited from entering the sewage treatment system. The acid-base waste liquid is discharged after harmless treatment.



Sewage Treatment Process and Monitoring

The combined process of "contact oxidation tank oxidation + secondary sedimentation tank solid-liquid separation + disinfection tank sterilization" is adopted, and online monitoring equipment is equipped to monitor key indicators such as chemical oxygen demand (COD), ammonia nitrogen (NH₃-N), pH value, and sewage flow in real time, ensuring that 100% of the sewage discharge meets the municipal pipe connection standards.

Waste Gas Management

Zhifei implements standardized control over the whole process of waste gas in all business operation scopes to ensure up-to-standard emissions and continuously explores the path of in-depth waste gas purification.

Categorized Treatment Measures for Waste Gas



Waste Embryo Treatment Waste Gas

The in-furnace circulating combustion technology is adopted to achieve organized up-to-standard emissions.



Waste Gas from Temporary Storage of Hazardous Waste

Organic volatile solvents are stored in sealed containers, and secondary activated carbon adsorption units are installed. After treatment, the exhaust gas is discharged through a tall stack, effectively reducing VOC emissions and fugitive emissions.



Waste Gas from the Production Workshop

It is purified through an activated carbon adsorption device, and real-time monitoring of the fan pressure is implemented to ensure the stable operation of the equipment and up-to-standard emissions.

In 2025, Zhifei Lvzhu set a emission reduction target of "the waste gas emissions meet the requirements of the Integrated Emission Standard of Air Pollutants in Beijing (DB11/501-2017), the cooking fume in the canteen meets the Emission Indicators of Air Pollutants for the Catering Industry (DB11/1488-2018), and the boiler waste gas meets the relevant pollutant emission limit requirements in the *Emission Standard of Air Pollutants for Boilers in Beijing* (DB11/139-2015)". The target was actually achieved, and all the waste gas was discharged up to standard.

In 2025, Zhifei Longcom set a emission reduction target of "the waste gas emissions meet the relevant pollutant emission limit requirements in the Integrated Emission Standard of Air Pollutants (GB16297-1996), the Emission Standard for Odor Pollutants (GB14554-93), and the *Emission Standard of Air Pollutants for Pharmaceutical Industry* (DB34/310005-2021)". The target was actually achieved, and all the waste gas was discharged up to standard.

Waste Management

To achieve waste reduction and recycling, Zhifei has established a full-process responsibility system covering "generation, collection, storage, transportation, utilization, and disposal" of waste in all business operation scopes.

Fine-grained Control of Waste

General Solid Waste

A management ledger is established to standardize the recording of information such as the types, quantities, storage, and disposal of solid waste to achieve traceability and queryability. A verified and qualified third-party institution is entrusted for compliant transportation, utilization, and disposal. Regular training on the standardized management of general industrial solid waste is carried out to strengthen the foundation of capabilities.

Hazardous Waste

Strictly implement "classified collection, storage in dedicated areas, and label management", and implement regular inspections by EHS specialists covering all production bases. A verified and qualified third-party institution is entrusted for harmless treatment, and the transfer bill system is strictly implemented. Strengthen the operation and management of production equipment, improve production processes, increase raw material utilization rates, introduce advanced production equipment, and implement clean production measures to reduce the generation of hazardous waste at the source. Develop special control and emission reduction plans for toxic solid waste, and continuously replace toxic and harmful reagents with non-toxic and harmless reagents to reduce environmental and health risks. Regular training on the standardized management of hazardous waste is carried out to strengthen the awareness of compliant disposal among all employees and ensure the "harmless, reduction, and recycling" of hazardous waste disposal.

In 2025

Zhifei Longcom set a waste reduction target of "a 5% year-on-year decrease in the disposal volume of hazardous waste" and has successfully achieved its annual waste reduction task.



Physical Environment and Ecological Protection

Zhifei strictly abides by the *Law of the People's Republic of China on Prevention and Control of Pollution from Environmental Noise*, refers to national and local standards such as the *Emission Standard for Industrial Enterprises Noise at Boundary*, regularly monitors the noise at the factory boundary, and minimizes the impact of noise on the surrounding environment through measures such as reasonable layout of the factory area and shock-absorption treatment of equipment.

In the process of business development, the Company always pays attention to the current and future possible impacts of its production and business activities on the ecosystem and biodiversity. Before project construction, the Company strictly conducts environmental impact assessments and gives priority to eco-friendly design and construction plans to ensure compliance with the requirements of the ecological protection red line. During operation, by strictly controlling and continuously monitoring pollutant discharge, the negative impact chain on the surrounding ecosystem is cut off.

During the Reporting Period, no production and business sites of the Company were found to involve ecological protection red lines, key ecological function areas, nature reserves, or other ecologically sensitive and fragile areas, and the production and business activities did not have a significant impact on the ecosystem and biodiversity.

Building Resilience in Response to Climate Change

Zhifei closely monitors the global climate change trend and actively embraces the challenges of climate resilience. The Company incorporates climate response issues into important development considerations, and with reference to the recommended framework of the Task Force on Climate-related Financial Disclosures (TCFD), systematically identifies potential risks and opportunities. While controlling the risk bottom line, it actively explores new growth drivers in the low-carbon economy.

Governance and Strategy

Zhifei integrates climate governance into its ESG governance framework to ensure the organic alignment of the top-level strategy with climate response issues. Relying on the ESG management process and collaborating with various functional departments, the Company has established a climate-related risk review mechanism to comprehensively assess its financial impact on the Company's short, medium, and long-term businesses. In addition, the Company continuously enhances the organization's climate adaptability and resilience by promoting energy conservation and emission reduction and green operations.

Climate-related Risks and Opportunities

Based on internal data and industry research, Zhifei has mapped out a clear picture of climate-related risks and opportunities and formulated targeted response and utilization strategies.

Risk Manifestations and Impacts	Risk Response Measures
<p>Physical Risks</p> <ul style="list-style-type: none"> Extreme weather events caused by climate change, such as heavy rain and typhoons, can cause equipment damage or power outages in the factory area, leading to a decline in production capacity. They may also affect the supply chain, resulting in insufficient supply of raw materials and equipment, which will affect business continuity to a certain extent. Extreme high temperatures caused by changes in the climate pattern can have an impact on the physical health of laborers working continuously in high-temperature environments. 	<ul style="list-style-type: none"> In response to extreme weather events, the Company establishes emergency response plans based on actual operating conditions and regularly strengthens employee safety protection and improves the Company's emergency response capabilities through emergency drills and other means. The Company maintains close contact with meteorological and water conservancy departments, studies defense strategies for possible disasters, and clarifies the key points of defense. The Company improves the efficiency of energy and water resource use through equipment technology transformation and the use of energy-saving equipment. For details on energy and resource conservation, please refer to the section <i>Reduction of Resource Consumption and Improvement of Quality and Efficiency</i> in this report.
<p>Transition Risks</p> <ul style="list-style-type: none"> The compliance disclosure requirements related to climate change are becoming increasingly strict. The state or local governments will successively introduce relevant policies, which may limit carbon emissions and affect production or operations. Under the trend of the low-carbon economy, effective management of carbon emissions of the Company and its suppliers will be required in the future. If management is poor, it will have negative impacts such as damage to the brand image and loss of customers. 	<ul style="list-style-type: none"> The Company continuously optimizes the production process, promotes energy conservation and emission reduction, effectively controls carbon emissions, creates a green and environmentally-friendly enterprise, and establishes a good brand image. The Company promptly tracks various laws and regulations issued by the state and local governments and strengthens the tracking and emission supervision of greenhouse gases. The Company actively explores the possibility of energy conservation and consumption reduction, takes climate change mitigation and adaptation as key tasks, and communicates with various stakeholders through diversified channels.

The Company firmly believes that "green is the future." Climate change may lead to new disease patterns. The Company will deeply understand its impact on human health, give full play to its R&D advantages, and provide innovative solutions for climate-sensitive diseases, creating new business value while safeguarding human health.


Emission Reduction Actions

Zhifei actively responds to the national dual carbon goals of "achieving carbon peaking by 2030 and carbon neutrality by 2060" and continuously practices the concept of low-carbon operations. In 2025, the Company continued to monitor the performance of greenhouse gas emissions.

Greenhouse Gas Emission Indicators	Unit	2025
Greenhouse gas emissions (Scope 1)	tCO ₂ e	9,870.83
Greenhouse gas emissions (Scope 2)	tCO ₂ e	62,105.98
Total greenhouse gas emissions	tCO ₂ e	71,976.81
Greenhouse gas emissions intensity	tCO ₂ e / RMB 10,000 of revenue	0.08

The Company strictly complies with the management regulations of carbon emissions trading. In 2025, as a key emission entity in the local carbon emissions trading, Zhifei Lvzhu has completed the full payment and fulfillment of the 5,208 tonnes of carbon dioxide equivalent of emissions exceeding allocated allowances on time. There has been no situation where the Company was required by relevant departments to make rectifications or was investigated for carbon emission issues, maintaining a good compliance record.

Diverse Carbon Offset Portfolio in 2025



For details on the Company's practices in greenhouse gas emission reduction, please refer to the section *Reduction of Resource Consumption and Improvement of Quality and Efficiency* in this report.

5

Employee Care and Talent Cultivation

Zhifei regards talent as the core capital for the Company's sustainable development and is committed to building a human capital ecology of "co-creating, sharing and sharing". The Company adheres to compliant employment and diversity and inclusion, builds a full-life-cycle career development path, provides a competitive compensation and welfare system, and creates a "career community" and a "fate community" for the common growth of employees and the Company.





Diversity and Inclusion, Laying the Foundation for Talent


Zhifei strictly abides by laws and regulations such as the *Labour Law of the People's Republic of China*, the *Labor Contract Law of the People's Republic of China*, the *Law of the People's Republic of China on the Protection of Women's Rights and Interests*, the *Provisions of the People's Republic of China on the Special Protection of Minor Workers*, and the *Provisions on the Prohibition of Child Labour*. It formulates and implements a series of institutional documents such as the *Personnel Recruitment Management System* and the *Employee Handbook*, and has established a comprehensive compliant employment management system.

In 2025, the Company further revised the core chapters in the *Employee Handbook* regarding salary and benefits, holidays, performance rewards and punishments, and labor relations, and newly issued the *Management System for Probation Period of New Employees in the Market*. It has achieved standardized management of the entire process from recruitment, job transfer to retirement, and has strengthened the institutional defense for the Company's compliant operation.

Talent Concept and Talent Recruitment Strategy⁷

In 2025, Zhifei systematically upgraded its talent concept and established a management idea centered on "Prioritizing Character, Empowering Growth, Empowering Innovation and Win-win Development", promoting the systematic implementation of the four major orientations of selection, education, employment, and retention.

Talent Concept



Based on the medium-and long-term development plan, combined with the business growth trend, organizational structure adjustment plan, and personnel flow forecast, the Company formulates the annual talent plan and introduction plan. At the same time, the Company analyzes the human resources gap by combining historical data and the future development plans of various business sectors, and anticipates the new demand for professional and technical positions around key nodes such as R&D project milestones and the commissioning of new production lines. It also calculates the replacement and reserve recruitment needs by referring to the turnover rate, retirement rate, and internal promotion trend. In addition, Zhifei has set quantitative indicators for the personnel allocation of the sales sector. It determines the recruitment needs of the sales sector based on regional market potential data, past performance data, and personnel turnover rate, and dynamically adjusts recruitment resources to ensure that talent introduction is precisely matched with the business development rhythm and organizational capacity building requirements.

7. All data in this section contain Chen'an Bio

The Company adheres to the recruitment principle of "Open, equal, competitive, merit-based", actively expands diversified talent recruitment channels such as internal job competitions, campus recruitment, online recruitment, talent markets, and RPO, and continuously optimizes the talent team structure. In 2025, the Company recruited a total of 164 new employees. As of the end of the Reporting Period, the total number of employees reached 6,292. The employee turnover rate of the Company was 18.35%, which is better than the level of the biopharmaceutical industry, demonstrating excellent organizational health and talent stickiness. At the same time, the Company focuses on campus recruitment, creates characteristic talent recruitment projects, recruited 23 fresh graduates during the Reporting Period, and provided high-quality internship opportunities for 31 students, reserving new forces for the long-term development of the enterprise.

Full-Process Compliance Management

Zhifei integrates the concept of compliance into the full life cycle management of employees. In the recruitment process, the Company strictly reviews the identity information of applicants, and will not hire those with false identities or inappropriate ages, resolutely eliminating child labor and compulsory labor. At the same time, the Company legally signs, terminates or cancels labor contracts with all formal employees on an equal and voluntary basis, pays salaries on time as agreed, fully pays the five social insurance premiums and housing provident fund, regularly conducts personnel file archiving and contract review to safeguard various legitimate rights and interests and ensure that the employment relationship is legal and compliant.

The Company advocates reasonable working hours and guarantees employees' rights to rest and leave. For employees who leave the Company, the Company strictly implements the *Provisions on Employee Retirement Management System* to ensure the compliance and proper handling of salary settlement and labor relations.

During the Reporting Period, the Company **did not** have any incidents of illegal employment, use of child labor, forced labor, or labor disputes.

Diverse, Inclusive and Equal Workplace⁸

Zhifei regards the diverse backgrounds, views and experiences of employees as a valuable source of corporate innovation. In the management structure, the Board of Directors serves as the highest supervision body for diversity matters; the senior management takes the lead in promoting the implementation of policies, and is responsible for goal setting, progress tracking and effectiveness evaluation. The Company integrates the principle of diversity into its recruitment and employment policies, treating all candidates and employees equally. The Company promises not to discriminate based on gender, age, ethnicity, region, religious belief or cultural background in key aspects such as recruitment, training and promotion.

As of the end of the Reporting Period

Female employees accounted for **42.21%**

and Female management personnel accounted for **33.99%**



8. All data in this section contain Chen'an Bio

In addition, the Company has established systems such as the *Interim Measures for the Administration of Retirement and Re-employment of Employees*. On the premise of meeting the employment needs, it provides suitable opportunities for experienced retired employees to return to work. At the same time, the Company actively pays attention to the employment needs of vulnerable groups, and promotes inclusive social development by providing equal employment opportunities and improving welfare guarantees.

As of the end of the Reporting Period

The Company employed **25** re-employed retired employees


actively recruited **31** Persons with disabilities

and the number of ethnic minority employees reached **326**



At the end of 2024, the Women's Federation of Zhifei was officially established, and its first Women's Congress was successfully convened, during which the first Executive Committee of the Women's Federation was elected. In 2025, the Women's Federation of Zhifei officially commenced operations, providing female employees with a dedicated platform for communication and development, and further demonstrating the Company's strong commitment to gender equality, women's advancement, and a diverse and inclusive culture.

During the Reporting Period, the Company did not have any incidents related to workplace discrimination.



● The Site of the Establishment Event of the Women's Federation of Zhifei

High-end Talent Introduction

Relying on the Municipal Postdoctoral Research Workstation approved in May 2023, Zhifei accelerates the integration of top experts' resources from multiple disciplines. In July 2024, the workstation welcomed its first full-time postdoctoral fellow. This year, the relevant research projects were carried out in an orderly manner, and the mid-term assessment was successfully completed, injecting strong scientific research impetus into the construction of the Company's high-level talent echelon.


The Beijing Innovation Incubation Center actively links up with universities, research institutions and innovative enterprises, integrates technology, talent and platform resources through cross-field collaborative innovation, and brings together more than 100 top technical talents from well-known national universities and research institutions such as Tsinghua University, Peking University and Chinese Academy of Sciences, covering majors such as biology, genetics, microbiology, pharmacy and biomedical engineering. There are 11 project leaders with a doctoral degree, and nearly 100% of the personnel have a master's degree or above.

In 2025, 3 master's students jointly cultivated by Zhifei Lvzhu and Shenyang Pharmaceutical University successfully obtained their graduation certificates and master's degrees. 2 jointly cultivated postgraduate students are currently conducting experiments related to their graduation projects.



Empower growth, drive innovation

Zhifei firmly implements the strategy of "driving business development with talents" and is committed to building a learning organization. The Company has built a comprehensive and full-cycle empowerment system, actively integrated high-quality internal and external resources, and encourages employees to be self-driven and pursue further education.



Systematized Empowerment Platform

Zhifei has formulated and implemented the *Training Management Protocol* and dynamically adjusted the annual training plan for all employees. The Company has established a three-dimensional training matrix featuring "value leadership, in-depth development of professional capabilities, and leapfrog development of leadership", covering multiple levels such as new-employee training, special post-specific training, and corporate culture training. The aim is to help employees meet job requirements, calmly cope with technological innovations, and achieve the synchronous resonance between personal value and corporate development.

In 2025

The Company invested RMB **9.886** million in training

with a cumulative training duration of **387,980.46** hours

an average training duration per person of **61.66** hours

and a training coverage rate of **100%**



Full-cycle Training Matrix

New Recruits Training

Zhifei regards new employees as the fresh force for corporate development and has implemented a special training mechanism of "empowering employees upon entry". The training content covers the core aspects of corporate culture such as historical evolution, corporate vision, organizational structure, rules and regulations, and salary and welfare. It is also accompanied by teaching of essential job skills to help new employees quickly achieve the role transformation of "understanding the industry, the Company, and themselves".

In 2025

A total of **5** sessions of new-employee training and assessment were completed

with **194** person-times participating.



New Recruits Clearance Assessment

To ensure the effectiveness of training, the Company has introduced a closed-loop mechanism of "training + assessment". In the 5 sessions of new training in 2025, the Company emphasized the courses on the Good Manufacturing Practice of Medical Products (GMP) and industry regulations. Through strict written examinations, new employees met the standards in terms of knowledge of the vaccine industry and compliance awareness, laying a solid foundation for them to quickly take on their jobs.



● New Recruits Training Site

Job-specific Training

For key positions such as R&D, clinical, production, quality control, storage and transportation, EHS (environment, health, and safety), and sales, Zhifei has formulated a differentiated annual professional training plan. The curriculum system is updated dynamically in line with business development and technological iteration, covering training content such as on-the-job skills and comprehensive quality improvement. It relies on an online learning platform to achieve efficient access to training resources and full-scale coverage, consolidating employees' ability to perform their duties.

In 2025

The administrative headquarters carried out **109** sessions of various types of training

More than **90,000** person-times participating

The online learning platform pushed learning content **248** times



Carried out **12** product knowledge assessments

covering nearly **900,000** person-times.

Training Key Points for Each Core Position

Research and development		A series of special training on R&D quality management has been carried out around the concept of Quality by Design (QbD) to promote scientific, standardized, and efficient R&D work.
Quality		The Company has carried out full-scale quality awareness training for all employees, covering key elements such as the Good Manufacturing Practice of Medical Products (GMP), quality management system, and quality inspection methods.
Sales		Training on product knowledge and compliant marketing responsibilities has been provided for all marketing personnel and employees of relevant departments.
Distribution		The content covers transportation safety, temperature control, emergency response, and return receipt management to ensure that delivery personnel comply with safety operating specifications during drug transportation.
Clinical trial		The content covers core topics such as drug clinical trial safety, clinical research ethics, and trial protocols to ensure that clinical trial personnel operate in a standardized and compliant manner.
Production		The content covers key areas such as production quality management and pollution control in workshops to strengthen aseptic awareness and operating specifications.
Pharmacovigilance		Training on pharmacovigilance risk management has been carried out in accordance with the requirements of Good Pharmacovigilance Practice (GVP), providing clear directional guidance for employees in relevant positions.

Zhifei Carried Out Job-specific Training

To strengthen talent development and organizational capabilities, Zhifei has continuously carried out special training for sales management personnel. Focusing on themes such as familiarity with product knowledge, strengthening of compliance awareness, mastery of promotion methods, and improvement of comprehensive quality, the Company systematically enhances the professional qualities and business combat capabilities of the team, helping employees improve their skills and achieve career growth.



● Photo of the Training Site for Sales Management Positions

Leadership Training

Zhifei relies on the "online management reading club" and "off-line management workshop" to organize management personnel to read classic management books together, discuss practical cases, extract best management practices, and jointly create management methods and strategies, continuously improving the strategic leadership ability of the senior management team.

Corporate Culture Training

Zhifei advocates a cultural atmosphere of active learning and continuously conducts diverse activities such as corporate culture theme lectures and e-publication reading clubs. By building an open communication platform, the Company promotes in-depth discussions and ideological exchanges among employees on corporate culture, deepens the whole staff's recognition of the Company's business purpose and core values, and mobilize the collective strength of the organization to overcome difficulties and challenges.

In 2025, Positive-energy article sharing activities were carried out for **365** days. **20** corporate culture forums for management personnel and **10** for back-office staff were held.

Support for Education and Qualifications

Zhifei encourages and substantially supports all full-time employees to improve their education through self-study exams, correspondence courses, distance education, on-the-job postgraduate programs, etc., and apply for professional titles and vocational qualification certifications. In 2025, the Company formulated the *Salary Adjustment Plan for Administrative Functional Departments, Market Back Office and Refrigerated Truck Drivers in 2025*, which incorporates the professional and technical titles, vocational qualifications, academic degrees and diplomas obtained by employees on their own into the salary accounting system. After verification and evaluation, the Company provides corresponding rewards and promotion opportunities to eligible employees, thereby motivating employees to continuously deepen their expertise and achieve personal value-added.



Value Sharing to Stimulate Vitality

Zhifei continuously improves the institutional system based on *the Remuneration Management System* and *the Performance Appraisal System*, implements the distribution principle of "Salary by post, pay by performance, and get more for more work", and constructs a remuneration and welfare system that is both fair and competitive in the market. Through clear career promotion paths and an internal talent flow mechanism, the Company fully taps the potential of talents and realizes the co-creation and win-win situation of personal value and corporate benefits.

Remuneration System

Zhifei has constructed a scientific remuneration management system centered on responsibility, ability, and performance. The Remuneration and Appraisal Committee is established under the Board of Directors to supervise the implementation and provide optimization suggestions.


The remuneration of all employees (including non-management and non-sales employees) consists of "fixed income + floating income". The floating income is linked to personal performance and corporate performance, and combined with regular incentives and additional reward mechanisms, which fully stimulates the vitality of the organization and ensures that employees reasonably share the Company's operating results.

Career Development

Zhifei is committed to building a "flyover" for career development that is vertically smooth and horizontally interconnected. The Company formulates differentiated standards for different sequences, determines promotion qualifications based on ability, performance, and contribution, and stimulates employees' internal motivation.


Functional Sequence

It is divided into 6 levels, covering the complete path from basic execution to strategic management.



Clinical Sequence

A full-chain path from a first-level monitor to a department general manager has been constructed, opening up the career development path for clinical professional talents.



Sales Sequence

It is divided into 3 levels, focusing on performance contribution and market expansion ability.



The Company adheres to the principle of "Objective and fair, matching people and posts" and organizes at least one promotion assessment every year. For non-sales functional departments, the Company has established special promotion rules to provide additional bonus incentives and promotion opportunities for high-performing employees. At the same time, relying on the internal competition platform, the Company conducts public competitions every year in accordance with the *Public Competition for Posts Management System*, fully mobilizing the enthusiasm and creativity of employees and realizing the dynamic optimization and adjustment of the team. In 2025, the Company focused on conducting competitions for market personnel, established a high-quality reserve pool of market management talents, and strengthened the echelon construction.

Performance Management

Zhifei strictly implements the *Performance Appraisal System* to ensure the openness, fairness and impartiality of the assessment work. The Company implements an assessment mechanism of "quarterly review + semi-annual comprehensive assessment" for all employees, and directly links the results with salary adjustment and position promotion, giving full play to the guiding role of the assessment. At the same time, the Company provides employees with fair performance feedback, and offers performance support training and performance guidance to help employees continuously improve their performance.

Performance Appraisal Dimensions



The Company has established a standardized closed-loop mechanism for performance appeals and feedback. The Human Resources Department serves as the acceptance window, responsible for receiving written appeal materials submitted by employees; the Performance Appraisal Committee undertakes the final review responsibility. If an employee has doubts about the performance result, the Company will immediately initiate an objective verification and feedback the conclusion to ensure that both parties reach an agreement and safeguard the employee's performance rights and interests.

Long-Term Incentives

To improve the long-term incentive mechanism of sharing interests and risks, Zhifei has launched multiple phases of employee stock ownership plans since 2016, enabling employees to become shareholders of the Company and share the development dividends. The number of participants in the plan has expanded from 445 in the first phase to 1,923 in the third phase, significantly broadening the scope of incentives and continuously releasing the incentive effectiveness. By binding core talents in the long term, it promotes the Company to maintain a leading position in the industry.



A Warm-Hearted Work Environment for a Happy Workplace

Zhifei is well aware that a harmonious labor relationship is the cornerstone of the stable development of an enterprise. The Company is committed to creating a workplace ecosystem full of humanistic care. Through building an equal and open communication platform and a diverse and inclusive welfare system, it effectively enhances employees' sense of belonging, gain and happiness, achieving the symbiotic development of the enterprise and employees.

Democratic Communication and Feedback

Zhifei regards employees' voices as the source of management improvement. It has established diverse communication channels to create a positive and harmonious communication atmosphere and comprehensively understand employees' needs. The Company optimizes the internal information sharing and appeal mechanism to ensure unobstructed feedback channels for employees, and quickly formulates improvement plans based on the feedback to promptly and effectively respond to and solve employees' demands.

Information Transparency

- Rely on the Zhifei Zhixun official WeChat account and *Zhifei Internal Journal* to promptly release updates on business operations and corporate culture.
- Promote compliance policies through the Xiaozhi Talks on Law platform to strengthen employees' awareness of rules and compliance.

Multi-dimensional Dialogue Mechanism

- Assign employee relations specialists to conduct one-on-one interviews.
- Hold regular management meetings to discuss challenges and opportunities.
- Organize Face-to-Face with the President forums, where senior management directly answers questions and addresses concerns.

Appeals and Reports

Zhifei has formulated and implemented *the Employee Complaints and Reports Management System*, and set up unobstructed and confidential appeal and reporting channels such as the Company's mailbox and the complaint and report suggestion box. It encourages employees to report various unreasonable and irregular behaviors such as discrimination, corruption and abuse of power in a timely manner to safeguard the legitimate rights and interests of employees and the Company. The Company promises to strictly keep confidential the information of the whistle-blowers and the investigation and handling process, and firmly resist any acts of retaliation, effectively safeguarding the legitimate rights and interests of the appellants, whistle-blowers and investigation participants.

Complaint Handling Process

Whistle-blower complaints Feedback to the Human Resources Director	Judgment and registration The Human Resources Director judges the severity of the situation and registers the report information.	Investigation and handling The Complaint and Report Handling Committee shall conduct an investigation and handling within 60 days. If an extension is needed, it shall not exceed 90 days.	Feedback to the whistle-blower Provide a written feedback within 5 days after the handling is completed.
--	---	--	--

Satisfaction Management

Zhifei carefully listens to the voices of every employee, continuously identifies and evaluates the key influencing factors of employee satisfaction, and dynamically optimizes the workplace environment. The Company conducts an anonymous satisfaction survey covering all employees every year to accurately assess the organizational health.

Training satisfaction

Conduct at least one training effectiveness assessment every year, with a coverage rate of no less than 50% of the participants in the current period, and continuously optimize the training quality. The training satisfaction rate will reach over 98% in 2025.

Management satisfaction

Conduct a "downward evaluation" for the market directors to promote the improvement of management efficiency and unblock the feedback channels for employees.

Employer satisfaction

A survey of employer power was conducted among personnel in the functional departments of the headquarters, some market management personnel, and grass-roots employees. Organizational issues were diagnosed from dimensions such as salary incentives, employee benefits, career development, work environment and atmosphere, leadership and management levels, corporate culture, and value recognition to enhance the attractiveness of talents.

Employee Benefits and Care

Zhifei adheres to the people-oriented concept. On the basis of legal benefits, it has built a comprehensive welfare map covering health, life, and festivals. The Company has formulated *the Welfare Management Policy* to provide all employees with additional benefits such as employee physical examinations, paid annual leave, paid parental leave, and festival gifts, and practices the principle of "healthy work and happy life". At the same time, the Company implements flexible work arrangements such as working from home according to employees' needs to provide more options for employees with real needs.

Diverse Welfare System

Special Benefits

Filial piety salary, nutritious work meals, employee dormitories, health examinations, education benefits, free canteens, special holidays, etc.

Labor Union Care

Birthday gifts, festival benefits, wedding and childbirth gifts, condolences for weddings and funerals, team-building activities, etc.

Basic Benefits

Paid annual leave, paid parental leave, communication subsidies, accidental injury insurance, etc.

Colorful Team-Building Activities to Unite the Team

In 2025, Zhifei organized a variety of team-building activities, which not only relaxed the employees' minds and bodies but also greatly enhanced the team's cohesion and combat effectiveness.

Fujian Market:

A themed activity titled Gather in Fuzhou, Walk the Fortune Trail, and Embrace Good Fortune was organized, with enthusiastic participation from employees, further strengthening cross-departmental communication and collaboration.

International Women's Day Condolences:


On March 8, 2025, the labor union sent holiday blessings and condolences to all female employees, conveying the Company's respect and gratitude for "her power".

Hubei Market:

A team-building activity named "Unite to Overcome Difficulties and Set Sail on a New Journey" was held, boosting the team's morale to overcome difficulties.

Summer Coolness Condolences:

As summer temperature continued to rise in summer, the Company had carefully prepared cool materials and delivered caring summer care to colleagues in time, truly conveying the Company's gratitude and care for the hard work of employees.



Zhifei actively creates a "mother-friendly" environment. It has set up nursing rooms in the office area, opened a dedicated dining channel and set up exclusive seats for pregnant employees, and ensures that all employees enjoy paid maternity and parental leave. Through meticulous care, the Company helps female employees balance work and family.




Female Employee-Friendly Work Environment

Maternity and Parental Leave Policy

<p>All female employees: Enjoy at least 98 days of paid maternity leave</p>	<p>All male employees: Enjoy at least 15 days of paid paternity leave.</p>	<p>All employees: Parents of children under 3 years old enjoy at least 5 days of parental leave per year.</p>
--	---	--

Labor Union Construction and Cohesion

The labor union of Zhifei adheres to the positioning of "what the party and government need, what the workers expect, and what the labor union can do" and gives full play to its role as a bridge and link. By strengthening the management and supervision functions of the employees' congress, establishing an effective information communication mechanism, and broadening the channels for democratic participation, the labor union stimulates the enthusiasm and creativity of employees to participate in enterprise management and consolidates the organizational foundation for building a harmonious labor relationship.





Cooperation and Industry Growth

Zhifei always adheres to the ecological positioning of "industry symbiosis" and is committed to building an open, collaborative, and resilient biomedical industry ecosystem. The Company regards suppliers, scientific research institutions, medical organizations, and universities as core partners for value co-creation, continuously deepens the in-depth integration of "industry, academia, research and healthcare" and the full-life cycle management of suppliers, and joins hands with all parties to jointly drive the high-quality development and sustainability of the biomedical industry.



Collaboration with Partners for a Responsible Supply Chain


Zhifei strictly abides by laws and regulations such as *the Law of the People's Republic of China* on Tendering and Bidding and combines the GMP quality management system to build a strict and efficient supplier management system. With the goal of building a compliant, efficient, and sustainable supply chain, the Company promotes the collaborative development of the upstream and downstream of the industrial chain through a trinity management strategy of "quality-resilience-responsibility".

Quality as the Foundation, Controlling the Full Life Cycle

Zhifei formulates and strictly implements internal management systems such as the *Supplier Management System*, the *Procurement Management System*, and the *Regulations on Classification and Grading Management of Materials and Materials*. It strictly standardizes the processes of supplier screening, access, and exit, achieving closed-loop management throughout the entire life cycle. In 2025, the Company updated and released systems such as the *Notice on Standardizing the Procurement of Service Projects*, the *Standard Operating Procedures for Supplier Selection*, the *Standard Operating Procedures for Supplier Audit*, and the *Emergency Management System for Cold Chain Abnormal Situations*, further standardizing the procurement and review processes of service-related projects.

Screening, Access, and Exit

Zhifei adheres to the principle of fairness and establishes a detailed mechanism for supplier screening, access, and exit.




Supply Chain Risk Management

Zhifei aims to build a supply chain system with stability, cost-competitiveness, and risk-resistance as the goal of supply chain risk management. It formulates and implements a risk management plan, committed to ensuring the long-term safe operation of the business. For key and bottleneck materials, the Company actively develops certified alternative suppliers and establishes a dynamic safety stock to deal with sudden disruptions. It implements classified management based on the importance of suppliers, deepens collaboration and shares risks with strategic and key suppliers, and focuses on efficiency and cost optimization for general suppliers. At the same time, for materials with high import dependence, it reduces supply risks through dual paths of inventory reserve and domestic substitution, and comprehensively considers multiple risk factors such as suppliers, logistics, and geopolitics in the inventory strategy to achieve forward-looking risk management.

Classification Management and Audit

Zhifei implements a refined supplier classification management strategy. Based on business needs, material characteristics, and the nature of suppliers themselves, suppliers are divided into three categories: material suppliers, service providers, and storage and transportation service providers. Special systems such as *the Material Supplier Audit Management Procedures*, *the Management Regulations for Service Providers*, and *the Management Regulations for Storage and Transportation Service Providers* are formulated respectively, clarifying the full-process control standards from screening, auditing, signing contracts to annual evaluation.

The Company conducts in-depth quality audits on all direct and indirect suppliers that have gained access. The audit content covers multi-dimensional indicators such as plant facilities, personnel allocation, and material management. Differentiated audit plans are customized according to the supply types of suppliers, and a flexible and efficient audit combination is adopted:



At the end of each year, the Company summarizes the annual supplier cooperation and audit data for comprehensive evaluation, continuously and dynamically tracks the quality status of suppliers, and ensures the stability and reliability of the supply chain.

In 2025

The Company completed a total of

64 supplier quality compliance audits

Covering most key suppliers, with an

audit pass rate of **100%**

Supplier Classification	Detailed Categories	Key Verification and Quality Audit Requirements (Partial)
Material Suppliers	According to the material usage and production process risks, they are divided into three levels: A, B, and C, corresponding to Class I, II, and III materials respectively.	<ul style="list-style-type: none"> Review and verify the qualifications of material suppliers quarterly. Evaluate the material inspection, usage, after-sales service, and the validity of supplier qualifications annually. Ensure that key suppliers have undergone formal audits. For Class A material suppliers, on-site quality audits are conducted by professional personnel every 2 years, and quality agreements are signed every 3 years.
Service Suppliers	According to the degree of impact on products, they are divided into Class I, II, and III suppliers.	<ul style="list-style-type: none"> Conduct qualification confirmation, questionnaires, on-site audits, and annual reviews respectively. Re-verify the qualifications every six months, and issue questionnaires when new suppliers are added or during regular re-verification. Sign quality agreements with major service providers every 3 years.
Storage and Transportation Service Providers	Manage them in a unified category. According to quarterly and annual evaluation reports, the assessment is divided into three levels: A, B, and C.	<ul style="list-style-type: none"> Only those with a perfect quality management system and no serious illegal or 违规行为 in the past 5 years can cooperate. Conduct on-site audits before delegation and regular audits on qualifications, storage and transportation facilities, personnel training, quality assurance, safe transportation, risk control, etc. If a supplier gets a B grade in quarterly/annual assessment, send a quality warning letter and require them to make rectifications within a time limit. For those that fail to meet the standards, their continuation or removal will be determined through risk assessment. Do not delegate tasks to suppliers whose storage and transportation facilities or automatic monitoring systems do not meet the regulations or have not been verified. Strictly implement the "Vaccine Entrusted Storage and Cold Chain Transportation Service Contract", and strictly prohibit entrusted distributors from re-delegating.

Quality Inspection

Zhifei regards raw material quality as the primary defense line for product safety. It regularly checks the quality of raw materials and has established a comprehensive quality closed-loop control system covering material acceptance, storage, self-testing, and entrusted inspection.

Refined Warehousing Management

Zhifei Longcom focuses on standardized acceptance and digital storage to improve warehousing operation efficiency.

<p>Strict inspection upon warehousing</p> <p>After the arrival of purchased materials, the warehouse management staff strictly conducts double checks of "physical goods + documents" according to the approved documents to ensure that the materials meet the procurement requirements.</p>	<p>Classified disposal</p> <p>Strictly implement the mechanism of "warehousing qualified materials and isolating abnormal ones", and simultaneously complete document archiving, ledger recording, and inspection applications.</p>	<p>Intelligent storage</p> <p>Relying on the WMS and strict environmental control, achieve precise control and full-process traceability of material storage, significantly reducing losses.</p>
--	--	---

Standardized Inspection System

Zhifei Lvzhu has formulated and implemented three core systems, namely the Standard Operating Procedures for Inspection Management, the Standard Operating Procedures for Establishment and Management of Quality Standards, and the Standard Operating Procedures for Entrusted Inspection Management, which have established a standard paradigm for inspection work.

Establish a full-coverage quality standard for raw and auxiliary materials, packaging materials, intermediate products, and finished products, and strictly implement the principle of "no release for unqualified products".

For projects that cannot be covered by its own equipment capabilities, entrust third-party inspection agencies with legal qualifications to conduct inspections to ensure the authority and compliance of each inspection report.

Two-way Communication and Empowerment

Zhifei regards suppliers as a key strategic force for the Company's development and actively conducts in-depth two-way communication on quality and technology. The Company has established a diversified interaction mechanism including online communication, on-site visits, high-level talks, and special training sessions, and implemented a closed-loop feedback mechanism to ensure that pain points in production and supply are resolved in a timely manner.

The Quality Center of the Company, in cooperation with relevant departments, conducts annual training for suppliers by category according to the requirements of classified management and actual needs. Based on supplier assessment reports and audit findings, the Company provides targeted guidance of "one-enterprise-one-strategy" to assist suppliers in obtaining relevant certification qualifications and building a mutually beneficial, stable, and long-term supply chain ecosystem.


This year, the Company's supplier quality assurance training covered key suppliers in various categories.

A total of **10** on-site and online training sessions were conducted for raw and auxiliary materials and packaging material service providers

with topics including sterilization processes and aseptic assurance

Join Hands With Key Raw and Auxiliary Material Partners to Strengthen Pollution Control Capabilities


In July 2025, Zhifei Longcom joined hands with Merc Group, a global key raw and auxiliary material supplier, to hold a special seminar on "In-depth Implementation of CCS Pollution Control Strategy and Practical Deviation Investigation". The seminar covered production and quality management personnel from all subsidiaries. By sharing international advanced practices and analyzing actual cases, the team's professional capabilities in pollution control and deviation management were systematically strengthened, contributing to the improvement of the full-life-cycle quality assurance system for drugs.



The Site of the Pollution Control Special Seminar

Conduct Key Material Audit Training to Jointly Build a Supply Chain Safety Defense Line

In 2025, according to the supplier audit plan, Zhifei Lvzhu completed key audit training for 9 first-category suppliers of raw and auxiliary materials, inner packaging materials, and key materials. The training, with topics such as "Sterilization process and aseptic assurance of aseptic inner packaging materials", was conducted in the form of on-site lectures, effectively improving the aseptic assurance capabilities of core suppliers, jointly fulfilling the supply chain safety responsibility, and ensuring the stability of product supply.



The Site Where Zhifei Lvzhu Conducts Quality Audit Training for Suppliers

Use Resilience as a Shield to Ensure Material and Logistics Supply

Facing the complex and changeable external environment, Zhifei adheres to the Supply chain resilience strategy of "preparing for a rainy day and diversifying layout". The Company formulates combined preventive measures such as dual procurement, pre-stocking, and domestic substitution to avoid the risk of supply interruption. At the same time, the Company promotes different production bases to serve as backups for each other, realizing flexible allocation of production capacity and emergency coordination, and further ensuring the continuity and stability of production and operation.

Robust Material Supply



In 2025, to effectively lock in procurement prices and high-quality production capacity

Zhifei Lvzhu has signed framework agreements with **47** regular cooperative suppliers

Zhifei Longcom has signed long-term agreements with **49** qualified suppliers,

the procurement amount accounting for **71.2%** of the total annual material procurement

the procurement amount accounting for **81.9%** of the total annual material procurement.



Approved as the First Pilot Unit of the Joint Supervision Mechanism for High-risk Special Imported Items in Hefei

In 2025, Zhifei Longcom was successfully approved as the first pilot unit of the joint supervision mechanism for high-risk special imported items in Hefei. By optimizing the approval process and supervision mode, the Company has shortened the delivery time of imported materials by 30%, significantly improving the supply chain response speed and customs clearance efficiency, and providing strong support for the timely supply of production materials.

Stable Storage and Distribution

Zhifei continuously strengthens the construction of warehousing and logistics capabilities, formulating and strictly implementing relevant systems such as the Operation Procedure and Specification for Driver Distribution, the Emergency Management System for Cold Chain Abnormal Situations, and the Road Transportation Safety Abnormality Disposal System. Relying on digital management, dynamic inventory, and emergency response mechanisms, the Company ensures the safe and efficient storage and circulation of materials.



Digital WMS System

Adopt the Warehouse Management System (WMS) to track the entire life cycle of materials, realizing automated management and real-time updates of inbound, outbound, and inventory queries, which greatly improves the management accuracy and efficiency.



Dynamic Safety Inventory

Establish a scientific safety inventory mechanism, and dynamically adjust the procurement plan monthly according to the production plan, inventory status, delivery time, and inspection cycle to ensure that the inventory reserve is always within the safe range.



Multi-location Warehousing Layout

Relying on the Phase IV warehouse of Zhifei Airport in Beijing Tianzhu Bonded Area and the Phase II warehouse of Chongqing Zhifei Warehousing and Logistics Base, the Company has strengthened the multi-location storage and safety guarantee capabilities of agency imported products in China.

The Company has established an emergency response team for cold chain anomalies, composed of the person in charge of quality, the operation department, the logistics department, the safety affairs management department, and the person in charge of the Quality Management. In case of any anomaly in cold chain facilities or equipment during storage and transportation, relevant personnel shall report to the person in charge immediately, isolate and store the relevant products while maintaining the temperature control condition of 2-8°C, strictly prevent the risk of temperature deviation, keep records of the above-mentioned cold chain anomaly handling process, and at the same time, keep records of equipment maintenance and report to the logistics department for filing.

Flexible Logistics Transportation Strategy

To ensure logistics safety, Zhifei Lvzhu requires suppliers to adopt a flexible logistics transportation strategy and reasonably plan logistics routes and transportation methods for highly temperature-sensitive materials. Suppliers need to plan transportation routes in advance and clarify backup plans for extreme weather, including transportation forms such as land-to-railway and land-to-air, to ensure the transportation safety of temperature-controlled materials.

Lead with Responsibility and Build a Sustainable Ecosystem Together

Zhifei is committed to building a responsible supply chain system. It focuses on suppliers' performance in aspects such as employment, occupational health and safety, business ethics, and environmental management, which are included as important criteria for cooperation screening, and promotes the upstream and downstream of the supply chain to jointly fulfill social responsibilities.

Build an Integrity Defense Line

Zhifei strictly abides by laws and regulations such as *the Law of the People's Republic of China on Tendering and Bidding*, formulates and implements internal regulations such as *the Procurement Management System*, *the Third-Party Behavior Norms Management System*, and *the Due Diligence and Risk Assessment Process of Third Party Organizations* such as *the Institute*, and constructs an *anti-corruption and business ethics compliance system* covering its own operations and the supply chain.

Due Diligence and Access Risk Control

Before cooperation, risk assessment is conducted on all customer units, with a focus on reviewing records of bribery and corruption, and due diligence is carried out when necessary. In this year, Zhifei has formulated and publicly published *the Anti-Commercial Bribery and Anti-Corruption Policy*, clearly requiring suppliers to formulate anti-commercial bribery and anti-corruption systems and verifying their compliance. In addition, the Company regularly conducts business ethics audits on cooperative suppliers to continuously supervise the effectiveness of their relevant risk control measures and promote suppliers to continuously improve internal governance.



Transparency in the Whole Bidding Process

Before the bidding meeting, the bidding discipline is read out to ensure the transparency of the process and price; after the meeting, the judges collectively evaluate the bidding documents to ensure the fairness, impartiality, and openness of the decision-making process.

The Company requires all key suppliers to sign *the Integrity Agreement*, clearly prohibiting irregularities such as fraud and improper benefit transfer in the contract. Once a supplier is found to have violated the regulations, it will be permanently included in the blacklist and will never be allowed to enter the supplier list. Through daily inspections and annual evaluations, the Company ensures the honest and compliant operation of the entire supply chain.

In 2025, the Company **did not** find any corruption or fraud incidents involving suppliers.

Drive Green Transformation

Zhifei integrates the green concept into the entire procurement life cycle. During the access evaluation, the Company gives priority to cooperate with suppliers who have environmental management system certifications and use environmental-friendly equipment, and refuses to cooperate with enterprises with environmental violations, ensuring the sustainability of the supply chain from the source.

Digital Procurement

Zhifei Lvzhu continuously assesses suppliers' environmental protection, social responsibility, and corporate governance. In 2025, a total of 43 suppliers cooperated with Zhifei Lvzhu in ESG-related surveys. Zhifei Lvzhu has realized the onlineization of the entire procurement process based on the ERP platform, reducing carbon emissions through paperless office work.

Packaging Material Environmental Assessment

In 2025, Zhifei Longcom continuously evaluated the sustainability capabilities of material suppliers, focusing on verifying suppliers of outer packaging materials such as vials, rubber stoppers, instructions, and packaging boxes. All relevant suppliers have passed environmental management system certifications such as ISO 14001, effectively ensuring the environmental compliance of the purchased materials.

Environmental Compliance Audit

During supplier screening and periodic reviews, Zhifei Longcom rigorously verifies the validity of suppliers' environmental management system certifications. Through on-site audits, the Company focuses on assessing suppliers' implementation of toxic waste management practices—such as the classification, storage, and disposal of chemical reagents and hazardous waste—to ensure compliance with environmental protection requirements and that disposal is carried out by certified entities. Additionally, these audits confirm suppliers' compliance with waste recycling and harmless disposal standards, thereby driving the reduction of toxic emissions across the supply chain.

Win-Win Cooperation across Industry, Academia, Research and Healthcare

Zhifei steadfastly implements an innovation strategy of "independent R&D as the mainstay, collaborative R&D as a supplement, and investment incubation as a complement, and is committed to building an open, collaborative, and efficient innovation ecosystem integrating industry, academia, research, and healthcare. With keen insight into the trend of integrated industry development, the Company proactively breaks down organizational boundaries and engages in in-depth collaboration with research institutions, pharmaceutical peers, and industry partners. While strengthening its own technological capabilities, the Company also promotes industry-wide knowledge sharing and technological iteration, jointly creating new value for the biopharmaceutical industry.



Industry: Build a High-End Industry Platform

Zhifei adheres to the Concept of "Openness, Inclusion, Co-construction and Sharing" and deeply integrates into the biomedical industry ecosystem. As a member of multiple national and provincial industry associations such as the China Vaccine Industry Association and the Chongqing Pharmaceutical Association, the Company earnestly fulfills its responsibilities, deeply participates in the formulation of industry standards, and leads the standardized development of the industry while achieving its own technological improvement.

Standard Leadership

Zhifei gives full play to its professional advantages and deeply participates in the drafting of multiple national industry standards, covering multiple key links in the entire chain from clinical trial management to cold chain storage and transportation, and contributes "Zhifei wisdom" to the improvement of the industry standard system.

Core Standards Participated in Drafting in 2025


Guidelines for Quality Management of Vaccine Clinical Trials (Trial Implementation)

Good Practice for the Management of On-site Personnel in Vaccine Clinical Trials

Guidelines for the Management of Contract Research Organizations by Vaccine Clinical Trial Institutions

Specifications for Cold Chain Monitoring and Disposal of Vaccines for Clinical Trials

Good Clinical Practice for Vaccines for Clinical Trials



Technical Exchange

Zhifei actively organizes the backbone of its production and Quality Center to "go out" and conduct in-depth technical dialogues with industry benchmarks and regulatory experts to continuously improve the professional skills and compliance awareness of all employees.

Discussion on Pharmaceutical Packaging Materials Standards and FDA The Second R&D Series Training of Zhifei


In June 2025, Zhifei Longcom participated in the Bidi Medical Pharmaceutical Systems Asia Pacific Integrated Technology Center Workshop. The team deeply understood the latest trends in national standards for pharmaceutical packaging materials, clarified the core compliance requirements of combination products under the supervision of the US FDA, and broadened the international compliance management vision.



● Workshop Site

Clinical Trial Quality Management Training

In August 2025, Zhifei participated in the New Trend High Quality Development Vaccine Clinical Trial Quality Management Training Course held by the Zhongguancun Jiutai Drug Clinical Trial Technology Innovation Alliance in Beijing. The Company deeply discussed the new paradigm and compliance points of clinical trial quality management with industry partners, learned from cutting-edge practices, and continuously improved the professionalism of its business.



● Photos of the Industry Specialized Training Event Site

The 34th Conference on Drug Quality Inspection and Testing Technology

In August 2025, the R&D department of Zhifei Longcom organized personnel to participate in the 34th Conference on Drug Quality Inspection and Testing Technology, aiming to deeply understand and implement the 2025 edition of the *Chinese Pharmacopoeia*. The conference focused on aspects such as the interpretation of the new edition of the pharmacopoeia and regulations, post-marketing change review, and GMP compliance inspection.

The team focused on the five enabling dimensions of AI technology in the field of drug inspection, which provided important inspiration for the construction of the Company's intelligent quality inspection system; at the same time, it absorbed professional interpretations of the revised content of the new edition of the pharmacopoeia, providing clear guidance for compliance implementation.



● Site of the 34th Conference on Drug Quality Inspection and Testing Technology

Specialized Exchange on the Bacterial Endotoxin Test Method in the *Chinese Pharmacopoeia*

In August 2025, Zhifei Longcom participated in the online exchange on the Bacterial Endotoxin Test Method in the 2025 edition of the *Chinese Pharmacopoeia* held by Fuzhou Xinbei Biochemical Industry Co., Ltd. The event focused on the innovation of detection technology, with a key discussion on the reduction of Limulus Amebocyte Lysate (LAL) use and the protection of scarce resources, practiced the concept of green monitoring, and promoted the two-way flow of professional knowledge.

The 5th China Conference on Quality Control of Biological Products

In September 2025, Zhifei Longcom went to Qingdao to participate in the 5th China Conference on Quality Control of Biological Products, keeping up with the global forefront of bioproduct quality control and supervision. The team mainly participated in multiple specialized sessions, deeply studied key contents such as the WHO pre-certification technical standards; and through closed-door exchanges with the drug review center and domestic peers, explored the implementation path to accelerate the alignment of domestic vaccines with international standards, laying a solid foundation for the formulation of subsequent registration strategies.



● Site of the 5th China Conference on Quality Control of Biological Products

Benchmarking with Industry-Leading Quality Management Experience

From September to October 2025, Zhifei Longcom went to core technical service platforms such as the Merck Life Sciences Shanghai Technology Application Testing Center and the Thermo Fisher China Customer Experience Center and Bioprocess Design Center for exchange and learning. The team deeply learned from the mature experience of international giants in quality management, process optimization, and risk prevention and control to help the Company upgrade its quality management system.



● Exchange and Learning Site

Learning: Deepening Industry-Education Integration


Zhifei regards talents as the primary resource for innovation and has established long-term cooperative relationships with multiple universities. Relying on platforms such as the Postdoctoral Research Workstation and the Industry-University-Research Cooperation Base, the Company has built a comprehensive industry-education integration system. The Company conducts a variety of school-enterprise cooperation and exchange projects every year, building a broad platform in scientific research, talent co-cultivation, internships, and employment, continuously expanding the reserve of high-quality talents, and injecting a continuous source of vitality into the long-term development of the enterprise.

Joint Training

In 2025, Zhifei Lvzhu continued to deepen its cooperation with Shenyang Pharmaceutical University and steadily advanced the joint postgraduate training program. By complementing each other's strengths, the two sides strengthened the high-level talent development model of "theory + practice", and provided the enterprise and the industry with professional talents with practical abilities.

Recruiting Talents from Campuses

In September 2025, graduates from the School of Life Sciences, Beijing University of Chemical Technology visited Zhifei Lvzhu and had in-depth discussions with the Company's leaders. The two sides had a lively exchange on the development path of the biomedical major and future career planning, effectively breaking the information barrier between campus and workplace and helping to achieve an accurate match between the talent development of universities and the employment needs of enterprises.



● The School of Life Sciences, Beijing University of Chemical Technology visited Zhifei Lvzhu

R & D: Driving Technological Breakthroughs

With a global perspective, Zhifei continuously collaborates with top-tier domestic and international technology teams and high-quality scientific research institutions. Through complementary advantages and joint research, it accelerates the breakthrough of key biomedical technologies and the application of research results.

Internationalization of R & D

Zhifei has joined hands with leading global Contract Research Organizations (CROs) and multiple international study sites to establish an efficient cross-border clinical collaboration system. The Company has focused on advancing international multi-center clinical trials for the Bivalent Shigella Conjugate Vaccine and the 26-valent Pneumococcal Conjugate Vaccine, marking the official advancement of its clinical R&D capabilities toward internationalization. Through in-depth cooperation, the Company has achieved comprehensive alignment with international standards in trial design, execution standards, and quality control, accumulating valuable practical experience for future participation in the formulation of industry standards.

★ Cutting-Edge Research: Therapeutic Vaccine for Human Cytomegalovirus (HCMV)

In 2025, the R&D Center of Zhifei Longcom jointly carried out in-depth technical exchanges with Sun Yat-sen University on Human Cytomegalovirus (HCMV). Based on the virus's pathogenic mechanism and technical feasibility, the two sides conducted a scientific assessment and clarified the strategic direction of prioritizing the R&D of HCMV therapeutic vaccines or biological products, laying a solid foundation for the collaborative research of industry-university-research.

Transformation of Academic Achievements

Zhifei is committed to promoting the in-depth integration of theoretical innovation and technical practice and accelerating the transformation and application of R&D results. The clinical trial results of Zhifei Longcom's projects such as the Quadrivalent recombinant noro vaccine and influenza vaccine (split virion), inactivated, quadrivalent have been published in professional journals such as *Practical Preventive Medicine* this year. These achievements not only enhance the Company's academic influence in the industry but also provide "Chinese data" with important reference value for global vaccine R&D.




Medicine: Accelerating Clinical Transformation

Relying on extensive clinical resources, Zhifei deepens the "medical-enterprise integration" model and accelerates the clinical verification and marketing process of innovative products. The Company has established in-depth cooperation with 13 scientific research institutions and multiple hospitals, focusing on fields such as *innovative vaccines and tuberculosis prevention and control*, and promoting the standardized and efficient implementation of clinical trials.

In 2025, the Company actively expanded the layout of clinical trials, adding 1 clinical trial institution and 2 trial sites in Chongqing, further improving the local network of clinical research and enhancing the trial-bearing capacity.

★ Clinical Transformation: Multi-center Trial of Therapeutic BCG Vaccine

In 2025, Zhifei Longcom, in collaboration with 39 hospitals including the Cancer Hospital of Fudan University, carried out a clinical trial on the Therapeutic BCG Vaccine. Through multi-center and large-scale clinical empirical research, the project R&D process is steadily advanced, aiming to optimize the clinical treatment plan in relevant fields and benefit more patients.



● The Site of the Cooperation Launch Meeting of the Cancer Hospital of Fudan University



● The Site of the Cooperation Launch Meeting of the First Affiliated Hospital of Nanchang University



● The Site of the Cooperation Launch Meeting of the Jiangsu Cancer Hospital

7

Public Welfare and Social Development

As a fighter in the health cause and a participant in people's livelihood construction, Zhifei always takes "safeguarding human health, by preventing the unseen & treating the ailing" as its mission and adheres to the business principle of "social benefits go before corporate profits". It strategically focuses on three major fields: health, education, and rural revitalization, systematically promotes social responsibility practices, and continuously contributes to social development and people's livelihood improvement, demonstrating the spirit of "Zhi' ai" (Wisdom & Love).



Standardized Management for Long-Term Drive

To promote the standardized, orderly, and long-term implementation of social welfare actions, Zhifei has incorporated social responsibility management into its daily operation system and established the principle of "Standardizing Large-Scale Projects and Systematizing Small-Scale Initiatives". The Company relies on the Project Management Committee to be responsible for the whole-process management of social public welfare projects, including project approval, budget management, process supervision, and implementation evaluation, ensuring the standardized operation of public welfare projects, efficient use of resources, and continuously improving the systematicness and sustainability of social responsibility practices.

Rural Revitalization

Targeted assistance to contribute to common prosperity

Three Major Areas of the Social Responsibility Strategy

Health

Inclusive healthcare for health equity

Education

Rewarding teachers and supporting students to cultivate the future of the industry

Focusing on key areas such as health, education, and rural revitalization, the Company continuously promotes the standardized implementation of public welfare and charity projects. Combining the nature of the projects with actual needs, it comprehensively formulates donation plans, implements the allocation of materials and funds, follows up on implementation, and provides feedback on the effectiveness of public welfare, so as to ensure that charitable resources are more accurately and efficiently invested in relevant fields. In 2025, the Company actively participated in 12 charity donation projects, including both direct cash donations and donations of materials such as vaccines, medicines, and medical equipment, with the actual donation amount reaching approximately RMB 3.22 million. Meanwhile, the Company actively organizes employees to participate in public welfare volunteer services and continuously expands the forms of social responsibility practices. Thanks to our long-term investment and solid actions, we have successively won many honors such as the "China Charity Award" and the "Chongqing Charity Award", demonstrating the nature of a caring enterprise and our sense of responsibility.

The Company has actively engaged in poverty-alleviation donations, inclusive healthcare, disaster relief, caring for the elderly and children, and rural revitalization. In recent years, the cumulative donations have

exceeded RMB **400** million



Inclusive Healthcare for Better Health

Zhifei closely aligns with the "Healthy China strategy and is committed to improving the overall health of the population and enhancing access to medical services. The Company continues to translate its professional capabilities in disease prevention into inclusive healthcare practices, contributing to the development of the public health system. Adhering to its business philosophy of "Innovative R&D, Serving the Public, the Company has been deeply engaged in infectious disease prevention and control for more than two decades. Leveraging advanced technology platforms, a portfolio-based product layout, and full lifecycle quality management, it builds a safe and effective immune barrier for people of all age groups. At the same time, the Company actively responds to the national policy direction on tiered diagnosis and treatment. Through public health initiatives, disease prevention support, and primary-level capacity building, it facilitates the flow of high-quality medical resources to key populations and key regions, making health services more equitable and accessible.

Caring for Female Health

Zhifei places female health protection at the core of its social responsibility strategy, aiming to enhance female health awareness and the accessibility of health services. The Company focuses on major health risks faced by females and deeply participates in female health public welfare projects. Through popular science education, professional services, and resource coordination, it helps to improve public scientific knowledge.

Empowering in Multiple Ways to Build a Publicity and Education Matrix

Since 2013, Zhifei has continuously invested funds to support the "China Female Cervical Health Promotion Program" initiated by the China Women's Development Foundation. Aiming to leverage its own resource advantages, it aims to convey the concept of scientific prevention and treatment to a large number of females. In 2025, the Company deepened the project cooperation and established a three-dimensional publicity and education matrix covering online live broadcasts, in-person exchanges with offline experts, female health classes, urban walking events, health color runs on college campuses, and the distribution of popular science brochures. This matrix precisely disseminates knowledge about cervical cancer prevention and treatment, effectively reaches the target population, significantly improves public awareness, and widely builds social consensus.

Professional Support to Ensure Vaccine Accessibility


In November 2024, Merck Sharp & Dohme (MSD) signed a donation agreement for the comprehensive prevention and control project of cervical cancer in low-health-resource areas in China with the China Cancer Foundation. It plans to provide free HPV vaccinations for approximately 27,000 junior high school girls in low-health-resource areas such as Shanxi, Yunnan, and Sichuan. Zhifei gave full play to its professional capabilities in vaccine market services and supply guarantee, becoming a solid backing for the implementation of this project. In 2025, the Company efficiently coordinated the implementation of the donation plan, provided all-round and professional service support, ensured that the donated vaccines were accurately, timely, and temperature-controlled delivered to disease control centers and designated vaccination points in various provinces and cities, strictly adhered to the quality of vaccine products and the safety of related services, and helped the public welfare initiative be implemented efficiently, truly benefiting the target population.

Promoting Medical Fairness

As a biopharmaceutical enterprise, Zhifei has always taken people's health as its responsibility and is committed to actively conveying the scientific value of vaccines, driving high-quality medical products and professional services to benefit a wider population. The Company adheres to combining public welfare actions with its own professional advantages. Focusing on major public health issues such as tuberculosis prevention and control, it continuously donates high-quality products to society, supports grass-roots infectious disease prevention and control work, and deepens collaborative cooperation with local disease prevention and control centers, research institutions, and universities, helping to improve the capacity and level of community medical services and promoting more equitable and accessible medical resources.

★ Tackle Tuberculosis Prevention and Control to Safeguard Plateau Health

The Tibet Autonomous Region is one of the high-incidence areas of tuberculosis in China, with an incidence rate significantly higher than the national average. With the technical support of the Tuberculosis Control Center of the Chinese Center for Disease Control and Prevention, Zhifei Longcom and the China Foundation for Prevention of STD & AIDS jointly established the "Tibet Autonomous Region Tuberculosis Public Welfare Project", with a total donation of over RMB 10 million in funds and tuberculosis prevention and treatment drugs, and it was officially launched at the Tibet Autonomous Region Center for Disease Control and Prevention in May 2023. This project covers 7 prefectures (cities), 23 counties (districts), and 36 townships (towns) across the region. As of the end of the Reporting Period, the project team has basically completed the work of tuberculosis infection screening, health education, and health promotion in the local area. On the basis of informed consent, immunoprophylactic treatment has been carried out on latent infection populations, effectively improving the early detection and accurate diagnosis capabilities of tuberculosis in the Tibet region and contributing to the in-depth development of tuberculosis prevention and control in Tibet.



● Project Launch Ceremony



● Tibet Tuberculosis Project Documentary

★ Care for Medical Workers and Strengthen the Service Foundation

Zhifei also pays attention to the professional development and physical and mental health of medical staff in the grass-roots medical service system and continuously supports the "Caring for Medical Workers" public welfare project. The Company, in cooperation with the China Women's Development Foundation, carried out the activity of distributing "Care Packages for Medical Workers" to medical workers in medical and health institutions such as hospitals, disease control centers, maternity and child health care hospitals, and community health service centers across the country, and implemented professional training and publicity work. It provides support to medical staff from multiple dimensions such as life care, professional skills, and professional growth. This initiative aims to improve the professional level and professional sense of gain of grass-roots medical staff, enhance the stability and cohesion of the medical team, and lay a solid foundation for improving the grass-roots medical service capacity and promoting the equitable accessibility of medical resources.

Integration of Industry and Education to Empower the Future

Focusing on the educational development of teenagers and the growth needs of children, Zhifei continuously drives high-quality educational resources to reach more groups through educational subsidies, campus support, and care actions. The Company conducts public welfare practices in both basic education and higher education fields in line with the actual needs of different educational stages. It not only pays attention to the learning, physical, and mental development of children in difficulty but also supports talent development and the construction of scientific research teams in universities, contributing to educational fairness and talent growth.

Cultivating the New Force in the Industry

The Company joined hands with universities such as Peking University and East China University of Science and Technology to jointly establish an education fund. By providing targeted support for discipline construction, student training, and teacher development, it helps universities improve the quality of talent development, incubate scientific research reserve forces, and continuously supply high-quality professional talents for the biopharmaceutical industry.

★ Promote the Integration of Industry, Academia, and Research and Cultivate the New Force in the Industry

East China University of Science and Technology has a solid scientific research and teaching foundation in fields such as bioengineering and pharmaceutical engineering and is an important talent development base for the biopharmaceutical industry in China. In 2021, Zhifei donated RMB 1 million to the Education Foundation of East China University of Science and Technology to establish an education fund, which is specifically used to support the construction of biopharmaceutical-related disciplines and talent development. In 2025, the Company continued to participate in this project and used the fund for:

- **Inspiring students:** Rewarding outstanding students majoring in biotechnology, pharmacy and other related fields to encourage them to delve into their studies and pursue excellence.
- **Commending excellent teachers:** Recognizing outstanding young teachers who have made remarkable achievements in teaching and scientific research to further stimulate the enthusiasm of teachers and students in teaching and research.
- **Empowering through practice:** Providing internship and scientific research opportunities for students and building a practical channel from campus to enterprises to help more young students realize their self-worth in a fair and open educational environment.



● Zhifei Scholarship of East China University of Science and Technology


Protecting Children's Growth

The Company continues to promote educational public welfare and charity practices, focusing on the growth rights and interests of orphaned, disabled, sick and vulnerable children. Through the "June 1st" love-assisted education activities carried out for many consecutive years, the Company has donated more than RMB 2 million to children in need in remote areas, successfully extending public welfare practices from "improving hardware" to "protecting the soul".



Rural Development and Industrial Revitalization

Zhifei actively integrates into the national rural revitalization strategy. Driven by "infrastructure construction + consumption assistance", it helps to improve the level of rural public services and economic vitality.



Improving Primary-level Medical Care

The Company has established the "Zhifei Rural Revitalization Charity and Glory Fund", aiming to improve the weak links in rural medical conditions and exploring a set of assistance paths that are "replicable in model, different in each village, and sustainable in development".



Focus on Primary-level Needs and Prevent Poverty Caused by Illness

In 2025, Zhifei actively participated in the drug donation work in key rural revitalization areas, donating tuberculosis prevention and treatment drugs and screening reagents to Weining in Guizhou, Weng'an in Guizhou, Kashgar in Xinjiang, Pengshui in Chongqing and other regions, with a donation value of more than RMB 236,000. Through in-depth demand research, the Company ensures that the donated drugs and reagents precisely match the local clinical actual needs, effectively improving the diagnosis and standardized treatment capabilities in the recipient areas, ensuring the accessibility of treatment for patients, and effectively reducing the economic burden on patients from low-income families, thus helping to prevent the risk of "falling into poverty due to illness and returning to poverty due to illness" from the health aspect.

Consumption Assistance for Rural Households

The Company actively broadens the sales channels for agricultural products, closely integrating the needs of employee benefits with the income increase of rural industries. In 2025, Zhifei Longcom made targeted purchases of agricultural and sideline products such as free-range chickens and free-range eggs from poverty-stricken farmers in Qingyang County, Chizhou City. Throughout the year, a total of 3,655 servings of free-range eggs and 1,307 servings of free-range chickens were purchased, with a total purchase expenditure of approximately RMB 520,000. This measure not only effectively solves the problem of agricultural product sales but also directly drives the growth of local household business income, which is beneficial to consolidating the achievements of poverty alleviation.



Appendix

Appendix I SZSE Guidelines Content Index

Corresponding Clauses of the SZSE Guidelines	Topic Names of the SZSE Guidelines	Report Chapters
Environment		
Articles 21 to 28	Climate response	Building Resilience in Response to Climate Change
Article 30	Pollutant discharge	Pollution Prevention and Ecological Protection
Article 31	Waste treatment	Pollution Prevention and Ecological Protection
Article 32	Ecosystem and biodiversity conservation	Pollution Prevention and Ecological Protection
Article 33	Environmental compliance management	Pollution Prevention and Ecological Protection
Article 35	Energy use	Resource Efficiency for Quality and Efficiency Improvement
Article 36	Water use	Resource Efficiency for Quality and Efficiency Improvement
Article 37	Circular economy	Resource Efficiency for Quality and Efficiency Improvement
Society		
Article 39	Rural revitalization	Rural Development and Industrial Revitalization
Article 40	Social contribution	Inclusive Healthcare for Better Health Integration of industry and education to empower the future Rural Development and Industrial Revitalization
Article 42	Innovation-driven development	Innovation Guided by Ethics
Article 43	Science and technology ethics	Innovation Guided by Ethics
Article 45	Supply chain security	Collaboration with Partners for a Responsible Supply Chain

Corresponding Clauses of the SZSE Guidelines	Topic Names of the SZSE Guidelines	Report Chapters
Society		
Article 46	Treat small and medium-sized enterprises equally	During the year, Zhifei did not have accounts payable (including notes payable) balance accounting for more than 50% of total assets.
Article 47	Product and service safety and quality	Quality Assurance, Responsibility First
Article 48	Data security and customer privacy protection	Responsible Marketing and Professional Services
Article 50	Employees	Diversity and inclusion, talent as the foundation Empower growth, drive innovation Share value, stimulate vitality A warm and friendly work environment, a happy workplace
Governance Related to Sustainability		
Article 52	Due diligence	Deepen compliance, strengthen the bottom line Collaboration with Partners for a Responsible Supply Chain
Article 53	Stakeholder engagement	Stakeholder engagement
Article 55	Anti-commercial bribery and anti-corruption	Deepen compliance, strengthen the bottom line
Article 56	Anti-unfair competition	Deepen compliance, strengthen the bottom line

Appendix II GRI Content Index

GRI Standards Disclosure Item Number	GRI Standards Disclosure Item Name	Report Chapter
GRI 2: General Disclosures 2021		
GRI 2-1	Organisational details	About Zhifei
GRI 2-2	Entities included in the organisation's sustainability reporting	About This Report
GRI 2-3	Reporting period, frequency and contact point	About This Report
GRI 2-4	Restatements of information	/
GRI 2-5	External assurance	/
GRI 2-6	Activities, value chain and other business relationships	Development model
GRI 2-7	Employees	Diversity and inclusion, talent as the foundation Empower growth, drive innovation Share value, stimulate vitality A warm and friendly work environment, a happy workplace
GRI 2-8	Workers who are not employees	Diversity and inclusion, talent as the foundation Empower growth, drive innovation Share value, stimulate vitality A warm and friendly work environment, a happy workplace
GRI2: Governance		
GRI 2-9	Governance structure and composition	Standardize governance, strengthen the foundation
GRI 2-10	Nomination and selection of the highest governance body	Standardize governance, strengthen the foundation
GRI 2-11	Chair of the highest governance body	Standardize governance, strengthen the foundation
GRI 2-12	Role of the highest governance body in overseeing the management of impacts	Standardize governance, strengthen the foundation
GRI 2-13	Delegation of responsibility for managing impacts	Standardize governance, strengthen the foundation
GRI 2-14	Role of the highest governance body in sustainability reporting	Sustainable Development Governance Structure
GRI 2-15	Conflicts of interest	Deepen compliance, strengthen the bottom line

GRI Standards Disclosure Item Number	GRI Standards Disclosure Item Name	Report Chapter
GRI 2: General Disclosures 2021		
GRI 2-16	Communication of critical concerns	Stakeholder engagement
GRI 2-17	Collective knowledge of the highest governance body	Standardize governance, strengthen the foundation
GRI 2-18	Evaluation of the performance of the highest governance body	Standardize governance, strengthen the foundation
GRI 2-19	Remuneration policies	Standardize governance, strengthen the foundation
GRI 2-20	Process to determine remuneration	Standardize governance, strengthen the foundation
GRI 2-21	Annual total compensation ratio	Standardize governance, strengthen the foundation
GRI 2-22	Statement on sustainable development strategy	Sustainable development strategy
GRI 2-23	Policy commitments	Sustainable Development Governance Structure
GRI 2-24	Embedding policy commitments	Sustainable Development Governance Structure
GRI 2-25	Processes to remediate negative impacts	Quality Assurance, Responsibility First
GRI 2-26	Mechanisms for seeking advice and raising concerns	A warm and friendly work environment, a happy workplace Bottom Line A warm and friendly work environment, a happy workplace
GRI 2-27	Compliance with laws and regulations	Standardized Governance and Consolidating the Foundation
GRI 2-28	Membership associations	Win-Win Cooperation across Industry, Academia, Research and Healthcare
GRI 2-29	Approach to stakeholder engagement	Stakeholder Engagement
GRI 2-30	Collective bargaining agreements	A warm and friendly work environment, a happy workplace
GRI 3: Material Topics 2021		
GRI 3-1	Process to determine material topics	Double Materiality Assessment
GRI 3-2	List of material topics	Double Materiality Assessment
GRI 3-3	Management of material topics	Double Materiality Assessment

GRI Standards Disclosure Item Number	GRI Standards Disclosure Item Name	Report Chapter
Economy		
GRI 201: Economic Performance 2016		
GRI 201-1	Directly Generated and Distributed Economic Value	Business Performance
GRI 201-2	Financial Impacts of Climate Change and Other Risks and Opportunities	Building Resilience in Response to Climate Change
GRI 201-3	Obligatory Defined Benefit Plans and Other Retirement Plans	A warm and friendly work environment, a happy workplace
GRI 201-4	Financial assistance received from government	/
GRI 202: Market Presence 2016		
GRI 202-1	Ratios of standard entry level wage by gender compared to local minimum wage	/
GRI 202-2	Proportion of senior management hired from the local community	/
GRI 203: Indirect Economic Impacts 2016		
GRI 203-1	Infrastructure investments and services supported	Rural Development and Industrial Revitalization
GRI 203-2	Significant indirect economic impacts	Inclusive Healthcare for Better Health Integration of industry and education to empower the future Rural Development and Industrial Revitalization
GRI 204: Procurement Practices 2016		
GRI 204-1	Proportion of spending on local suppliers	/
GRI 205: Anti-corruption 2016		
GRI 205-1	Operating Sites Where Corruption Risk Assessments Have Been Conducted	Deepening Compliance and Strengthening the Bottom Line
GRI 205-2	Communication and Training on Anti-corruption Policies and Procedures	Deepening Compliance and Strengthening the Bottom Line
GRI 205-3	Confirmed incidents of corruption and actions taken	Deepening Compliance and Strengthening the Bottom Line
GRI 206: Anti-competitive Behaviour 2016		
GRI 206-1	Legal actions for anti-competitive behaviour, anti-trust, and monopoly practices	Deepening Compliance and Strengthening the Bottom Line
GRI 207: Tax 2019		
GRI 207-1	Approach to tax	Deepening Compliance and Strengthening the Bottom Line
GRI 207-2	Tax governance, control, and risk management	Deepening Compliance and Strengthening the Bottom Line
GRI 207-3	Stakeholder engagement and management of concerns related to tax	/

GRI Standards Disclosure Item Number	GRI Standards Disclosure Item Name	Report Chapter
Economy		
GRI 207-4	Country-by-country reporting	/
Environment		
GRI 101: Biodiversity 2024		
GRI 101-1	Policies to halt and reverse biodiversity loss	Pollution Prevention and Ecological Protection
GRI 101-2	Management of biodiversity impacts	Pollution Prevention and Ecological Protection
GRI 101-3	Access and benefit-sharing	Pollution Prevention and Ecological Protection
GRI 101-4	Identification of biodiversity impacts	Pollution Prevention and Ecological Protection
GRI 101-5	Locations with biodiversity impacts	Pollution Prevention and Ecological Protection
GRI 101-6	Direct drivers of biodiversity loss	Pollution Prevention and Ecological Protection
GRI 101-7	Changes to the state of biodiversity	Pollution Prevention and Ecological Protection
GRI 101-8	Ecosystem services	Pollution Prevention and Ecological Protection
GRI 102: Climate Change 2025		
GRI 102-1	Transition plan for climate change mitigation	Building Resilience in Response to Climate Change
GRI 102-2	Climate change adaptation plan	Building Resilience in Response to Climate Change
GRI 102-3	Just transition	/
GRI 102-4	GHG emissions reduction targets and progress	/
GRI 102-5	Scope 1 GHG emissions	Building Resilience in Response to Climate Change Appendix III Environmental Indicators
GRI 102-6	Scope 2 GHG emissions	Building Resilience in Response to Climate Change Appendix III Environmental Indicators
GRI 102-7	Scope 3 GHG emissions	/
GRI 102-8	GHG emissions intensity	Building Resilience in Response to Climate Change Appendix III Environmental Indicators
GRI 102-9	GHG removals in the value chain	Building Resilience in Response to Climate Change Appendix III Environmental Indicators
GRI 102-10	Carbon credits	/

GRI Standards Disclosure Item Number	GRI Standards Disclosure Item Name	Report Chapter
Environment		
GRI 103: Energy 2025		
GRI 103-1	Energy policies and commitments	Resource Efficiency for Quality and Efficiency Improvement
GRI 103-2	Energy consumption and self-generation within the organisation	Appendix III Environmental Indicators
GRI 103-3	Upstream and downstream energy consumption	/
GRI 103-4	Energy intensity	Appendix III Environmental Indicators
GRI 103-5	Reduction in energy consumption	Resource Efficiency for Quality and Efficiency Improvement Appendix III Environmental Indicators
GRI 301: Materials 2016		
GRI 301-1	Materials used by weight or volume	Appendix III Environmental Indicators
GRI 301-2	Recycled input materials used	Resource Efficiency for Quality and Efficiency Improvement Appendix III Environmental Indicators
GRI 301-3	Reclaimed products and their packaging materials	In this year, Zhifei has no situation of recycling products and product packaging.
GRI 303: Water and Effluents 2018		
GRI 303-1	The interaction between the organization and water	Resource Efficiency for Quality and Efficiency Improvement
GRI 303-2	Managing impacts related to drainage	Pollution Prevention and Ecological Protection
GRI 303-3	Water intake	Resource Efficiency for Quality and Efficiency Improvement Appendix III Environmental Indicators
GRI 303-4	Water discharge	Appendix III Environmental Indicators
GRI 303-5	Water consumption	Resource Efficiency for Quality and Efficiency Improvement Appendix III Environmental Indicators
GRI 305: Emissions 2016		
GRI 305-6	Emissions of ozone-depleting substances (ODS)	During the Year, Zhifei has not found ozone-depleting substances (ODS) emissions
GRI 305-7	Nitrogen oxides (NOx), sulfur oxides (SOx), and other significant air emissions	Appendix III Environmental Indicators

GRI Standards Disclosure Item Number	GRI Standards Disclosure Item Name	Report Chapter
Environment		
GRI 306: Waste 2020		
GRI 306-1	Waste generation and significant waste-related impacts	Resource Efficiency for Quality and Efficiency Improvement Pollution Prevention and Ecological Protection
GRI 306-2	Management of significant waste-related impacts	Resource Efficiency for Quality and Efficiency Improvement Pollution Prevention and Ecological Protection
GRI 306-3	Waste generated	Pollution Prevention and Ecological Protection Appendix III Environmental Indicators
GRI 306-4	Waste diverted from disposal	Pollution Prevention and Ecological Protection Appendix III Environmental Indicators
GRI 306-5	Waste directed to disposal	Pollution Prevention and Ecological Protection Appendix III Environmental Indicators
Society		
GRI 308: Supplier Environmental Assessment 2016		
GRI 308-1	New suppliers that were screened using environmental criteria	Collaboration with Partners for a Responsible Supply Chain
GRI 308-2	Negative environmental impacts in the supply chain and actions taken	Collaboration with Partners for a Responsible Supply Chain
GRI 401: Employment 2016		
GRI 401-1	New employee hires and employee turnover	Diversity and inclusion, building a talent foundation
GRI 401-2	Benefits provided to full-time employees that are not provided to temporary or part-time employees	A warm and friendly work environment for a happy workplace
GRI 401-3	Parental leave	A warm and friendly work environment for a happy workplace
GRI 402: Labour/Management Relations 2016		
GRI 402-1	Minimum notice periods regarding operational changes	/
GRI 403: Occupational Health and Safety 2018		
GRI 403-1	Occupational health and safety management system	Ensuring Safety and Protecting Health
GRI 403-2	Hazard identification, risk assessment, and incident investigation	Ensuring Safety and Protecting Health
GRI 403-3	Occupational health services	Ensuring Safety and Protecting Health

GRI Standards Disclosure Item Number	GRI Standards Disclosure Item Name	Report Chapter
Society		
GRI 403-4	Worker participation, consultation, and communication on occupational health and safety	Ensuring Safety and Protecting Health
GRI 403-5	Worker training on occupational health and safety	Ensuring Safety and Protecting Health
GRI 403-6	Promotion of worker health	Ensuring Safety and Protecting Health
GRI 403-7	Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	Ensuring Safety and Protecting Health
GRI 403-8	Workers covered by an occupational health and safety management system	Ensuring Safety and Protecting Health
GRI 403-9	Work-related injuries	Ensuring Safety and Protecting Health Appendix III Governance and Social Indicators
GRI 403-10	Work-related ill health	Ensuring Safety and Protecting Health Appendix III Governance and Social Indicators
GRI 404: Training and Education 2016		
GRI 404-1	Average hours of training per year per employee	Empower growth, drive innovation
GRI 404-2	Programs for upgrading employee skills and transition assistance programs	Empower growth, drive innovation
GRI 404-3	Percentage of employees receiving regular performance and career development reviews	Empower growth, drive innovation Share value, stimulate vitality Appendix III Governance and Social Indicators
GRI 405: Diversity and Equal Opportunity 2016		
GRI 405-1	Diversity of the governance body and employees	Diversity and inclusion, building a talent foundation
GRI 405-2	Ratio of basic salary and remuneration between men and women	Diversity and inclusion, building a talent foundation Share value, stimulate vitality

GRI Standards Disclosure Item Number	GRI Standards Disclosure Item Name	Report Chapter
Society		
GRI 406: Non-discrimination 2016		
GRI 406-1	Incidents of discrimination and corrective actions taken	Diversity and inclusion, building a talent foundation
GRI 407: Freedom of Association and Collective Bargaining 2016		
GRI 407-1	Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk	During the current year, Zhifei has no operating sites or suppliers at risk.
GRI 408: Child Labour 2016		
GRI 408-1	Operations and suppliers at significant risk for incidents of child labour	During the current year, Zhifei has no operational sites or suppliers facing major risks of child labor incidents.
GRI 409: Forced or Compulsory Labour 2016		
GRI 409-1	Operations and suppliers at significant risk for incidents of forced or compulsory labour	During the current year, Zhifei has no operational sites or suppliers facing major risks of forced or compulsory labor incidents.
GRI 410: Security Practices 2016		
GRI 410-1	Security personnel trained in human rights policies or procedures	/
GRI 411: Rights of Indigenous Peoples 2016		
GRI 411-1	Incidents of violations involving rights of indigenous peoples	During the current year, Zhifei Biotech found no incidents involving aboriginal rights infringement.
GRI 413: Local Communities 2016		
GRI 413-1	Operations with local community engagement, impact assessments, and development programs	Inclusive Healthcare for Better Health Integration of Industry and Education to Empower the Future Rural Development and Industrial Revitalization
GRI 413-2	Operations with significant actual and potential negative impacts on local communities	During the current year, Zhifei has no operational sites facing actual or potential major negative impacts on local communities.

GRI Standards Disclosure Item Number	GRI Standards Disclosure Item Name	Report Chapter
Society		
GRI 414: Supplier Social Assessment 2016		
GRI 414-1	New suppliers that were screened using social criteria	Collaboration with Partners for a Responsible Supply Chain
GRI 414-2	Negative social impacts in the supply chain and actions taken	Collaboration with Partners for a Responsible Supply Chain
GRI 415: Public Policy 2016		
GRI 415-1	Political contributions	/
GRI 416: Customer Health and Safety 2016		
GRI 416-1	Assessment of the health and safety impacts of product and service categories	Responsible Marketing and Professional Services
GRI 416-2	Incidents of non-compliance concerning the health and safety impacts of products and services	Responsible Marketing and Professional Services
GRI 417: Marketing and Labeling 2016		
GRI 417-1	Requirements for product and service information and labeling	/
GRI 417-2	Incidents of non-compliance concerning product and service information and labeling	During the current year, Zhifei has no incidents of non-compliance concerning product and service information and labeling.
GRI 417-3	Incidents of non-compliance concerning marketing communications	During the current year, Zhifei has no incidents of non-compliance concerning marketing communications.
GRI 418: Customer Privacy 2016		
GRI 418-1	Substantiated complaints concerning breaches of customer privacy and losses of customer data	During the current year, Zhifei has not received any confirmed complaints related to violation of customer privacy and loss of customer data.

Appendix III: Summary of ESG Key Performance Indicators

Governance and Social Indicators⁹

ESG Indicators	Unit	2024	2025
Employee Employment			
Total number of employees	Person	7,220	6,292
By gender			
Male	Person	4,376	3,636
Female	Person	2,844	2,656
By age			
Under 31 years old	Person	4,040	2,926
31-40 years old	Person	2,638	2,746
41-50 years old	Person	450	520
Over 50 years old	Person	92	100
By region			
China (including Hong Kong, Macao, and Taiwan)	Person	7,220	6,292
By educational level			
Doctor	Person	22	24
Master	Person	791	768
Undergraduate and below	Person	6,407	5,500
Divided by professional composition			
Production staff	Person	1,128	1,177
Sales staff	Person	4,562	3,533
R&D staff	Person	1,072	1,109
Financial staff	Person	69	70
Management staff	Person	389	403

9. Employee employment, New employees, employment diversity and equal opportunity, Compliant employment, Product R&D and innovation, Data security incidents, violations of scientific and technological ethics, anti-corruption, the total number of major violations of laws and regulations occurred during the reporting period, violations of environmental laws and regulations, and supplier indicators data include Chen'an Bio

ESG Indicators	Unit	2024	2025
By position level			
Senior management	Person	41	44
Middle management	Person	970	924
General personnel	Person	6,209	5,324
New Employees ¹⁰			
Total number of new employees	Person	1,268	164
By gender			
Male	Person	810	76
Female	Person	458	88
By age group			
Under 31 years old	Person	1,005	133
31-40 years old	Person	256	30
41-50 years old	Person	6	1
Over 50 years old	Person	1	0
By geographical region			
China (including Hong Kong, Macao and Taiwan)	Person	1,268	164
Employment Diversity and Equal Opportunity			
Board of Directors			
Male	Person	7	7
Female	Person	2	2
Management			
Male	Person	693	635
Female	Person	318	327

10. During the Year, affected by multiple factors such as the adjustment of industry policies, the decline in people's willingness to vaccinate, and changes in market demand structure, the Company adjusted its human resources allocation strategy in a timely manner and tightened the recruitment demand in stages, resulting in a year-on-year decrease in the number of new employees during the Reporting Period.

ESG Indicators	Unit	2024	2025
General personnel			
Male	Person	3,683	2,995
Female	Person	2,526	2,329
Others			
Ethnic minorities	Person	367	326
Disabled persons	Person	30	31
Rehired retirees	Person	22	25
Compliant Employment			
Operating points and suppliers with major risks of child labor incidents	Case	0	0
Operating points and suppliers with major risks of forced or compulsory labor incidents	Case	0	0
Total number of discrimination incidents during the Reporting Period	Case	0	0
Employee turnover rate ¹¹	%	11.73	18.35
Total number of trade union members	Person	7,176	6,246
Employee membership rate	%	99.36	99.27
Training and Development			
Employee training coverage rate	%	100	100
Employee training expenditure ¹²	RMB 10,000	3,641.89	988.60
Total number of hours employees received training	Hour	440,456.24	387,980.46
Average number of hours employees receive training per year	Hour	61.01	61.66
By gender			
Male	Hour per person	62.95	61.94
Female	Hour per person	58.02	61.28

11. Employee turnover rate calculation formula: Employee turnover rate = Total number of departures ÷ (Total number of employees at the end of the period + Total number of departures). During the Year, affected by multiple factors such as the adjustment of industry policies, the decline in people's willingness to vaccinate, and changes in market demand structure, the Company adjusted its human resources allocation strategy in a timely manner and tightened the recruitment demand in stages, resulting in a year-on-year decrease in the number of new employees during the Reporting Period.

12. During the Year, the Company innovated its training model and achieved lean management and control of training costs by relying on online platforms and internal lecturer resources, which effectively reduced the procurement and travel expenses incurred by external centralized training while ensuring training coverage, resulting in a year-on-year decrease in employee training expenses during the Reporting Period.

ESG Indicators	Unit	2024	2025
Training and Development			
By position level			
Senior management ¹³	Hour per person	21.24	32.13
Middle and lower management	Hour per person	59.99	68.95
Ordinary employees	Hour per person	63.17	60.64
Percentage of employees regularly evaluated on performance and career development	%	100	100
Health and Safety¹⁴			
Investment in health and safety	RMB 10,000	1,482.99	786.68
Investment in work safety	RMB 10,000	750.84	453.86
Investment in occupational health and safety	RMB 10,000	101.81	54.33
Investment in work-related injury insurance and work safety liability insurance	RMB 10,000	630.34	278.49
Coverage rate of detection of occupational disease risk factors	%	100	100
Work safety training			
Total hours of work safety training	Hour	15,859.50	17,764.40
Total number of employees trained in work safety training ¹⁵	Person-time	5,382.00	9,965
Work-related injuries			
Number and mortality rate of employee deaths caused by work-related injuries	Person; %	0; 0	0; 0

13. During the Year, in response to the complex and ever-changing market environment and the in-depth adjustment of the industry, the Company tilted its core resources towards top-level governance and focused on strengthening the strategic focus and compliance and risk control capabilities of the senior management, resulting in an increase in the average training hours of the senior management during the Reporting Period year-on-year.
14. The health and safety indicators cover the two main production and R&D bases of Zhifei Longcom and Zhifei Lvzhu. During the Year, affected by multiple factors such as the adjustment of industry policies, the decline in people's willingness to vaccinate, and changes in market demand structure, the Company adjusted its human resources allocation strategy in a timely manner, resulting in a year-on-year decrease in investment in health and safety.
15. During the Year, the Company adjusted its human resources allocation strategy in a timely manner due to the overlapping influence of various factors such as the adjustment of industry policies, the decline in people's willingness to vaccinate, and changes in market demand structure, resulting in a year-on-year decrease in the total number of employees trained in safety production training.

ESG Indicators	Unit	2024	2025
Health and Safety			
Work-related health problems			
Number of employee deaths caused by work-related health problems	Person	0	0
Number and rate of all employees covered by the management system and workers who are not employees but whose work and/or workplace is controlled by the Company	Person; %	/	2,371; 100
Number and percentage of all employees covered by the internally audited management system and non-employees whose work and/or workplace is controlled by the Company	Person; %	/	1,946; 82.08
Number and percentage of all employees and non-employees whose work and/or workplace is controlled by the Company covered by externally audited or certified management systems	Person; %	/	1,946; 82.08
Product Quality and Safety			
Number of product quality training sessions	Case	109	130
Participation rate of employees in product quality training	%	100	100
Number of incidents where fines or penalties have been imposed for violations of health and safety related regulations	Case	/	0
Number of incidents warned for violations of health and safety related regulations	Case	/	0
Number of incidents of violations of the voluntary code on health and safety of products and services	Case	/	0
Product R&D and Innovation			
Amount of R&D investment	RMB 100 million	15.27	14.36
Cumulative number of granted patents ¹⁶	Case	57	89

16. During the Year, due to the pressure on the Company's phased operating performance, the Company moderately tightened the total community investment budget, resulting in a year-on-year decrease in the total charitable donations during the Reporting Period; At the same time, the Company actively optimized the allocation structure of charitable resources, focused its limited resources on responding to the national macro strategy, and tilted towards the special area of rural revitalization, resulting in a year-on-year increase in such investment during the Reporting Period.

ESG Indicators	Unit	2024	2025
Marketing and Labeling			
Incidents of non-compliance concerning product and service information and labeling			
Incidents resulting in fines or penalties due to violations	Case	0	0
Incidents resulting in warnings due to violations	Case	0	0
Incidents of violations of voluntary codes	Case	0	0
Incidents of non-compliance concerning marketing communications			
Incidents resulting in fines or penalties due to violations	Case	0	0
Incidents resulting in warnings due to violations	Case	0	0
Incidents of violations of voluntary codes	Case	0	0
Customer Service Management			
Customer service satisfaction	%	99.37	98.39
Response rate of customer satisfaction surveys	%	100	100
Response rate to customer complaints	%	100	100
Resolution rate of customer complaints	%	100	100
Incidents of non-compliance concerning the health and safety impacts of products and services			
Incidents resulting in fines or penalties due to violations	Case	0	0
Incidents resulting in warnings due to violations	Case	0	0
Incidents of violations of voluntary codes	Case	0	0

ESG Indicators	Unit	2024	2025
Customer Service management			
Confirmed complaints related to violation of customer privacy and loss of customer data			
Complaints from external parties confirmed by the organization	Case	0	0
Complaints from regulatory authorities	Case	0	0
Total number of confirmed leaks, thefts or losses of customer data	Case	0	0
Total number of confirmed complaints related to violation of customer privacy received	Case	0	0
Data Security Incident			
Number of data security incidents	Case	/	0
Amount involved in the event	RMB	/	0
Violation of Science and Technology Ethics			
Total number of confirmed illegal science and technology ethics incidents	Time	/	0
Infrastructure Investments and Services Supported			
Charitable donations ¹⁷	RMB 10,000	Over 1,096	322.89
Number of public welfare projects participated in during the year	Item	12	12
Investment in support of rural revitalization	RMB 10,000	20.03	52
Anti-Corruption			
Number of anti-corruption training sessions	Session	190	154
Attendance of anti-corruption training	Person-time	83,030	72,167
Number of operating sites assessed for corruption risks	Unit	6	7
Percentage of operating sites assessed for corruption risks	%	100	100
Percentage of employees receiving moral standard training	%	100	100
Number of compliance training sessions	Session	190	154
Cumulative attendance of compliance training	Person-time	83,030	72,167

17. During the Year, due to the pressure on the Company's phased operating performance, the Company moderately tightened the total community investment budget, resulting in a year-on-year decrease in the total charitable donations during the Reporting Period; At the same time, the Company actively optimized the allocation structure of charitable resources, focused its limited resources on responding to the national macro strategy, and tilted towards the special area of rural revitalization, resulting in a year-on-year increase in such investment during the Reporting Period.

ESG Indicators	Unit	2024	2025
Anti-Corruption			
Total number of major violations of laws and regulations occurred during the Reporting Period (except environmental violations)			
Incident where a fine occurred	Time	/	0
Incidents where non-monetary sanctions occur	Time	/	0
Violation of environmental laws and regulations			
Total number of cases of monetary sanctions arising from environmental incidents	Time	/	0
Total number of cases of non-monetary sanctions arising from environmental incidents	Time	/	0
Gross monetary value of significant penalties arising from environmental incidents	RMB	/	0
Total number of incidents subject to major administrative penalties or criminal responsibility for pollutant discharge	Time	/	0
Suppliers			
Supplier type			
Equipment	Unit	/	239
Others	Unit	/	786
By geography			
Northeast	Unit	/	4
North China	Unit	/	161
East China	Unit	/	633
South China	Unit	/	47
Central China	Unit	/	37
Northwest	Unit	/	6
Southwest	Unit	/	128
Total	Unit	/	1,016
Supplier compliance audit			
Supplier quality compliance audit ¹⁸	Time	47	64
Key supplier qualification rate	%	100	100

18. During the Year, in order to effectively prevent potential quality and compliance risks in the supply chain, the Company further strengthened the review of suppliers due to the combined effects of multiple factors such as the adjustment of industry policies, the decline in people's willingness to vaccinate, and changes in market demand structure. At the same time, in line with the advancement of many of the Company's product candidates to the middle and late clinical stages and the expansion of new business pipelines, the admission and qualification audit of relevant material suppliers were added, resulting in a year-on-year increase in the number of supplier quality compliance audits during the Reporting Period.

Environmental Indicators¹⁹

ESG Indicators	Unit	2024	2025
Energy			
Direct energy consumption ²⁰	tce	6,723.92	5,515.97
Gasoline	tce	18.00	13.53
Diesel	tce	132.68	110.38
Pipeline natural gas	tce	6,573.24	5,392.05
Indirect energy consumption	tce	19,806.49	16,172.78
Electricity consumption	tce	11,353.06	9,126.34
Heat consumption	tce	8,453.43	7,046.44
Total energy consumption	tce	26,530.41	21,688.75
Energy intensity	tce/RMB 10,000 of revenue	0.01	0.02
Water Resources			
Total water withdrawal	Tonne	1,532,948.16	1,185,055.43
Third-party facilities (municipal water supply)	Tonne	1,482,659.56	1,148,188.23
Others (reclaimed water usage)	Tonne	50,288.60	36,867.20
Water withdrawal intensity	Tonne/RMB 10,000 of revenue	0.59	1.32
Total wastewater discharge	m ³	1,149,361.64	920,063.53
Wastewater discharge intensity	m ³ /RMB 10,000 of revenue	0.44	1.03
Total water consumption ²¹	Tonne	383,586.52	228,124.70
Water consumption intensity	Tonne/RMB 10,000 of revenue	0.15	0.25

19. The data of environmental indicators cover the two main production and R&D bases of Zhifei Longcom and Zhifei Lvzhu. The calculations for the environmental intensity indicators listed in this Report for the 2024 fiscal year are based on the revenue data disclosed in the Company's 2024 Annual Report. Although the Company announced on April 28, 2026, that it had made retrospective adjustments to certain financial statement data for the 2024 fiscal year, given that the actual total amounts of energy, water, greenhouse gases, waste, and materials consumed by the Company in 2024 did not undergo any material changes, this Report has not made retrospective adjustments to the relevant intensity indicators for that fiscal year in order to maintain the objectivity of the situation at that time.

20. The factors of the total energy consumption of each category in terms of standard coal equivalent refer to the *General Rules for the Calculation of Comprehensive Energy Consumption (GB/T 2589-2020)* published by the People's Republic of China, in which the volume-to-weight conversion factors for gasoline refer to the *2006 IPCC Guidelines for National Greenhouse Gas Inventories* published by the Intergovernmental Panel on Climate Change (IPCC).

21. This year, the Company adjusted the operating mode of its purified water production system, effectively reducing water consumption year-over-year during the Reporting Period.

ESG Indicators	Unit	2024	2025
Greenhouse Gas Emissions			
Scope 1 greenhouse gas emission ²²	tCO ₂ e	13,444.53	9,870.83
Stationary source emissions	tCO ₂ e	/	9,595.58
Mobile source emissions	tCO ₂ e	/	275.25
Scope 2 greenhouse gas emission ²³	tCO ₂ e	76,807.20	62,105.98
Total greenhouse gas emissions	tCO ₂ e	90,382.72	71,976.81
Greenhouse gas emissions intensity ²⁴	tCO ₂ e/RMB 10,000 of revenue	0.03	0.08
Waste			
Total volume of non-hazardous waste generated ²⁵	Tonne	12,210.01	1,108.04
Non-hazardous waste generation intensity	Tonne/RMB 10,000 of revenue	0.0047	0.0012
Total volume of hazardous waste generated ²⁶	Tonne	531.18	281.86
Hazardous waste generation intensity	Tonne/RMB 10,000 of revenue	0.0002	0.0003

22. The sources of direct (Scope 1) GHG emissions generated include: fuel combustion from stationary sources (pipeline natural gas); and emissions from mobile combustion sources during fuel consumption, including gasoline consumption in business vehicles and diesel consumption in cold chain vehicles. Emission factors for stationary sources are referenced to the *2006 IPCC Guidelines for National Greenhouse Gas Inventories* published by the Intergovernmental Panel on Climate Change (IPCC); emission factors for mobile combustion sources and global warming potentials refer to the IPCC sixth Assessment Report (AR6).
23. The sources of indirect (Scope 2) GHG emissions generated include: emissions from purchased electricity and heat. The emission factor of location-based electricity refer to the National grid average emission factor from the *Announcement of the release of the 2023 CO₂ emission factors for electricity* issued by the Ministry of Ecology and Environment of the People's Republic of China; the emission factors of heat refer to the *Guidelines for Accounting and Reporting of Greenhouse Gas Emissions of Enterprises in Other Industries* issued by the Development and Reform Commission of the People's Republic of China on July 6, 2015.
24. GHG emissions intensity is calculated by taking the sum of the Company's direct (Scope 1) and indirect (Scope 2) GHG emissions for the year as the numerator and the Company's operating income for the year as the denominator.
25. The Company's non-hazardous waste consists mainly of solid waste, and a small amount of office waste and food waste. This year, as process validation at the relevant plants has progressed and stabilized, the volume of solid waste generated has decreased, resulting in a year-over-year decline in the volume of non-hazardous waste generated during the Reporting Period.
26. This year, the Company strengthened its management of laboratory reagents and related supplies, effectively reducing the volume of hazardous waste generated during the Reporting Period compared to the same period last year.

ESG Indicators	Unit	2024	2025
Material Usage			
Material consumption	Tonne	254.08	220.76
Non-renewable material consumption ²⁷	Tonne	140.26	122.13
Renewable material consumption ²⁸	Tonne	113.82	98.63
Material usage intensity	Tonne/RMB 10,000 of revenue	0.0001	0.0002
Environmental Compliance			
Total EHS investment ²⁹	RMB 10,000	1,246.62	722.35
Total environmental protection investment	RMB 10,000	393.97	214.16
Total safety investment	RMB 10,000	852.65	508.19
Violation of environmental laws and regulations			
Total value of significant fines	RMB	0	0
Total number of non-monetary sanctions	Time	0	0
Cases filed through the dispute resolution mechanism	Time	0	0

27. The Company's non-renewable materials consist primarily of glass.
28. The Company's renewable materials mainly include plastics, paper, silicone tubing, paper tray, cardboard boxes, rubber plugs, and PVC.
29. This year, while ensuring the orderly implementation of EHS management, the Company made timely adjustments to its investment plans, resulting in a year-over-year decrease in total EHS expenditures during the Reporting Period.

ESG Indicators		2025			
Pollutant Emissions					
Air pollutants					
Name of the company or subsidiary	Name of pollutant	Emissions concentration in 2025	Total emissions in 2025	Total emissions allowance for 2025	Excess emissions in 2025
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. (Tongji North Road Plant)	Particulate matter	0.6mg/m ³	/	/	N/A
	Cooking fumes	0.8mg/m ³	/	/	N/A
	Total non-methane hydrocarbons	2.59mg/m ³	0.0934 tonnes	1.2264 tonnes	Within limits
	Hydrogen chloride	1.03mg/m ³	/	/	N/A
	Sulfuric acid mist	<0.2mg/m ³	/	/	N/A
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. (Taihe Third Street Plant)	Particulate matter (particulate matter from kitchen fumes)	0.2mg/m ³	/	/	N/A
	Particulate matter (particulate matter in boiler exhaust)	<1mg/m ³	/	/	N/A
	Nitrogen oxides	20.03mg/m ³	0.8534 tonnes	4.7407 tonnes	Within limits
	Cooking fumes	0.2mg/m ³	/	/	N/A
	Total non-methane hydrocarbons	1.58mg/m ³	/	/	N/A
	Ringelmann scale	< Level 1	/	/	N/A
	Hydrogen chloride	3.75mg/m ³	/	/	N/A
	Formaldehyde	0.28mg/m ³	/	/	N/A
	Ammonia (ammonia gas)	2.565mg/m ³	/	/	N/A
	Sulfur dioxide	<3mg/m ³	/	/	N/A
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. (Yongchang Middle Road Plant)	Hydrogen sulfide	<0.01mg/m ³	/	/	N/A
	Odor concentration	233 dimensionless	/	/	N/A
	Sulfuric acid mist	<0.2mg/m ³	/	/	N/A
	Total non-methane hydrocarbons	2.34mg/m ³	/	/	N/A
	Hydrogen chloride	<0.2mg/m ³	/	/	N/A
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. (Mingzhu Avenue Industrial Park Plant)	Formaldehyde	<0.05mg/m ³	/	/	N/A
	Methanol	<0.07mg/m ³	/	/	N/A
	Sulfuric acid mist	<0.2mg/m ³	/	/	N/A

ESG Indicators		2025			
Pollutant Emissions					
Air pollutants					
Name of the company or subsidiary	Name of pollutant	Emissions concentration in 2025	Total emissions in 2025	Total emissions allowance for 2025	Excess emissions in 2025
Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Fushan Road Plant)	Ammonia (ammonia gas) (exhaust gas from the wastewater treatment plant)	0.96mg/m ³	/	/	N/A
	Hydrogen sulfide (exhaust gas from the wastewater treatment plant)	0.56mg/m ³	/	/	N/A
	Odor concentration (exhaust gas from the wastewater treatment plant)	460 dimensionless	/	/	N/A
	Vocs (exhaust gases from the temporary storage of hazardous waste)	0.32mg/m ³	/	/	N/A
	Odor concentration (exhaust gas from temporary storage of hazardous waste)	605 dimensionless	/	/	N/A
	Ammonia (ammonia gas) (exhaust gas from waste embryo processing)	0.91mg/m ³	/	/	N/A
	Sulfur dioxide (exhaust gas from scrap processing)	3.33mg/m ³	/	/	N/A
	Hydrogen sulfide (exhaust gas from waste embryo processing)	0.01mg/m ³	/	/	N/A
	Nitrogen oxides (exhaust gas from scrap embryo processing)	23mg/m ³	/	/	N/A
	Particulate matter (exhaust gas from waste blank processing)	2.33mg/m ³	/	/	N/A
Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Mingzhu Avenue Industrial Park Plant)	Odor concentration (exhaust gas from waste embryo processing)	808 dimensionless	/	/	N/A
	Ammonia (ammonia gas) (exhaust gas from the wastewater treatment plant)	0.38mg/m ³	/	/	N/A
	Hydrogen sulfide (exhaust gas from the wastewater treatment plant)	0.12mg/m ³	/	/	N/A
	Odor concentration (exhaust gas from the wastewater treatment plant)	407 dimensionless	/	/	N/A
	Ammonia (ammonia gas) (exhaust gas from animal housing)	0.22mg/m ³	/	/	N/A
	Hydrogen sulfide (exhaust gas from animal housing facilities)	0.045mg/m ³	/	/	N/A
	Odor concentration (exhaust air from animal housing)	25 dimensionless	/	/	N/A
	Odor concentration (exhaust gas from temporary storage of hazardous waste)	610 dimensionless	/	/	N/A

ESG Indicators		2025			
Pollutant Emissions					
Water pollutants					
Name of the company or subsidiary	Name of pollutant	Emissions concentration in 2025	Total emissions in 2025	Total emissions allowance for 2025	Excess emissions in 2025
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. (Tongji North Road Plant)	Total wastewater discharge	/	89,247m ³	/	N/A
	Chemical oxygen demand	27.9mg/L	2.5591 tonnes	900 tonnes	Within limits
	Ammonia nitrogen	/	0.0592 tonnes	81 tonnes	Within limits
	Total nitrogen	3.38mg/L	/	/	N/A
	Five-day biochemical oxygen demand	8.25mg/L	/	/	N/A
	pH value	7.62	/	/	N/A
	Total organic carbon	12.2mg/L	/	/	N/A
	Vegetable and animal oils	0.14mg/L	/	/	N/A
	Chroma	<2 times	/	/	N/A
	Total residual chlorine	3.13mg/L	/	/	N/A
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. (Taihe Third Street Plant)	Total wastewater discharge	/	235,874m ³	/	N/A
	Chemical oxygen demand	/	4.4805 tonnes	12.3224 tonnes	Within limits
	Ammonia nitrogen	/	0.1303 tonnes	2.6068 tonnes	Within limits
	Total nitrogen	4.08mg/L	/	/	N/A
	Total phosphorus	1.865mg/L	/	/	N/A
	Suspended solids	19mg/L	/	/	N/A
	Formaldehyde	0.103mg/L	/	/	N/A
	Five-day biochemical oxygen demand	13.55mg/L	/	/	N/A
	pH value	7.66	/	/	N/A
	Total organic carbon	15.15mg/L	/	/	N/A

ESG Indicators		2025			
Pollutant Emissions					
Water pollutants					
Name of the company or subsidiary	Name of pollutant	Emissions concentration in 2025	Total emissions in 2025	Total emissions allowance for 2025	Excess emissions in 2025
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. (Yongchang Middle Road Plant)	Vegetable and animal oils	0.23mg/L	/	/	N/A
	Volatile phenols	0.075mg/L	/	/	N/A
	Chroma	<2 times	/	/	N/A
	Total residual chlorine	1.207mg/L	/	/	N/A
	Fecal coliforms	1000MPN/L	/	/	N/A
	Total salt content	607mg/L	/	/	N/A
	Chemical oxygen demand	121mg/L	/	/	N/A
	Ammonia nitrogen	0.15mg/L	/	/	N/A
	Total nitrogen	1.09mg/L	/	/	N/A
	Total phosphorus	0.043mg/L	/	/	N/A
Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Fushan Road Plant)	Suspended solids	18mg/L	/	/	N/A
	Five-day biochemical oxygen demand	32.4mg/L	/	/	N/A
	pH value	8	/	/	N/A
	Total residual chlorine	0.22mg/L	/	/	N/A
	Fecal coliforms	<20MPN/L	/	/	N/A
	Total salt content	250mg/L	/	/	N/A
	Total wastewater discharge	/	286,622.12m ³	/	N/A
	Chemical oxygen demand	36.86mg/L	18.03t/a	51.49t/a	Within limits
	Ammonia nitrogen	35mg/L	0.271t/a	2.81t/a	Within limits
	Total nitrogen	50mg/L	1.25t/a	2.11t/a	Within limits

ESG Indicators		2025			
Pollutant Emissions					
Water pollutants					
Name of the company or subsidiary	Name of pollutant	Emissions concentration in 2025	Total emissions in 2025	Total emissions allowance for 2025	Excess emissions in 2025
Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Fushan Road Plant)	Total phosphorus	0.043mg/L	/	/	N/A
	Suspended solids	/	/	20.92mg/L	N/A
	Formaldehyde	/	/	0.1mg/L	N/A
	Five-day biochemical oxygen demand	/	/	8.91mg/L	N/A
	pH value	/	/	7.01	N/A
	Total organic carbon	/	/	15.75mg/L	N/A
	Vegetable and animal oils	/	/	0.07mg/L	N/A
	Chroma	/	/	4 times	N/A
	Total residual chlorine	/	/	0.41mg/L	N/A
	Fecal coliforms	/	/	206MPN/L	N/A
	Acute toxicity	/	/	0.06mg/L	N/A
	Acetonitrile	/	/	0.04mg/L	N/A

ESG Indicators		2025			
Pollutant Emissions					
Water pollutants					
Name of the company or subsidiary	Name of pollutant	Emissions concentration in 2025	Total emissions in 2025	Total emissions allowance for 2025	Excess emissions in 2025
Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Mingzhu Avenue Industrial Park Plant)	Total wastewater discharge	/	308,320.81m ³	/	N/A
	Chemical oxygen demand	14mg/L	4.238t/a	17.2t/a	Within limits
	Ammonia nitrogen	0.6mg/L	0.171t/a	0.86t/a	Within limits
	Total nitrogen	4.26mg/L	1.31t/a	2.11t/a	Within limits
	Total phosphorus	0.41mg/L	/	/	N/A
	Suspended solids	11.8mg/L	/	/	N/A
	Formaldehyde	0.06mg/L	/	/	N/A
	Five-day biochemical oxygen demand	5.55mg/L	/	/	N/A
	pH value	6.7	/	/	N/A
	Total organic carbon	6.05mg/L	/	/	N/A
	Vegetable and animal oils	0.08mg/L	/	/	N/A
	Volatile phenols	0.01mg/L	/	/	N/A
	Chroma	4 times	/	/	N/A
	Total residual chlorine	0.38mg/L	/	/	N/A
	Fecal coliforms	115MPN/L	/	/	N/A
	Acute toxicity	0.03mg/L	/	/	N/A
	Acetonitrile	0.04mg/L	/	/	N/A